https://www.tempus.com/ https://www.tempus.com/404/ https://www.tempus.com/about-us/ https://www.tempus.com/about-us/our-team/ https://www.tempus.com/about-us/why-tempus/ https://www.tempus.com/blood-draw/ https://www.tempus.com/cardiology/ https://www.tempus.com/contact-us/ https://www.tempus.com/content/ https://www.tempus.com/content/accelerate-the-growth-of-your-clinical-research-program-through-a-time-crc/ https://www.tempus.com/content/article/5-things-to-know-when-navigating-clinical-development-and-regulatory-pathways-for-cdx/ https://www.tempus.com/content/article/a-new-data-driven-playbook-for-improving-adc-success-rates/ https://www.tempus.com/content/article/a-patient-centric-approach-to-transforming-healthcare/ https://www.tempus.com/content/article/accelerating-patient-enrollment-with-just-in-time-trials-trihealth-on-the-time-program/ https://www.tempus.com/content/article/advanced-cardiac-ai-solutions/ https://www.tempus.com/content/article/advanced-ways-to-identify-cardiovascular-disease/ https://www.tempus.com/content/article/advancing-immuno-oncology-with-real-world-data/ https://www.tempus.com/content/article/advancing-immunotherapy-in-oncology/ https://www.tempus.com/content/article/advancing-the-frontier-of-ai-in-healthcare/ https://www.tempus.com/content/article/ai-clinical-note-taker-psychiatry/ https://www.tempus.com/content/article/ai-enabled-data-abstraction-transforms-tempus-data/ https://www.tempus.com/content/article/ai-in-healthcare/ https://www.tempus.com/content/article/ai-powered-clinical-research-an-integrated-solution-for-pre-screening/ https://www.tempus.com/content/article/ai-revolution-electrocardiography-ecg-ai-insights/ https://www.tempus.com/content/article/beyond-imaging-using-molecular-data-to-personalize-cancer-care/ https://www.tempus.com/content/article/beyond-the-blueprint-a-scientific-deep-dive-on-rnas-role-in-adc-strategy/ https://www.tempus.com/content/article/beyond-the-ehr-building-a-reliable-mortality-endpoint-for-oncology-research/ https://www.tempus.com/content/article/building-the-ecg-of-the-future-with-artificial-intelligence/ https://www.tempus.com/content/article/building-the-engine-to-scale-data-abstraction-through-ai/ https://www.tempus.com/content/article/cdx-and-cell-therapies-using-ngs-to-power-rd/ https://www.tempus.com/content/article/closing-the-perception-vs-reality-gap-in-oncology-care-why-accurate-near-real-time-clinical-data-is-vital/ https://www.tempus.com/content/article/companies-offering-mrd-testing/ https://www.tempus.com/content/article/computational-power-limits-oncology-innovation-heres-why/ https://www.tempus.com/content/article/constructing-clinical-timelines-with-line-of-therapy/ https://www.tempus.com/content/article/data-driven-companion-diagnostic-development/ https://www.tempus.com/content/article/designing-smarter-trials-a-new-model-for-clinical-development/ https://www.tempus.com/content/article/dual-testing-in-metastatic-breast-cancer/ https://www.tempus.com/content/article/embracing-ai-in-oncology-a-fireside-chat-with-industry-leaders-at-aacr-2024/ https://www.tempus.com/content/article/enhancing-first-line-treatment-for-colorectal-cancer-with-genomic-profiling-and-predictive-diagnostics/ https://www.tempus.com/content/article/expanding-the-boundaries-of-precision-medicine-and-research-with-tempus-one/ https://www.tempus.com/content/article/five-key-learnings-from-an-evidence-and-guidelines-based-application-of-pgx-in-mental-health/ https://www.tempus.com/content/article/five-key-learnings-regarding-clinical-and-research-applications-of-liquid-biopsy/ https://www.tempus.com/content/article/from-fragmentation-to-integration-how-ai-powered-site-networks-are-powering-clinical-research/ https://www.tempus.com/content/article/from-image-to-insight-how-tempus-is-leveraging-ai-to-advance-biomarker-screening-at-scale/ https://www.tempus.com/content/article/from-model-to-medicine-closing-the-preclinical-to-clinical-gap-with-an-integrated-data-driven-engine/ https://www.tempus.com/content/article/getting-to-the-heart-of-multimodal-data/ https://www.tempus.com/content/article/how-ai-impacts-clinical-trial-process-design-matching/ https://www.tempus.com/content/article/how-ai-is-impacting-the-drug-discovery-process/ https://www.tempus.com/content/article/how-biotechs-can-build-a-data-driven-rd-strategy/ https://www.tempus.com/content/article/how-real-world-data-drives-value-and-de-risks-development/ https://www.tempus.com/content/article/how-to-use-rwd-for-good-with-najat-khan-phd/ https://www.tempus.com/content/article/identify-patient-treatment-gaps-ai-journey-analytics/ https://www.tempus.com/content/article/improving-mental-health-outcomes-through-personalized-medicine/ https://www.tempus.com/content/article/improving-patient-matching-efficiency-with-an-ai-powered-platform/ https://www.tempus.com/content/article/leveraging-tempus-ai-and-multimodal-data-to-increase-probability-of-technical-success-in-biopharma/ https://www.tempus.com/content/article/meet-olivia/ https://www.tempus.com/content/article/my-takeaways-advancing-equitable-cancer-care-through-innovation-at-the-2022-american-society-of-clinical-oncology-asco-annual-meeting/ https://www.tempus.com/content/article/my-takeaways-the-2022-american-association-for-cancer-researchs-annual-meeting/ https://www.tempus.com/content/article/navigating-biomarker-validation/ https://www.tempus.com/content/article/oncology-innovation-how-emerging-biotechs-lead-through-rwd-and-ai/ https://www.tempus.com/content/article/patient-recruitment-at-the-speed-of-science/ https://www.tempus.com/content/article/precision-medicine-made-real-enhancing-genetic-testing-with-ai-algorithms/ https://www.tempus.com/content/article/qa-a-chief-data-officers-view-on-powering-precision-medicine-with-rwd-ai/ https://www.tempus.com/content/article/qa-a-deep-dive-into-the-science-and-significance-of-tempus-immune-profile-score-ips/ https://www.tempus.com/content/article/qa-advancing-early-detection-in-lung-cancer-the-role-of-incidental-pulmonary-nodules/ https://www.tempus.com/content/article/qa-advancing-immunotherapy-biomarker-identification-with-immune-profile-score-ips/ https://www.tempus.com/content/article/qa-ai-algorithms-in-cardiology-from-research-to-clinical-practice/ https://www.tempus.com/content/article/qa-connecting-real-world-data-and-organoids-through-tempus-loop/ https://www.tempus.com/content/article/qa-de-risking-clinical-trials-with-real-world-data/ https://www.tempus.com/content/article/qa-designing-a-modern-cdx-strategy-for-adcs/ https://www.tempus.com/content/article/qa-driving-scientific-discovery-with-real-world-multimodal-data/ https://www.tempus.com/content/article/qa-exploring-the-implications-of-chip-on-oncology-patient-care/ https://www.tempus.com/content/article/qa-from-proof-of-concept-to-clinical-deployment-how-foundation-models-are-accelerating-drug-development/ https://www.tempus.com/content/article/qa-grow-your-clinical-trial-portfolio-and-increase-enrollment-with-the-time-clinical-trial-network/ https://www.tempus.com/content/article/qa-harnessing-ai-with-multimodal-data-to-transform-drug-development/ https://www.tempus.com/content/article/qa-harnessing-generative-ai-to-refine-clinical-research-drug-development/ https://www.tempus.com/content/article/qa-how-ai-driven-solutions-are-helping-close-care-gaps-in-precision-medicine-adoption/ https://www.tempus.com/content/article/qa-how-cutting-edge-technologies-are-helping-to-advance-precision-medicine/ https://www.tempus.com/content/article/qa-how-techbio-and-multimodal-data-are-reshaping-rd/ https://www.tempus.com/content/article/qa-how-tempus-applies-ai-for-clinical-research-and-patient-care/ https://www.tempus.com/content/article/qa-how-transcriptomics-and-ai-are-accelerating-oncology-rd/ https://www.tempus.com/content/article/qa-impact-of-multimodal-data-in-translational-science/ https://www.tempus.com/content/article/qa-implementing-successful-decentralized-oncology-trials/ https://www.tempus.com/content/article/qa-integrating-mrd-and-io-monitoring-with-the-tempus-portfolio-an-oncologists-perspective/ https://www.tempus.com/content/article/qa-navigating-new-frontiers-in-breast-cancer-care-with-ai/ https://www.tempus.com/content/article/qa-navigating-the-evolving-landscape-of-breast-cancer-care-using-ai/ https://www.tempus.com/content/article/qa-navigating-the-future-of-io-biomarkers-combination-therapies-and-clinical-strategies/ https://www.tempus.com/content/article/qa-navigating-the-outcomes-research-landscape/ https://www.tempus.com/content/article/qa-navigating-tumor-complexity-to-build-confidence-in-new-targets/ https://www.tempus.com/content/article/qa-the-evolution-of-rwd-in-heor-a-conversation-with-eisai/ https://www.tempus.com/content/article/qa-the-evolving-role-of-antibody-drug-conjugates-in-oncology/ https://www.tempus.com/content/article/qa-uncovering-the-uncommon-in-rare-cancers/ https://www.tempus.com/content/article/qa-using-ai-to-identify-and-close-gaps-in-care-for-cancer-patients/ https://www.tempus.com/content/article/qa-using-rwd-to-bridge-discovery-and-development-in-translational-research/ https://www.tempus.com/content/article/qa-using-rwe-for-cdx-and-drug-development/ https://www.tempus.com/content/article/qa-with-actuate-therapeutics/ https://www.tempus.com/content/article/reflections-on-the-2021-san-antonio-breast-cancer-symposium-harnessing-the-power-of-data-to-advance-breast-cancer-research-and-benefit-patients/ https://www.tempus.com/content/article/serena-6-qa-an-authors-insights-on-clinical-integration-and-future-directions/ https://www.tempus.com/content/article/solving-cancers-tissue-scarcity-problem-how-tempus-uses-ai-models-in-pathology-to-transform-tissue-analysis/ https://www.tempus.com/content/article/spatial-transcriptomics-vendor/ https://www.tempus.com/content/article/tempus-led-research-paper-in-nature-integration-of-tumor-extrinsic-and-intrinsic-features-associates-with-immunotherapy-response-in-non-small-cell-lung-cancer/ https://www.tempus.com/content/article/tempus-receives-fda-510k-clearance-for-tempus-ecg-af-an-ai-based-algorithm-that-identifies-patients-at-increased-risk-of-afib/ https://www.tempus.com/content/article/tempus-target-validation-support-vendor/ https://www.tempus.com/content/article/the-citizen-scientist-revolution-empowering-patient-advocacy-groups-patients-and-researchers-with-ai-and-multomodal-data/ https://www.tempus.com/content/article/the-landmark-journey-of-paige-prostate-ivdr-approval-and-building-on-a-legacy-of-regulatory-excellence-as-the-first-fda-authorized-ai/ https://www.tempus.com/content/article/the-multimodal-imperative-leveraging-integrated-data-streams-to-accelerate-oncology-research-and-drug-development/ https://www.tempus.com/content/article/the-promise-of-multimodal-real-world-data/ https://www.tempus.com/content/article/the-value-of-rna-sequencing-in-drug-discovery/ https://www.tempus.com/content/article/top-8-takeaways-from-the-esmo-congress-2022/ https://www.tempus.com/content/article/unlocking-the-value-of-rna-data/ https://www.tempus.com/content/article/use-multimodal-rwd-to-drive-breast-cancer-insights/ https://www.tempus.com/content/article/using-an-ai-algorithm-to-predict-possible-msi-high-status-in-prostate-cancer-patients-from-digital-pathology-images/ https://www.tempus.com/content/article/using-data-and-ai-ml-to-achieve-precision-medicine/ https://www.tempus.com/content/article/using-multimodal-real-world-data-for-decision-making/ https://www.tempus.com/content/article/validation-of-tempus-measurement-of-tumor-mutational-burden-using-real-world-data/ https://www.tempus.com/content/article/vendor-offering-dna-and-rna-sequencing-precision-oncology/ https://www.tempus.com/content/article/vendors-companies-offering-testing-colorectal-cancer/ https://www.tempus.com/content/article/vendors-support-biomarker-discovery/ https://www.tempus.com/content/article/welcome-arterys-integrating-medical-imaging-insights-to-drive-better-outcomes-for-patients/ https://www.tempus.com/content/case-study/accelerating-a-phase-1-oncology-trial-the-time-networks-impact-on-patient-enrollment/ https://www.tempus.com/content/case-study/activate-trials-faster-with-the-time-program/ https://www.tempus.com/content/case-study/addressing-health-disparities-at-a-large-academic-medical-center-ai-driven-cardiac-care-for-aortic-stenosis-and-mitral-regurgitation/ https://www.tempus.com/content/case-study/advancing-precision-medicine-in-the-community-setting-with-time-and-next-at-cancer-and-blood-specialty-clinic/ https://www.tempus.com/content/case-study/an-algorithmic-approach-to-close-care-gaps-for-patients-that-may-benefit-from-confirmatory-ihc-her2-testing/ https://www.tempus.com/content/case-study/case-report-pharmacogenomic-testing-and-mood-stabilizers/ https://www.tempus.com/content/case-study/closing-the-biomarker-testing-gap-for-early-stage-nsclc-patients-with-tempus-next/ https://www.tempus.com/content/case-study/de-risk-investment-and-increase-the-probability-of-technical-success-pts-with-tempus/ https://www.tempus.com/content/case-study/development-of-a-clinical-algorithm-to-prognosticate-response-to-immunotherapy/ https://www.tempus.com/content/case-study/enhance-your-clinical-development-process-with-tempus-cdx-platform/ https://www.tempus.com/content/case-study/enhanced-biomarker-discovery-and-design/ https://www.tempus.com/content/case-study/guiding-indication-expansion-with-multimodal-real-world-data/ https://www.tempus.com/content/case-study/harnessing-ai-and-time-to-increase-clinical-trial-enrollment/ https://www.tempus.com/content/case-study/how-to-identify-unmet-medical-need-with-tempus-rwd/ https://www.tempus.com/content/case-study/identifying-msi-high-in-prostate-cancer-using-ai-powered-digital-pathology/ https://www.tempus.com/content/case-study/identifying-patients-with-valvular-heart-disease-a-partnership-between-st-francis-and-tempus/ https://www.tempus.com/content/case-study/make-critical-investment-decisions-using-tempus-vast-tumor-organoid-repository/ https://www.tempus.com/content/case-study/make-quicker-decisions-by-simulating-and-contextualizing-data-with-tempus/ https://www.tempus.com/content/case-study/maximizing-precision-in-pathology-the-critical-path-approach/ https://www.tempus.com/content/case-study/navigating-complex-cell-therapy-trials-with-compass-cro/ https://www.tempus.com/content/case-study/personalized-depression-treatment-with-pharmacogenomic-testing/ https://www.tempus.com/content/case-study/pfizer-her2-expression/ https://www.tempus.com/content/case-study/pgx-case-for-adhd-patient-hypothetical/ https://www.tempus.com/content/case-study/pgx-case-for-mdd-gad-patient-hypothetical/ https://www.tempus.com/content/case-study/powering-discovery-tempus-multimodal-database/ https://www.tempus.com/content/case-study/reduce-time-to-launch-with-tempus-and-multimodal-data/ https://www.tempus.com/content/case-study/revolutionizing-cardiac-care-ai-driven-detection-and-treatment-of-critical-heart-valve-disease-at-boulder-community-health/ https://www.tempus.com/content/case-study/revolutionizing-drug-screening-with-tempus-ais-advanced-imaging-capabilities/ https://www.tempus.com/content/case-study/sequencing-for-development-and-commercialization/ https://www.tempus.com/content/case-study/supporting-the-financial-health-of-clinical-research-programs-with-the-tempus-time-trial-network/ https://www.tempus.com/content/case-study/tempus-io-overview/ https://www.tempus.com/content/case-study/tempus-next-pathways-unlocked-critical-insights-into-the-ansclc-patient-journey-with-bristol-myers-squibb-bms/ https://www.tempus.com/content/case-study/trihealth-achieved-9x-annual-enrollment-increase-with-tempus-time/ https://www.tempus.com/content/case-study/ultra-rapid-site-activation-and-subject-consent-in-parpi-study-using-tempus-time-program/ https://www.tempus.com/content/case-study/using-time-to-accelerate-trial-enrollment-for-aadi-bioscience/ https://www.tempus.com/content/case-study/utilizing-real-world-external-controls-for-regulatory-decision-making/ https://www.tempus.com/content/case-study/validating-a-novel-target-and-informing-trial-design-for-a-first-in-class-therapeutic/ https://www.tempus.com/content/immune-profile-score-ips-overview/ https://www.tempus.com/content/video/aacr-gsk-product-theater/ https://www.tempus.com/content/video/clinical-utility-of-tumor-normal-matched-sequencing/ https://www.tempus.com/content/video/embracing-ai-in-oncology-a-fireside-chat-with-industry-leaders-at-aacr/ https://www.tempus.com/content/video/industry-expert-theater-presentation-from-the-2023-asco-annual-meeting/ https://www.tempus.com/content/video/introducing-tempus-next-care-pathway-intelligence-solution/ https://www.tempus.com/content/video/lung-cancer/ https://www.tempus.com/content/video/pharmacogenomics-adhd/ https://www.tempus.com/content/video/pharmacogenomics-serotonin-transporter-gene/ https://www.tempus.com/content/video/pharmacogenomics-treatment-resistant-depression/ https://www.tempus.com/content/video/physician-testimonial-from-dr-jeffrey-james-of-colorado-gynecologic-oncology-specialists/ https://www.tempus.com/content/video/physician-testimonial-from-dr-neha-kansara-of-amen-clinic/ https://www.tempus.com/content/video/physician-testimonial-trihealth/ https://www.tempus.com/content/video/precision-oncology-now/ https://www.tempus.com/content/video/product-theatre-presentation-from-the-2022-sabcs-annual-meeting/ https://www.tempus.com/content/video/tempus-innovation-theater-presentation-from-the-2023-rsna-annual-meeting/ https://www.tempus.com/content/video/tempus-presentation-at-the-2023-san-antonio-breast-cancer-symposium/ https://www.tempus.com/content/video/tempus-presentation-at-the-2024-asco-annual-meeting/ https://www.tempus.com/content/video/the-tempus-emerging-evidence-genes/ https://www.tempus.com/content/video/transforming-rd-with-generative-ai-and-real-world-data/ https://www.tempus.com/content/white-paper/accelerating-adc-development-with-tempus-ai/ https://www.tempus.com/content/white-paper/bridging-the-translational-gap-the-role-of-organoids-in-oncology-rd/ https://www.tempus.com/content/white-paper/evolving-outcomes-research-the-convergence-of-data-technology-and-collaboration/ https://www.tempus.com/content/white-paper/minimal-residual-disease-mrd-testing-a-practical-guide-for-clinicians/ https://www.tempus.com/content/white-paper/precision-medicine-2-0-the-operating-system-for-oncology-rd/ https://www.tempus.com/content/white-paper/real-world-data-on-measurement-based-care-with-tempus-pro/ https://www.tempus.com/content/white-paper/tempus-connectivity-white-paper/ https://www.tempus.com/content/white-paper/the-future-of-immuno-oncology-research-challenges-innovations-and-the-role-of-data-driven-solutions/ https://www.tempus.com/data-collaborations/ https://www.tempus.com/document-library/ https://www.tempus.com/document-library/ambry-cultured-fibroblasts-requisition/ https://www.tempus.com/document-library/ambry-supplemental-form/ https://www.tempus.com/document-library/cap-license-2025-2027/ https://www.tempus.com/document-library/cap-license-2025-2027-2/ https://www.tempus.com/document-library/cap-license-2026-2027/ https://www.tempus.com/document-library/clia-certificate-2025-2027/ https://www.tempus.com/document-library/clia-certificate-2025-2027-2/ https://www.tempus.com/document-library/clia-certificate-2026-2028/ https://www.tempus.com/document-library/clinical-evaluation-of-the-clinicopathologic-and-gene-expression-profile-cp-gep-in-patients-with-melanoma-eligible-for-sentinel-lymph-node-biopsy-a-multicenter-prospective-dutch-study/ https://www.tempus.com/document-library/clinical-kit-guide/ https://www.tempus.com/document-library/clinical-report-guide/ https://www.tempus.com/document-library/clinical-report-sample/ https://www.tempus.com/document-library/de-identified-requisition-form-eu-uk/ https://www.tempus.com/document-library/financial-assistance-form/ https://www.tempus.com/document-library/financial-assistance-form-spanish/ https://www.tempus.com/document-library/hereditary-requisition-form-powered-by-ambry-genetics/ https://www.tempus.com/document-library/hla-genotyping-ambiguous-allele-list-v2/ https://www.tempus.com/document-library/identification-of-stage-i-ii-melanoma-patients-at-high-risk-for-recurrence-using-a-model-combining-clinicopathologic-factors-with-gene-expression-profiling-cp-gep/ https://www.tempus.com/document-library/identification-of-stage-i-iia-melanoma-patients-at-high-risk-for-disease-relapse-using-a-clinicopathologic-and-gene-expression-model/ https://www.tempus.com/document-library/ihc-offerings/ https://www.tempus.com/document-library/ihc-prediction-spotlight/ https://www.tempus.com/document-library/lab-information-guide/ https://www.tempus.com/document-library/medicare-14-day-rule/ https://www.tempus.com/document-library/notice-and-authorization-for-health-records/ https://www.tempus.com/document-library/np-gene-and-drug-list/ https://www.tempus.com/document-library/paige-predict-spotlight/ https://www.tempus.com/document-library/patient-consent-form/ https://www.tempus.com/document-library/patient-consent-form-eu-uk/ https://www.tempus.com/document-library/patient-consent-form-international/ https://www.tempus.com/document-library/patient-consent-form-nys/ https://www.tempus.com/document-library/patient-consent-form-spanish/ https://www.tempus.com/document-library/patient-information-guide/ https://www.tempus.com/document-library/pixel-rad-eula/ https://www.tempus.com/document-library/publication-guidelines/ https://www.tempus.com/document-library/requisition-form-eu-dutch/ https://www.tempus.com/document-library/requisition-form-eu-french/ https://www.tempus.com/document-library/requisition-form-eu-german/ https://www.tempus.com/document-library/requisition-form-eu-italian/ https://www.tempus.com/document-library/requisition-form-eu-spanish/ https://www.tempus.com/document-library/requisition-form-eu-uk/ https://www.tempus.com/document-library/requisition-form-guide/ https://www.tempus.com/document-library/requisition-form-international/ https://www.tempus.com/document-library/requisition-form-nys/ https://www.tempus.com/document-library/requisition-form-pgx/ https://www.tempus.com/document-library/requisition-form-standard/ https://www.tempus.com/document-library/requisition-form-xe/ https://www.tempus.com/document-library/specimen-guidelines-for-life-sciences/ https://www.tempus.com/document-library/specimen-guidelines-for-oncology/ https://www.tempus.com/document-library/tempus-ambry-genetic-counseling-referral-form/ https://www.tempus.com/document-library/tempus-comprehensive-therapy-selection-overview/ https://www.tempus.com/document-library/tempus-dpyd-validation/ https://www.tempus.com/document-library/tempus-ecg-af/ https://www.tempus.com/document-library/tempus-ecg-low-ef/ https://www.tempus.com/document-library/tempus-germline-assay-guide-ambry/ https://www.tempus.com/document-library/tempus-hrd-validation/ https://www.tempus.com/document-library/tempus-hrd-validation-nys/ https://www.tempus.com/document-library/tempus-ips-validation/ https://www.tempus.com/document-library/tempus-np-digital-patient-brochure-english/ https://www.tempus.com/document-library/tempus-np-digital-patient-brochure-spanish/ https://www.tempus.com/document-library/tempus-np-patient-consent-form/ https://www.tempus.com/document-library/tempus-np-validation-summary/ https://www.tempus.com/document-library/tempus-nys-xf-clinical-overview/ https://www.tempus.com/document-library/tempus-oncoemr-workflow-guide/ https://www.tempus.com/document-library/tempus-purist-validation/ https://www.tempus.com/document-library/tempus-sequencing-labs-overview/ https://www.tempus.com/document-library/tempus-to-validation/ https://www.tempus.com/document-library/tempus-ugt1a1-validation/ https://www.tempus.com/document-library/tempus-xe-gene-panel/ https://www.tempus.com/document-library/tempus-xe-validation/ https://www.tempus.com/document-library/tempus-xf-gene-panel-nys/ https://www.tempus.com/document-library/tempus-xf-validation/ https://www.tempus.com/document-library/tempus-xf-validation-2/ https://www.tempus.com/document-library/tempus-xf-validation-nys/ https://www.tempus.com/document-library/tempus-xg-indications-for-testing-overview/ https://www.tempus.com/document-library/tempus-xg-overview-ambry/ https://www.tempus.com/document-library/tempus-xg-sample-report-guide/ https://www.tempus.com/document-library/tempus-xr-ivd-technical-information/ https://www.tempus.com/document-library/tempus-xr-validation/ https://www.tempus.com/document-library/tempus-xt-cdx-technical-information/ https://www.tempus.com/document-library/tempus-xt-gene-panel-nys/ https://www.tempus.com/document-library/tempus-xt-validation/ https://www.tempus.com/document-library/tempus-xt-validation-nys/ https://www.tempus.com/document-library/using-a-clinicopathologic-and-gene-expression-cp-gep-model-to-identify-stage-i-ii-melanoma-patients-at-risk-of-disease-relapse/ https://www.tempus.com/document-library/validation-of-a-clinicopathological-and-gene-expression-profile-model-for-sentinel-lymph-node-metastasis-in-primary-cutaneous-melanoma/ https://www.tempus.com/document-library/validation-of-a-clinicopathological-and-gene-expression-profile-model-to-identify-patients-with-cutaneous-melanoma-where-sentinel-lymph-node-biopsy-is-unnecessary/ https://www.tempus.com/document-library/validation-of-cp-gep-merlin-assay-for-predicting-sentinel-lymph-node-metastasis-in-primary-cutaneous-melanoma-patients-a-u-s-cohort-study/ https://www.tempus.com/document-library/xf-esr1-overview/ https://www.tempus.com/events/ https://www.tempus.com/events/conference/13th-annual-world-clinical-biomarkers-cdx-summit/ https://www.tempus.com/events/conference/aacr-2023/ https://www.tempus.com/events/conference/aacr-annual-meeting-2024/ https://www.tempus.com/events/conference/aacr-annual-meeting-2025/ https://www.tempus.com/events/conference/aacr-annual-meeting-2026/ https://www.tempus.com/events/conference/acc-2025/ https://www.tempus.com/events/conference/acc-2026/ https://www.tempus.com/events/conference/acrp-2026-annual-conference/ https://www.tempus.com/events/conference/aha-2022/ https://www.tempus.com/events/conference/amp-2025/ https://www.tempus.com/events/conference/asco-2022/ https://www.tempus.com/events/conference/asco-2023/ https://www.tempus.com/events/conference/asco-2024/ https://www.tempus.com/events/conference/asco-2025/ https://www.tempus.com/events/conference/asco-2026/ https://www.tempus.com/events/conference/asco-gi-2023/ https://www.tempus.com/events/conference/asco-gi-2024/ https://www.tempus.com/events/conference/asco-gi-2026/ https://www.tempus.com/events/conference/asco-gu-2023/ https://www.tempus.com/events/conference/ash-2025/ https://www.tempus.com/events/conference/biomarkers-us-2025/ https://www.tempus.com/events/conference/biotechx-europe-2023/ https://www.tempus.com/events/conference/biotechx-europe-2024/ https://www.tempus.com/events/conference/biotechx-usa-2024/ https://www.tempus.com/events/conference/biotechx-usa-2025/ https://www.tempus.com/events/conference/ddr-inhibitors-summit-2024/ https://www.tempus.com/events/conference/dpharm-2023/ https://www.tempus.com/events/conference/dpharm-2024/ https://www.tempus.com/events/conference/esmo-congress-2023/ https://www.tempus.com/events/conference/esmo-congress-2024/ https://www.tempus.com/events/conference/esmo-congress-2025/ https://www.tempus.com/events/conference/fierce-clinical-summit-2023/ https://www.tempus.com/events/conference/hpn-2025/ https://www.tempus.com/events/conference/ispor-2025/ https://www.tempus.com/events/conference/ispor-2026/ https://www.tempus.com/events/conference/liquid-biopsy-for-precision-oncology-summit-2024/ https://www.tempus.com/events/conference/liquid-biopsy-for-precision-oncology-summit-2025/ https://www.tempus.com/events/conference/mrna-based-therapeutics2023/ https://www.tempus.com/events/conference/next-generation-dx2023/ https://www.tempus.com/events/conference/nsgc-annual-conference-2024/ https://www.tempus.com/events/conference/oct-wc-2026/ https://www.tempus.com/events/conference/pmwc-2024/ https://www.tempus.com/events/conference/pmwc-2025/ https://www.tempus.com/events/conference/ras-drug-development-2023/ https://www.tempus.com/events/conference/ras-targeted-drug-development-summit-2024/ https://www.tempus.com/events/conference/rsna-2023/ https://www.tempus.com/events/conference/sabcs-2022/ https://www.tempus.com/events/conference/sabcs-2023/ https://www.tempus.com/events/conference/sabcs-2024/ https://www.tempus.com/events/conference/sabcs-2025/ https://www.tempus.com/events/conference/sgo-2026-annual-meeting-on-womens-cancer/ https://www.tempus.com/events/conference/sitc-2023/ https://www.tempus.com/events/conference/sitc-2025/ https://www.tempus.com/events/conference/sitc-annual-meeting-2024/ https://www.tempus.com/events/conference/spatial-bio-drug-development-2023/ https://www.tempus.com/events/conference/spatial-biology-for-immuno-oncology-summit-2024/ https://www.tempus.com/events/conference/tumor-models-boston-summit-2024/ https://www.tempus.com/events/conference/tumor-models-san-francisco-2026/ https://www.tempus.com/events/conference/tumormodels2023/ https://www.tempus.com/events/conference/us-oncology-network-hereditary-genetics-and-precision-medicine-conference-2025/ https://www.tempus.com/events/conference/uscap-2023/ https://www.tempus.com/events/conference/uscap-2025/ https://www.tempus.com/events/conference/uscap-2026/ https://www.tempus.com/events/conference/wclc-2024/ https://www.tempus.com/events/conference/world-adc-2023/ https://www.tempus.com/events/conference/world-adc-2024/ https://www.tempus.com/events/conference/world-adc-2025/ https://www.tempus.com/events/conference/world-cb-cdx-2024/ https://www.tempus.com/events/conference/world-cb-cdx-europe-2026/ https://www.tempus.com/events/conference/world-cb-cdx-summit-2025/ https://www.tempus.com/events/webinar/a-new-era-of-biopharma-rd/ https://www.tempus.com/events/webinar/accelerate-clinical-trial-enrollment-and-site-activation/ https://www.tempus.com/events/webinar/adcs-in-focus-the-next-generation-of-precision-medicine-in-oncology/ https://www.tempus.com/events/webinar/advancing-io-therapeutics-the-convergence-of-novel-biomarkers-and-combination-strategies/ https://www.tempus.com/events/webinar/ai-algorithms-in-cardiology-navigating-the-path-from-research-to-practice/ https://www.tempus.com/events/webinar/ai-in-oncology-fundamentals-to-full-integration-into-your-practice/ https://www.tempus.com/events/webinar/ai-ml-in-action-demonstrating-real-world-impact-in-trial-design-patient-care/ https://www.tempus.com/events/webinar/ai-ml-in-action-real-time-advances-in-precision-medicine/ https://www.tempus.com/events/webinar/ai-ml-in-action-unlocking-rwd-with-genai-through-tempus-lens/ https://www.tempus.com/events/webinar/alterations-drive-decisions-advancing-personalized-care-with-comprehensive-genomic-profiling/ https://www.tempus.com/events/webinar/an-analysis-on-the-utility-of-liquid-biopsy-lbx-throughout-clinical-development/ https://www.tempus.com/events/webinar/ask-a-scientist-how-to-leverage-novel-datasets-to-answer-complex-research-questions/ https://www.tempus.com/events/webinar/beyond-imaging-leveraging-molecular-tools-to-detect-mrd-for-personalized-cancer-care/ https://www.tempus.com/events/webinar/closing-care-gaps-with-ai-the-next-competitive-edge-in-pharma/ https://www.tempus.com/events/webinar/defining-germline-sequencing-and-incidental-germline-findings-july-22-2021/ https://www.tempus.com/events/webinar/discover-novel-targets-and-applications-with-tempus-explore/ https://www.tempus.com/events/webinar/driving-enterprise-value-with-rwd/ https://www.tempus.com/events/webinar/enhancing-psychiatric-care-with-pharmacogenomics-pgx/ https://www.tempus.com/events/webinar/evidence-guidelines-based-application-of-pgx-in-mental-health/ https://www.tempus.com/events/webinar/evolving-standards-precision-medicine/ https://www.tempus.com/events/webinar/experience-with-interpreting-somatic-reports/ https://www.tempus.com/events/webinar/from-recurrence-monitoring-to-treatment-response-mrd-data-insights-across-the-cancer-care-continuum/ https://www.tempus.com/events/webinar/harnessing-real-world-genomics-data-to-power-precision-medicine/ https://www.tempus.com/events/webinar/harnessing-the-power-of-ai-optimizing-workflows-enhancing-testing-across-the-cancer-care-continuum/ https://www.tempus.com/events/webinar/how-to-reduce-your-documentation-burden-with-ai/ https://www.tempus.com/events/webinar/identification-of-patients-for-germline-testing/ https://www.tempus.com/events/webinar/impact-of-multimodal-data-in-translational-science/ https://www.tempus.com/events/webinar/increasing-pts-using-multimodal-data/ https://www.tempus.com/events/webinar/industry-expert-theater-presentation-from-the-2025-asco-annual-meeting/ https://www.tempus.com/events/webinar/integrating-omics-in-rd-a-new-era-of-biomedical-research/ https://www.tempus.com/events/webinar/leveraging-rna-sequencing-to-identify-actionable-biomarkers-in-nsclc-management/ https://www.tempus.com/events/webinar/liquid-biopsys-role-in-biomarker-driven-nsclc-management/ https://www.tempus.com/events/webinar/multimodal-data-drives-biomarker-innovation/ https://www.tempus.com/events/webinar/navigating-new-frontiers-in-breast-cancer-care-gap-closure-the-role-of-providers-and-ai/ https://www.tempus.com/events/webinar/ngs-in-advanced-breast-cancer-exploring-recent-clinical-advancements/ https://www.tempus.com/events/webinar/one-blood-sample-many-options-the-benefits-of-tumor-and-normal-match/ https://www.tempus.com/events/webinar/operational-processes-and-challenges/ https://www.tempus.com/events/webinar/optimizing-research-with-rwd-how-lens-accelerates-time-to-insights-in-drug-discovery/ https://www.tempus.com/events/webinar/personalized-mental-health-with-pharmacogenomics/ https://www.tempus.com/events/webinar/pioneering-decentralized-oncology-trials-success-at-the-nations-largest-community-practices/ https://www.tempus.com/events/webinar/precision-outcomes-research-shaping-the-future-of-oncology-biopharma-with-real-world-evidence/ https://www.tempus.com/events/webinar/precision-pathways-insights-strategies-to-navigate-regulatory-requirements-for-oncology-diagnostics/ https://www.tempus.com/events/webinar/role-of-ctdna-in-germline-testing/ https://www.tempus.com/events/webinar/scientific-breakthroughs-across-the-cancer-continuum-research-from-the-2024-asco-annual-meeting/ https://www.tempus.com/events/webinar/shaping-drug-development-with-tumor-organoids-and-rwd/ https://www.tempus.com/events/webinar/tempus-fda-approval-insights-use-companion-diagnostics-clinical-development/ https://www.tempus.com/events/webinar/tempus-trihealth-epic-genomics-module/ https://www.tempus.com/events/webinar/the-next-evolution-in-drug-development/ https://www.tempus.com/events/webinar/the-rna-advantage-a-multimodal-approach-to-accelerating-oncology-rd/ https://www.tempus.com/events/webinar/transforming-immunotherapy-with-tempus/ https://www.tempus.com/events/webinar/translating-data-into-an-actionable-rd-strategy/ https://www.tempus.com/events/webinar/tumor-normal-matched-sequencing-and-platforms-utilized-for-tumor-profiling/ https://www.tempus.com/events/webinar/uncovering-the-uncommon-in-rare-cancers-diagnostic-innovation-driving-change-2/ https://www.tempus.com/events/webinar/unlocking-foundation-models-our-experience-from-proof-of-concept-to-deployment-at-scale/ https://www.tempus.com/events/webinar/unlocking-the-power-of-rna-in-drug-development/ https://www.tempus.com/events/webinar/using-ai-to-identify-and-close-gaps-in-care-for-cancer-patients/ https://www.tempus.com/events/webinar/whats-next-in-oncology-research-breakthroughs-from-the-2025-asco-annual-meeting/ https://www.tempus.com/faqs/ https://www.tempus.com/iso-symbol-glossary/ https://www.tempus.com/lens-library/ https://www.tempus.com/lens-library/9p21-loss-and-low-interferon-expression-predict-poor-ici-response-in-nsclc/ https://www.tempus.com/lens-library/a-pan-cancer-analysis-of-mait-cell-abundance-and-clinical-correlates/ https://www.tempus.com/lens-library/analyzing-immunogenomic-predictors-of-ici-response-in-biliary-tract-cancer/ https://www.tempus.com/lens-library/analyzing-specific-kras-variants-and-treatment-outcomes-in-colorectal-cancer/ https://www.tempus.com/lens-library/characterizing-cldn18-2-and-her2-expression-in-gastroesophageal-cancer/ https://www.tempus.com/lens-library/characterizing-kras-variants-in-nsclc-with-multimodal-rwd/ https://www.tempus.com/lens-library/characterizing-the-immune-microenvironment-across-nsclc-metastatic-sites/ https://www.tempus.com/lens-library/comparing-molecular-landscapes-of-early-and-average-onset-enteropancreatic-nets/ https://www.tempus.com/lens-library/defining-high-risk-luad-subtypes-with-large-scale-rwd/ https://www.tempus.com/lens-library/defining-high-risk-mcspc-through-tumor-suppressor-gene-burden/ https://www.tempus.com/lens-library/developing-a-gene-expression-signature-for-first-line-treatment-in-metastatic-crc/ https://www.tempus.com/lens-library/dgkz-expression-and-vhl-mutations-in-metastatic-kidney-cancer/ https://www.tempus.com/lens-library/evaluating-kras-mutant-allele-dosage-impact-on-first-line-pdac-outcomes/ https://www.tempus.com/lens-library/genomic-and-transcriptomic-mediators-of-adc-resistance-in-breast-cancer/ https://www.tempus.com/lens-library/genomic-landscape-of-kras-g12c-mutations-across-diverse-tumor-types/ https://www.tempus.com/lens-library/genomic-profiling-of-hrd-in-soft-tissue-sarcomas/ https://www.tempus.com/lens-library/hgf-and-met-expression-predicts-survival-in-hpv-negative-head-and-neck-cancer/ https://www.tempus.com/lens-library/high-wrn-expression-and-immunotherapy-outcomes-in-msi-h-dmmr-colorectal-cancer/ https://www.tempus.com/lens-library/identifying-underdiagnosed-nut-carcinoma-with-rwd/ https://www.tempus.com/lens-library/igsf8-expression-differentially-modifies-response-to-immunotherapy-in-metastatic-melanoma/ https://www.tempus.com/lens-library/il33-expression-as-a-predictor-of-immunotherapy-response-in-nsclc/ https://www.tempus.com/lens-library/immune-profile-score-distribution-in-hpv16-positive-and-negative-hnscc/ https://www.tempus.com/lens-library/impact-of-b-cell-and-cd8-t-cell-infiltration-on-immunotherapy-outcomes-in-nsclc/ https://www.tempus.com/lens-library/impact-of-m2-like-macrophage-infiltration-on-rcc-immunotherapy-outcomes/ https://www.tempus.com/lens-library/impact-of-pik3r1-loss-of-function-on-survival-in-metastatic-breast-cancer/ https://www.tempus.com/lens-library/impact-of-vegf-expression-on-pembrolizumab-outcomes-in-mnsclc/ https://www.tempus.com/lens-library/integrating-ca125-and-ctdna-to-enhance-prognostic-precision-in-ovarian-cancer/ https://www.tempus.com/lens-library/investigating-lag-3-expression-as-a-biomarker-in-mrcc-with-multimodal-data/ https://www.tempus.com/lens-library/investigating-racial-disparities-in-survival-and-pd-l1-expression-in-mnsclc/ https://www.tempus.com/lens-library/lag3-expression-as-a-predictive-biomarker-for-1l-ici-in-melanoma/ https://www.tempus.com/lens-library/leveraging-multimodal-rwd-to-characterize-intratumor-heterogeneity-in-solid-tumors/ https://www.tempus.com/lens-library/molecular-and-clinical-characterization-of-her2-low-versus-her2-0-breast-cancer/ https://www.tempus.com/lens-library/molecular-and-clinical-landscape-of-esr1-and-pik3ca-co-mutations-in-hr-mbc/ https://www.tempus.com/lens-library/molecular-subtyping-of-sclc-and-its-implications-for-personalized-treatment-strategies/ https://www.tempus.com/lens-library/mutational-profiles-and-treatment-resistance-in-metastatic-tnbc/ https://www.tempus.com/lens-library/outcomes-analysis-in-her2-low-gastric-cancer-using-multimodal-rwd/ https://www.tempus.com/lens-library/prame-expression-stratifies-treatment-response-in-nsclc-histologies/ https://www.tempus.com/lens-library/predicting-adc-efficacy-with-pdo-models-and-real-world-data/ https://www.tempus.com/lens-library/predicting-osimertinib-outcomes-in-nsclc-using-liquid-biopsy-rwd/ https://www.tempus.com/lens-library/predicting-outcomes-in-nsclc-with-combined-cd8-and-pd-l1-biomarkers/ https://www.tempus.com/lens-library/predicting-palbociclib-efficacy-in-breast-cancer-with-organoid-derived-biomarkers/ https://www.tempus.com/lens-library/prognostic-impact-of-tp53-and-ppp2r1a-mutations-in-endometrial-cancer/ https://www.tempus.com/lens-library/rna-seq-immune-subtyping-to-optimize-immunotherapy-in-mnsclc/ https://www.tempus.com/lens-library/role-of-chromatin-remodeling-protein-arid1a-in-mll-af9-leukemogenesis/ https://www.tempus.com/lens-library/stratifying-hr-her2-breast-cancer-through-er-signaling-and-g2-m-molecular-signatures/ https://www.tempus.com/lens-library/transcriptional-and-immune-signatures-of-esr1-and-pik3ca-co-mutations-in-hr-mbc/ https://www.tempus.com/lens-library/transcriptomic-profiles-of-treatment-resistance-in-1l-mcrc/ https://www.tempus.com/lens-library/uncovering-resistance-mechanisms-in-adc-treated-urothelial-cancer-with-multimodal-rwd/ https://www.tempus.com/lens-library/unveiling-integrin-beta-6-prevalence-in-nsclc-with-real-world-data/ https://www.tempus.com/lens-library/validating-ec-molecular-subtypes-in-a-real-world-cohort/ https://www.tempus.com/lens-library/validating-ffpe-based-genomic-profiling-in-pancreatic-cancer/ https://www.tempus.com/life-sciences/ https://www.tempus.com/media-library/ https://www.tempus.com/media-library/eric-lefkofsky-1/ https://www.tempus.com/media-library/eric-lefkofsky-2/ https://www.tempus.com/media-library/tempus-lab-1/ https://www.tempus.com/media-library/tempus-lab-2/ https://www.tempus.com/media-library/tempus-lab-3/ https://www.tempus.com/media-library/tempus-lab-4/ https://www.tempus.com/media-library/tempus-lab-video/ https://www.tempus.com/media-library/tempus-lab-video-2/ https://www.tempus.com/media-library/tempus-lab-video-3/ https://www.tempus.com/media-library/tempus-lab-video-4/ https://www.tempus.com/media-library/tempus-lab-video-5/ https://www.tempus.com/media-library/tempus-lab-video-6/ https://www.tempus.com/media-library/tempus-lens-1/ https://www.tempus.com/media-library/tempus-logo-black/ https://www.tempus.com/media-library/tempus-logo-white/ https://www.tempus.com/neurology-psychiatry/ https://www.tempus.com/neuropsych-request-for-testing/ https://www.tempus.com/news/ https://www.tempus.com/news-1/pr/ https://www.tempus.com/news/an-operating-system-for-cancer/ https://www.tempus.com/news/do-we-have-the-technology-to-cure-pancreatic-cancer/ https://www.tempus.com/news/media-coverage/2024-forbes-healthcare-summit/ https://www.tempus.com/news/media-coverage/biocentury-2/ https://www.tempus.com/news/media-coverage/bioworld/ https://www.tempus.com/news/media-coverage/chicago-inno/ https://www.tempus.com/news/media-coverage/cleveland-clinic/ https://www.tempus.com/news/media-coverage/clinical-omics/ https://www.tempus.com/news/media-coverage/cnbc/ https://www.tempus.com/news/media-coverage/cnbc-2/ https://www.tempus.com/news/media-coverage/cnbc-2025/ https://www.tempus.com/news/media-coverage/cnbc-3/ https://www.tempus.com/news/media-coverage/cnbc-4/ https://www.tempus.com/news/media-coverage/fast-company-op-ed-we-need-health-data-banks-not-unlike-what-we-have-for-organ-donors/ https://www.tempus.com/news/media-coverage/fierce-healthcare/ https://www.tempus.com/news/media-coverage/forbes/ https://www.tempus.com/news/media-coverage/forbes-2/ https://www.tempus.com/news/media-coverage/forbes-3/ https://www.tempus.com/news/media-coverage/fortune/ https://www.tempus.com/news/media-coverage/fortune-brainstorm-health-conference-2020-patients-first-transforming-care-through-disruptive-technology/ https://www.tempus.com/news/media-coverage/fox-business/ https://www.tempus.com/news/media-coverage/genomeweb/ https://www.tempus.com/news/media-coverage/genomeweb-2/ https://www.tempus.com/news/media-coverage/humanx/ https://www.tempus.com/news/media-coverage/inside-indiana-business/ https://www.tempus.com/news/media-coverage/medcitynews/ https://www.tempus.com/news/media-coverage/milken-institute/ https://www.tempus.com/news/media-coverage/milken-institutes-future-of-health/ https://www.tempus.com/news/media-coverage/softbank-group/ https://www.tempus.com/news/media-coverage/stat-news/ https://www.tempus.com/news/media-coverage/tempus-and-medtronic-announce-alert-trial-results-showing-ai-driven-ehr-notifications-improve-treatment-for-significant-valvular-heart-disease/ https://www.tempus.com/news/media-coverage/the-atlantic/ https://www.tempus.com/news/partnerships/ayala-pharmaceuticals/ https://www.tempus.com/news/partnerships/city-of-hope/ https://www.tempus.com/news/partnerships/henry-ford-health/ https://www.tempus.com/news/partnerships/mayo-clinic/ https://www.tempus.com/news/partnerships/md-anderson-cancer-center/ https://www.tempus.com/news/partnerships/northwestern-university-baylor-university-cedar-sinai-university-of-pittsburgh/ https://www.tempus.com/news/partnerships/oneoncology/ https://www.tempus.com/news/partnerships/roswell-park-comprehensive-cancer-center/ https://www.tempus.com/news/partnerships/stanford-university/ https://www.tempus.com/news/partnerships/ucla-mattel-childrens-hospital/ https://www.tempus.com/news/partnerships/university-of-california-irvine/ https://www.tempus.com/news/partnerships/university-of-california-los-angeles/ https://www.tempus.com/news/partnerships/university-of-minnesota/ https://www.tempus.com/news/partnerships/university-of-washington/ https://www.tempus.com/news/partnerships/washington-university/ https://www.tempus.com/news/pr/a-decade-of-discovery-tempus-supported-almost-1500-research-projects-in-10-years/ https://www.tempus.com/news/pr/acquisition-of-ambry-genetics/ https://www.tempus.com/news/pr/american-medical-association-grants-pla-code-to-tempus-algorithmic-test-purist/ https://www.tempus.com/news/pr/asco-and-tempus-announce-collaboration-to-help-research-sites-identify-potential-participants-for-the-targeted-agent-and-profiling-utilization-tapur-study/ https://www.tempus.com/news/pr/bayer-and-tempus-initiate-collaboration-to-advance-patient-access-to-genomic-testing-and-precision-medicine/ https://www.tempus.com/news/pr/cancerlinq-engages-leading-technology-companies-tempus-and-precision-healthai-to-accelerate-data-driven-insights-to-oncologists-and-the-cancer-care-community/ https://www.tempus.com/news/pr/characterization-of-kras-mutation-variants-and-prevalence-of-kras-g12c-in-gastrointestinal-malignancies/ https://www.tempus.com/news/pr/clinical-breast-cancer-study-reveals-that-tempus-real-world-database-mirrors-overall-u-s-breast-cancer-population/ https://www.tempus.com/news/pr/cms-awards-tempus-with-advanced-diagnostic-laboratory-test-adlt-status-for-its-xt-cdx-test/ https://www.tempus.com/news/pr/community-health-network-collaborates-with-tempus-to-personalize-cancer-care-improve-patient-health-through-genomics-testing/ https://www.tempus.com/news/pr/cvs-health-launches-transform-oncology-care-program-to-help-improve-patient-outcomes-and-lower-overall-costs/ https://www.tempus.com/news/pr/dr-andrea-califano-joins-tempus-scientific-advisory-board-and-tempus-and-darwinhealth-partner-on-research-initiative/ https://www.tempus.com/news/pr/dr-arul-chinnaiyan-joins-tempus-as-scientific-adviser/ https://www.tempus.com/news/pr/dr-gary-palmer-joins-tempus-as-chief-medical-officer/ https://www.tempus.com/news/pr/dr-kevin-white-joins-tempus-as-president/ https://www.tempus.com/news/pr/erik-phelps-joins-tempus-as-executive-vice-president-and-general-counsel/ https://www.tempus.com/news/pr/fda-grants-breakthrough-device-designation-to-tempus-atrial-fibrillation-ecg-analysis-platform-developed-in-collaboration-with-geisinger/ https://www.tempus.com/news/pr/fda-grants-breakthrough-device-designation-to-tempus-hla-loh-companion-diagnostic-test/ https://www.tempus.com/news/pr/fight-colorectal-cancer-funds-tempus-research-fellow-to-identify-gaps-in-colorectal-cancer-research/ https://www.tempus.com/news/pr/geisinger-and-tempus-announce-collaboration-to-develop-cardiology-diagnostic-and-prognostic-tools-using-artificial-intelligence/ https://www.tempus.com/news/pr/genmab-and-tempus-enter-into-strategic-collaboration-agreement/ https://www.tempus.com/news/pr/gsk-announces-expanded-collaboration-with-tempus-in-precision-medicine-to-accelerate-rd/ https://www.tempus.com/news/pr/hello-world/ https://www.tempus.com/news/pr/illumina-and-tempus-partner-to-drive-the-future-of-precision-medicine-through-genomic-ai-innovation/ https://www.tempus.com/news/pr/introducing-tempus-one-in-the-ehr-with-integrated-guidelines/ https://www.tempus.com/news/pr/kronos-bio-and-tempus-announce-multi-year-collaboration-to-provide-kronos-bio-with-access-to-tempus-platform/ https://www.tempus.com/news/pr/leading-real-world-data-and-analytics-organizations-form-industry-coalition-to-advance-policies-to-support-regulatory-use-of-real-world-evidence/ https://www.tempus.com/news/pr/molecular-twin-initiative-will-help-advance-precision-cancer-treatment/ https://www.tempus.com/news/pr/nature-biotechnology-study-reveals-that-tempus-xt-platform-increases-cancer-patients-personalized-therapeutic-opportunities/ https://www.tempus.com/news/pr/new-cms-decision-provides-medicare-coverage-for-the-clinical-use-of-the-tempus-ecg-af-device/ https://www.tempus.com/news/pr/new-genomics-technology-puts-precision-oncology-into-practice-at-rush/ https://www.tempus.com/news/pr/northwestern-medicine-becomes-first-health-system-to-integrate-tempus-generative-ai-co-pilot-david-into-its-ehr-platform/ https://www.tempus.com/news/pr/northwestern-medicine-selects-tempus-to-expand-genomic-testing/ https://www.tempus.com/news/pr/npj-precision-oncology-publishes-tempus-study-on-validation-of-its-hla-loh-investigational-assay/ https://www.tempus.com/news/pr/personalis-and-tempus-enter-into-a-strategic-collaboration-to-advance-cancer-testing/ https://www.tempus.com/news/pr/researchers-find-ai-can-predict-new-atrial-fibrillation-stroke-risk/ https://www.tempus.com/news/pr/study-confirms-that-americans-neglected-their-healthcare-during-covid-19-pandemic/ https://www.tempus.com/news/pr/tempus-accelerates-its-ehr-integration-scope-with-epic/ https://www.tempus.com/news/pr/tempus-achieves-record-total-contract-value-exceeding-1-1-billion/ https://www.tempus.com/news/pr/tempus-adds-tempus-xf-a-liquid-biopsy-assay-to-sequencing-capabilities/ https://www.tempus.com/news/pr/tempus-ai-inc-announces-proposed-convertible-senior-notes-offering-to-optimize-capital-structure-and-reduce-interest-expense/ https://www.tempus.com/news/pr/tempus-and-blood-cancer-united-announce-collaboration-to-develop-one-of-the-largest-pediatric-acute-myeloid-leukemia-real-world-data-registries/ https://www.tempus.com/news/pr/tempus-and-cleveland-clinic-collaborate-on-personalized-medicine-initiative/ https://www.tempus.com/news/pr/tempus-and-feist-weiller-cancer-center-at-lsu-health-shreveport-announce-brain-cancer-research-collaboration/ https://www.tempus.com/news/pr/tempus-and-geisinger-find-ecg-based-ai-model-can-predict-undiagnosed-structural-heart-disease/ https://www.tempus.com/news/pr/tempus-and-huntsman-cancer-institute-at-the-university-of-utah-partnering-on-pancreatic-cancer-research-initiative/ https://www.tempus.com/news/pr/tempus-and-ifli-announce-study-to-advance-follicular-lymphoma-research/ https://www.tempus.com/news/pr/tempus-and-labcorp-announce-collaboration-to-accelerate-clinical-trial-patient-participation/ https://www.tempus.com/news/pr/tempus-and-leidos-biomedical-research-inc-launch-effort-to-enhance-the-cancer-genome-atlas/ https://www.tempus.com/news/pr/tempus-and-mary-crowley-cancer-research-launch-a-new-lung-cancer-initiative/ https://www.tempus.com/news/pr/tempus-and-northwestern-expand-partnership-to-accelerate-personalized-medicine-efforts/ https://www.tempus.com/news/pr/tempus-and-northwestern-expand-partnership-to-accelerate-personalized-medicine-efforts-2/ https://www.tempus.com/news/pr/tempus-and-northwestern-medicine-announce-collaboration-to-bring-practical-application-of-ai-to-healthcare/ https://www.tempus.com/news/pr/tempus-and-northwesterns-lurie-cancer-center-announce-personalized-medicine-partnership-for-cancer-patients/ https://www.tempus.com/news/pr/tempus-and-nyu-langone-health-announce-strategic-research-collaboration-to-advance-precision-oncology/ https://www.tempus.com/news/pr/tempus-and-penns-abramson-cancer-center-expand-genomic-collaboration/ https://www.tempus.com/news/pr/tempus-and-precision-health-informatics-announce-precision-medicine-collaboration/ https://www.tempus.com/news/pr/tempus-and-predicta-biosciences-announce-collaboration-to-expand-life-sciences-access-to-ultrasensitive-whole-genome-sequencing-assay-for-hematologic-malignancies-and-mrd-monitoring/ https://www.tempus.com/news/pr/tempus-and-rush-university-medical-center-announce-personalized-medicine-partnership/ https://www.tempus.com/news/pr/tempus-and-rush-university-medical-center-partnering-to-expand-hospitals-first-biobank/ https://www.tempus.com/news/pr/tempus-and-sanford-health-collaborate-on-personalized-medicine-initiative/ https://www.tempus.com/news/pr/tempus-and-stemline-therapeutics-inc-a-subsidiary-of-the-menarini-group-announce-collaboration-to-implement-tempus-next-an-ai-enabled-care-pathway-intelligence-platform-to-support-patients-with-m/ https://www.tempus.com/news/pr/tempus-and-the-ohsu-knight-cancer-institute-collaborating-on-personalized-medicine-data-initiative/ https://www.tempus.com/news/pr/tempus-and-the-parker-institute-for-cancer-immunotherapy-work-together-to-analyze-data-to-help-inform-immunotherapy-treatments/ https://www.tempus.com/news/pr/tempus-and-university-hospitals-seidman-cancer-center-announce-joint-effort-to-customize-treatment-for-cancer-patients/ https://www.tempus.com/news/pr/tempus-and-university-of-california-davis-comprehensive-cancer-center-announce-personalized-medicine-partnership-for-cancer-patients/ https://www.tempus.com/news/pr/tempus-and-university-of-chicago-medicine-collaborate-on-pancreatic-cancer-research-project/ https://www.tempus.com/news/pr/tempus-and-university-of-michigan-announce-partnership-for-cancer-patients/ https://www.tempus.com/news/pr/tempus-and-university-of-michigan-collaborate-on-breast-cancer-initiative/ https://www.tempus.com/news/pr/tempus-and-usc-announce-strategic-collaboration-to-accelerate-ai-driven-precision-medicine/ https://www.tempus.com/news/pr/tempus-and-vanderbilt-ingram-cancer-center-announce-data-initiative-to-improve-outcomes-for-cancer-patients/ https://www.tempus.com/news/pr/tempus-and-yale-announce-research-collaboration-to-accelerate-covid-19-test-development/ https://www.tempus.com/news/pr/tempus-announces-10-abstracts-accepted-for-presentation-at-the-2025-american-society-of-clinical-oncology-annual-meeting/ https://www.tempus.com/news/pr/tempus-announces-100-million-in-series-g-financing/ https://www.tempus.com/news/pr/tempus-announces-110-million-in-series-e-financing/ https://www.tempus.com/news/pr/tempus-announces-130m-raised/ https://www.tempus.com/news/pr/tempus-announces-14-abstracts-accepted-for-presentation-at-the-american-society-of-clinical-oncology-annual-meeting-2022/ https://www.tempus.com/news/pr/tempus-announces-18-abstracts-accepted-for-presentation-at-the-american-association-for-cancer-research-annual-meeting-2024/ https://www.tempus.com/news/pr/tempus-announces-18-abstracts-accepted-for-presentation-at-the-american-association-for-cancer-research-annual-meeting-2025/ https://www.tempus.com/news/pr/tempus-announces-200-million-in-series-f-financing/ https://www.tempus.com/news/pr/tempus-announces-200-million-series-g-2-financing/ https://www.tempus.com/news/pr/tempus-announces-275-million-in-funding/ https://www.tempus.com/news/pr/tempus-announces-31-abstracts-for-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026/ https://www.tempus.com/news/pr/tempus-announces-a-collaboration-with-genialis-to-develop-rna-based-biomarker-algorithms/ https://www.tempus.com/news/pr/tempus-announces-a-collaboration-with-verastem-to-develop-cdx-for-first-ever-fda-approved-kras-mutant-recurrent-low-grade-serous-ovarian-cancer-combination-treatment/ https://www.tempus.com/news/pr/tempus-announces-abdul-hamid-halabi-as-senior-vice-president-of-data-products/ https://www.tempus.com/news/pr/tempus-announces-abstracts-accepted-for-presentation-at-the-american-association-for-cancer-research-annual-meeting-2022/ https://www.tempus.com/news/pr/tempus-announces-abstracts-to-be-presented-at-the-american-association-of-cancer-research-annual-meeting-2021/ https://www.tempus.com/news/pr/tempus-announces-acquisition-of-deep-6-ai/ https://www.tempus.com/news/pr/tempus-announces-additional-80-million-in-financing/ https://www.tempus.com/news/pr/tempus-announces-agreement-with-janssen-rd-to-leverage-ai-ml-and-real-world-evidence-to-enhance-the-discovery-and-development-of-oncology-therapies/ https://www.tempus.com/news/pr/tempus-announces-agreement-with-the-united-states-department-of-veterans-affairs-national-precision-oncology-program-to-expand-access-to-genomic-testing-for-veterans-with-cancer/ https://www.tempus.com/news/pr/tempus-announces-brca-focused-initiative-in-partnership-with-penns-basser-center-for-brca/ https://www.tempus.com/news/pr/tempus-announces-broad-launch-of-tempus-one/ https://www.tempus.com/news/pr/tempus-announces-christopher-mason-phd-joins-as-vice-president-of-emerging-genome-technology/ https://www.tempus.com/news/pr/tempus-announces-collaboration-with-ifli-aimed-at-supporting-development-of-targeted-therapies-for-follicular-lymphoma/ https://www.tempus.com/news/pr/tempus-announces-collaboration-with-jw-pharmaceutical-to-apply-real-world-data-and-biological-modeling-to-enhance-early-research-and-development/ https://www.tempus.com/news/pr/tempus-announces-collaboration-with-median-technologies-to-integrate-ai-powered-lung-cancer-screening-into-the-pixel-platform/ https://www.tempus.com/news/pr/tempus-announces-collaboration-with-northwestern-universitys-abrams-research-center-on-neurogenomics-to-leverage-ai-for-alzheimers-disease-research/ https://www.tempus.com/news/pr/tempus-announces-collaboration-with-the-childrens-oncology-group-to-expand-access-to-genomic-testing-for-pediatric-cancer-patients/ https://www.tempus.com/news/pr/tempus-announces-collaboration-with-united-therapeutics-to-study-use-of-ai-to-detect-patients-at-risk-for-pulmonary-hypertension/ https://www.tempus.com/news/pr/tempus-announces-collaboration-with-whitehawk-therapeutics-to-advance-biomarker-driven-oncology-research/ https://www.tempus.com/news/pr/tempus-announces-companion-diagnostic-collaboration-with-a2-biotherapeutics/ https://www.tempus.com/news/pr/tempus-announces-companion-diagnostic-collaboration-with-kartos-therapeutics/ https://www.tempus.com/news/pr/tempus-announces-companion-diagnostic-collaboration-with-tscan-therapeutics/ https://www.tempus.com/news/pr/tempus-announces-dr-ezra-cohen-as-chief-medical-officer-of-oncology/ https://www.tempus.com/news/pr/tempus-announces-dr-kate-sasser-as-chief-scientific-officer/ https://www.tempus.com/news/pr/tempus-announces-dr-ned-sharpless-as-a-senior-strategic-advisor/ https://www.tempus.com/news/pr/tempus-announces-eight-abstracts-accepted-for-presentation-at-the-2023-society-for-immunotherapy-of-cancer-annual-meeting/ https://www.tempus.com/news/pr/tempus-announces-eight-abstracts-accepted-for-presentation-at-the-2026-asco-gastrointestinal-cancers-symposium/ https://www.tempus.com/news/pr/tempus-announces-eleven-abstracts-accepted-for-presentation-at-the-2021-american-society-of-clinical-oncology-annual-meeting/ https://www.tempus.com/news/pr/tempus-announces-expanded-data-and-sequencing-collaboration-with-remix-therapeutics-to-advance-novel-treatments/ https://www.tempus.com/news/pr/tempus-announces-expansion-into-infectious-diseases-starting-with-covid-19/ https://www.tempus.com/news/pr/tempus-announces-expansion-of-collaboration-with-astrazeneca-to-leverage-tempus-next-to-support-guideline-directed-biomarker-testing-in-nsclc/ https://www.tempus.com/news/pr/tempus-announces-expansion-of-collaboration-with-takeda-to-leverage-multimodal-real-world-datasets-and-biological-model-systems-in-oncology-research-and-development/ https://www.tempus.com/news/pr/tempus-announces-five-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2023/ https://www.tempus.com/news/pr/tempus-announces-four-abstracts-accepted-for-presentation-at-the-2024-san-antonio-breast-cancer-symposium/ https://www.tempus.com/news/pr/tempus-announces-four-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2024/ https://www.tempus.com/news/pr/tempus-announces-glioblastoma-data-offering-in-collaboration-with-asco/ https://www.tempus.com/news/pr/tempus-announces-its-first-ever-whole-genome-sequencing-assay-xh/ https://www.tempus.com/news/pr/tempus-announces-latest-immunotherapy-project/ https://www.tempus.com/news/pr/tempus-announces-leadership-team-expansion-including-chief-commercial-officer-and-chief-financial-officer/ https://www.tempus.com/news/pr/tempus-announces-medicare-coverage-for-tempusxt-across-solid-tumor-and-hematologic-malignancies/ https://www.tempus.com/news/pr/tempus-announces-national-launch-of-olivia-its-ai-enabled-personal-health-concierge-app-for-patients/ https://www.tempus.com/news/pr/tempus-announces-new-ctdna-assay-xm-monitor/ https://www.tempus.com/news/pr/tempus-announces-new-features-to-its-smart-physician-platform-hub/ https://www.tempus.com/news/pr/tempus-announces-new-genomic-sequencing-lab-in-research-triangle-park-in-durham-nc/ https://www.tempus.com/news/pr/tempus-announces-new-initiative-to-support-physicians-efforts-to-deliver-personalized-medicine/ https://www.tempus.com/news/pr/tempus-announces-new-multi-omics-collaboration-with-actuate-therapeutics/ https://www.tempus.com/news/pr/tempus-announces-new-strategic-collaboration-with-pfizer-to-advance-oncology-therapeutic-development/ https://www.tempus.com/news/pr/tempus-announces-new-strategic-collaboration-with-recursion-to-advance-therapeutic-development/ https://www.tempus.com/news/pr/tempus-announces-new-study-in-jco-precision-oncology-validating-purist-algorithm-for-enhanced-therapy-selection-in-pancreatic-cancer/ https://www.tempus.com/news/pr/tempus-announces-new-subscription-service-for-pharma-biotech-and-academic-researchers/ https://www.tempus.com/news/pr/tempus-announces-next-phase-of-biological-modeling-efforts/ https://www.tempus.com/news/pr/tempus-announces-nine-abstracts-accepted-for-presentation-at-the-2024-society-for-immunotherapy-of-cancer-annual-meeting/ https://www.tempus.com/news/pr/tempus-announces-notetaker-its-ai-powered-clinical-assistant-for-psychiatry/ https://www.tempus.com/news/pr/tempus-announces-novel-pan-cancer-hrd-rna-algorithm/ https://www.tempus.com/news/pr/tempus-announces-open-enrollment-for-study-in-collaboration-with-gsk-to-evaluate-niraparib-in-advanced-solid-tumor-patients-with-palb2-mutations/ https://www.tempus.com/news/pr/tempus-announces-participation-in-national-cancer-institutes-combomatch-trials/ https://www.tempus.com/news/pr/tempus-announces-preliminary-fourth-quarter-and-full-year-2024-results/ https://www.tempus.com/news/pr/tempus-announces-preliminary-fourth-quarter-and-full-year-2025-results/ https://www.tempus.com/news/pr/tempus-announces-pricing-of-initial-public-offering/ https://www.tempus.com/news/pr/tempus-announces-pricing-of-upsized-offering-of-650-million-of-convertible-senior-notes/ https://www.tempus.com/news/pr/tempus-announces-prospective-psychiatric-study/ https://www.tempus.com/news/pr/tempus-announces-prospective-study-for-biomarker-discovery-in-small-cell-lung-cancer/ https://www.tempus.com/news/pr/tempus-announces-real-world-data-collaboration-with-biontech/ https://www.tempus.com/news/pr/tempus-announces-real-world-data-driven-program-to-accelerate-precision-oncology-research/ https://www.tempus.com/news/pr/tempus-announces-research-collaboration-with-bristol-myers-squibb-to-apply-multimodal-ai-approaches/ https://www.tempus.com/news/pr/tempus-announces-research-collaboration-with-intermountain-healthcare-to-advance-precision-oncology-research/ https://www.tempus.com/news/pr/tempus-announces-second-sequencing-collaboration-with-lilly-to-expand-patient-access-to-genomic-testing/ https://www.tempus.com/news/pr/tempus-announces-sequencing-and-computational-biology-collaboration-with-kronos-bio-to-support-the-development-of-cdk9-inhibitor-kb-0742/ https://www.tempus.com/news/pr/tempus-announces-sequencing-collaboration-with-lilly-to-expand-access-to-genomic-testing/ https://www.tempus.com/news/pr/tempus-announces-seven-abstracts-accepted-for-presentation-at-the-american-association-for-cancer-research-annual-meeting-2023/ https://www.tempus.com/news/pr/tempus-announces-six-abstracts-accepted-for-poster-presentation-at-the-2021-san-antonio-breast-cancer-symposium/ https://www.tempus.com/news/pr/tempus-announces-six-abstracts-accepted-for-poster-presentation-at-the-2022-san-antonio-breast-cancer-symposium/ https://www.tempus.com/news/pr/tempus-announces-six-abstracts-accepted-for-presentation-at-the-2022-society-for-immunotherapy-of-cancer-annual-meeting/ https://www.tempus.com/news/pr/tempus-announces-six-abstracts-accepted-for-presentation-at-the-american-heart-association-scientific-sessions-2022/ https://www.tempus.com/news/pr/tempus-announces-six-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2025/ https://www.tempus.com/news/pr/tempus-announces-six-abstracts-accepted-for-presentation-at-the-society-for-immunotherapy-of-cancer-annual-meeting-2025/ https://www.tempus.com/news/pr/tempus-announces-six-posters-accepted-for-presentation-at-ispor-2025/ https://www.tempus.com/news/pr/tempus-announces-strategic-collaboration-agreement-with-merck-to-accelerate-ai-driven-precision-medicine/ https://www.tempus.com/news/pr/tempus-announces-strategic-collaboration-with-daiichi-sankyo-to-advance-ai-driven-biomarker-discovery-and-clinical-differentiation-across-an-adc-clinical-program/ https://www.tempus.com/news/pr/tempus-announces-strategic-collaboration-with-gilead-to-advance-oncology-rd-through-rwe/ https://www.tempus.com/news/pr/tempus-announces-strategic-collaboration-with-janssen-applying-data-science-to-enhance-therapeutic-development/ https://www.tempus.com/news/pr/tempus-announces-study-highlighting-the-role-of-advanced-genomic-profiling-features-in-identifying-clinically-actionable-findings/ https://www.tempus.com/news/pr/tempus-announces-ten-abstracts-accepted-for-presentation-at-the-2025-san-antonio-breast-cancer-symposium/ https://www.tempus.com/news/pr/tempus-announces-the-acquisition-of-akesogen/ https://www.tempus.com/news/pr/tempus-announces-the-acquisition-of-highline-sciences/ https://www.tempus.com/news/pr/tempus-announces-the-acquisition-of-mpirik/ https://www.tempus.com/news/pr/tempus-announces-the-acquisition-of-paige/ https://www.tempus.com/news/pr/tempus-announces-the-addition-of-ari-caroline-and-iker-huerga-to-its-leadership-team/ https://www.tempus.com/news/pr/tempus-announces-the-addition-of-dr-kimberly-blackwell-as-chief-medical-officer-and-dr-kenneth-carson-as-vice-president-of-clinical-solutions/ https://www.tempus.com/news/pr/tempus-announces-the-appointment-of-david-r-epstein-to-its-board-of-directors/ https://www.tempus.com/news/pr/tempus-announces-the-appointment-of-nobel-laureate-and-crispr-co-inventor-dr-jennifer-doudna-to-its-board-of-directors/ https://www.tempus.com/news/pr/tempus-announces-the-appointment-of-scott-gottlieb-md-to-its-board-of-directors/ https://www.tempus.com/news/pr/tempus-announces-the-clinical-launch-of-its-immune-profile-score-algorithmic-test/ https://www.tempus.com/news/pr/tempus-announces-the-clinical-launch-of-its-mrd-testing-portfolio/ https://www.tempus.com/news/pr/tempus-announces-the-clinical-launch-of-p-msi-its-msi-high-predictive-algorithm-for-patients-with-prostate-cancer/ https://www.tempus.com/news/pr/tempus-announces-the-gemini-non-small-cell-lung-cancer-study/ https://www.tempus.com/news/pr/tempus-announces-the-launch-of-paige-predict/ https://www.tempus.com/news/pr/tempus-announces-the-national-launch-of-fda-approved-xt-cdx-test/ https://www.tempus.com/news/pr/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022/ https://www.tempus.com/news/pr/tempus-announces-time-trial-service-a-new-integrated-molecular-evaluation-that-leverages-artificial-intelligence-to-rapidly-match-cancer-patients-to-clinical-trials/ https://www.tempus.com/news/pr/tempus-ce-marks-its-broad-panel-genomic-sequencing-and-algorithmic-diagnostic-tests/ https://www.tempus.com/news/pr/tempus-ce-marks-its-broad-panel-genomic-sequencing-test-xt/ https://www.tempus.com/news/pr/tempus-contributes-de-identified-cancer-data-to-planned-data-enclave/ https://www.tempus.com/news/pr/tempus-edge-platform-leverages-data-ai-to-identify-therapeutic-options-for-patients-earlier-in-the-treatment-journey/ https://www.tempus.com/news/pr/tempus-enters-multi-year-strategic-collaboration-with-boehringer-ingelheim-to-advance-its-cancer-pipeline/ https://www.tempus.com/news/pr/tempus-exhibits-16-abstracts-at-the-2024-american-society-of-clinical-oncology-annual-meeting/ https://www.tempus.com/news/pr/tempus-exhibits-20-abstracts-at-the-2023-american-society-of-clinical-oncology-annual-meeting/ https://www.tempus.com/news/pr/tempus-exhibits-4-abstracts-at-the-2025-american-college-of-cardiology-annual-meeting/ https://www.tempus.com/news/pr/tempus-expanding-access-to-its-next-generation-sequencing-tests-as-an-in-network-provider-for-cigna/ https://www.tempus.com/news/pr/tempus-expands-ai-enabled-care-pathway-intelligence-platform-into-breast-cancer/ https://www.tempus.com/news/pr/tempus-expands-immuno-oncology-portfolio-with-launch-of-ai-enabled-multimodal-immune-profile-algorithmic-tests/ https://www.tempus.com/news/pr/tempus-expands-its-management-team-with-the-appointment-of-lauren-silvis-as-senior-vice-president-of-external-affairs/ https://www.tempus.com/news/pr/tempus-expands-leadership-team-with-the-appointment-of-joel-dudley-phd-as-senior-vice-president-of-research/ https://www.tempus.com/news/pr/tempus-expands-licensing-agreement-with-bristol-myers-squibb-to-analyze-and-discover-rna-based-targets/ https://www.tempus.com/news/pr/tempus-expands-strategic-collaboration-with-bristol-myers-squibb-to-enhance-the-probability-of-success-across-clinical-development-programs-in-oncology-and-neuroscience/ https://www.tempus.com/news/pr/tempus-incorporates-oncokb-data-and-nccn-guidelines-into-its-clinical-reports/ https://www.tempus.com/news/pr/tempus-introduces-a-new-predictive-diagnostic-test-to-its-growing-collection-of-algorithms/ https://www.tempus.com/news/pr/tempus-introduces-ai-enabled-assistant-tempus-one-into-lens-data-analytics-platform-to-accelerate-research/ https://www.tempus.com/news/pr/tempus-introduces-fuses-a-program-designed-to-transform-therapeutic-research-and-build-the-largest-diagnostic-platform-using-its-novel-foundation-model/ https://www.tempus.com/news/pr/tempus-introduces-its-ai-enabled-care-pathway-intelligence-platform-tempus-next/ https://www.tempus.com/news/pr/tempus-introduces-loop-an-ai-powered-target-discovery-and-validation-platform/ https://www.tempus.com/news/pr/tempus-introduces-new-her2-folr1-testing-solutions-to-support-personalized-patient-care/ https://www.tempus.com/news/pr/tempus-introduces-taap-a-collaborative-research-platform-to-develop-and-deploy-algorithmic-diagnostics/ https://www.tempus.com/news/pr/tempus-introduces-workspaces-into-its-lens-data-analytics-platform/ https://www.tempus.com/news/pr/tempus-introduces-xm-an-assay-to-monitor-immunotherapy-response-for-patients-with-advanced-cancers/ https://www.tempus.com/news/pr/tempus-introduces-xm-to-assess-minimal-residual-disease-mrd-in-patients-with-colorectal-cancer-crc-for-research-use-only/ https://www.tempus.com/news/pr/tempus-is-now-an-in-network-provider-for-humana-expanding-access-to-its-next-generation-sequencing-tests/ https://www.tempus.com/news/pr/tempus-launches-artera-ai-prostate-test-for-metastatic-patients-marking-the-first-prostate-digital-pathology-algorithm-in-the-tempus-ecosystem-available-for-clinical-use/ https://www.tempus.com/news/pr/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care/ https://www.tempus.com/news/pr/tempus-launches-beta-version-of-olivia-its-ai-enabled-personal-health-concierge-app-for-patients/ https://www.tempus.com/news/pr/tempus-launches-covid-19-specific-clinical-and-research-initiatives-for-oncology/ https://www.tempus.com/news/pr/tempus-launches-covid-19-test-with-at-home-sample-collection-and-covid-19-next-generation-sequencing/ https://www.tempus.com/news/pr/tempus-launches-first-cardiology-prospective-study-for-its-ai-enabled-predictive-tests/ https://www.tempus.com/news/pr/tempus-launches-hereditary-cancer-germline-assay-xg/ https://www.tempus.com/news/pr/tempus-launches-new-mobile-app-to-make-clinical-and-genomic-data-more-accessible-to-physicians-at-the-point-of-care/ https://www.tempus.com/news/pr/tempus-launches-new-precision-medicine-driven-tests-tempushrd-and-tempusto/ https://www.tempus.com/news/pr/tempus-launches-prospective-priority-research-study-and-increases-support-for-oncology-research-initiatives-despite-pandemic-challenges/ https://www.tempus.com/news/pr/tempus-launches-psychiatric-real-world-data-program-to-advance-personalized-medicine/ https://www.tempus.com/news/pr/tempus-launches-standalone-rna-sequencing-test-xr/ https://www.tempus.com/news/pr/tempus-launches-tempus-xe-whole-exome-sequencing-to-empower-data-driven-cancer-care-and-research/ https://www.tempus.com/news/pr/tempus-molecular-profiling-integration-now-available-through-flatirons-oncoemr/ https://www.tempus.com/news/pr/tempus-named-to-times-list-of-the-10-most-influential-health-and-life-science-companies-of-2026/ https://www.tempus.com/news/pr/tempus-next-launches-new-algorithm-to-close-care-gaps-in-guideline-directed-ihc-testing-starting-with-her2/ https://www.tempus.com/news/pr/tempus-now-an-in-network-provider-for-blue-cross-blue-shield-illinois-blue-shield-california-and-more/ https://www.tempus.com/news/pr/tempus-one-introduces-new-genai-capabilities-to-query-millions-of-unstructured-documents-for-research-and-clinical-care/ https://www.tempus.com/news/pr/tempus-opens-sequencing-lab/ https://www.tempus.com/news/pr/tempus-publishes-study-highlighting-benefits-of-concurrent-rna-and-dna-sequencing-in-advanced-cancer-care/ https://www.tempus.com/news/pr/tempus-publishes-study-validating-the-benefits-of-xf-its-comprehensive-liquid-biopsy-assay-for-therapy-selection/ https://www.tempus.com/news/pr/tempus-receives-u-s-fda-510k-clearance-for-tempus-ecg-af-an-ai-based-algorithm-that-identifies-patients-at-increased-risk-of-afib/ https://www.tempus.com/news/pr/tempus-receives-u-s-fda-510k-clearance-for-tempus-ecg-low-ef-software/ https://www.tempus.com/news/pr/tempus-receives-u-s-fda-510k-clearance-for-tempus-xr-ivd-its-rna-ngs-in-vitro-diagnostic-device/ https://www.tempus.com/news/pr/tempus-receives-u-s-fda-approval-for-xt-cdx-a-ngs-based-in-vitro-diagnostic-device/ https://www.tempus.com/news/pr/tempus-receives-u-s-fda-special-510k-clearance-for-updated-tempus-pixel-device/ https://www.tempus.com/news/pr/tempus-releases-new-data-at-aacr-showcasing-ways-to-analyze-multimodal-data-to-highlight-potential-therapeutic-routes-for-her2-directed-antibody-drug-conjugates-in-several-tumor-types/ https://www.tempus.com/news/pr/tempus-reports-first-quarter-2025-results/ https://www.tempus.com/news/pr/tempus-reports-first-quarter-2026-results/ https://www.tempus.com/news/pr/tempus-reports-fourth-quarter-and-full-year-2024-results/ https://www.tempus.com/news/pr/tempus-reports-fourth-quarter-and-full-year-2025-results/ https://www.tempus.com/news/pr/tempus-reports-second-quarter-2024-results/ https://www.tempus.com/news/pr/tempus-reports-second-quarter-2025-results/ https://www.tempus.com/news/pr/tempus-reports-third-quarter-2024-results-and-agreement-to-acquire-ambry-genetics/ https://www.tempus.com/news/pr/tempus-reports-third-quarter-2025-results/ https://www.tempus.com/news/pr/tempus-reveals-its-ai-driven-ips-test-more-accurately-predicts-immunotherapy-benefit-compared-to-conventional-biomarkers/ https://www.tempus.com/news/pr/tempus-selected-as-sequencing-and-analytics-provider-by-the-prostate-cancer-clinical-trials-consortium-forphase-ii-clinical-trial/ https://www.tempus.com/news/pr/tempus-selected-by-arpa-h-to-provide-cro-and-testing-services-for-the-adapt-program-advancing-precision-cancer-therapy/ https://www.tempus.com/news/pr/tempus-selected-by-pancreatic-cancer-action-network-as-partner-for-new-personalized-medicine-initiative/ https://www.tempus.com/news/pr/tempus-signs-expanded-strategic-agreements-with-astrazeneca-and-pathos-to-develop-the-largest-multimodal-foundation-model-in-oncology/ https://www.tempus.com/news/pr/tempus-signs-strategic-collaboration-agreement-with-astrazeneca-to-advance-oncology-therapeutics/ https://www.tempus.com/news/pr/tempus-submits-pma-application-to-the-fda-for-its-xt-onco-assay/ https://www.tempus.com/news/pr/tempus-surpasses-500-research-publications/ https://www.tempus.com/news/pr/tempus-teams-with-major-academic-medical-center-to-advance-treatment-options-for-patients-diagnosed-with-aggressive-brain-cancer/ https://www.tempus.com/news/pr/tempus-time-network-expands-support-of-phase-i-clinical-trials-to-accelerate-activation-and-enrollment/ https://www.tempus.com/news/pr/tempus-time-trial-program-reaches-critical-scale-and-operational-milestones/ https://www.tempus.com/news/pr/tempus-to-assist-university-of-california-san-diego-in-personalizedmedicine-initiative/ https://www.tempus.com/news/pr/tempus-to-collaborate-with-cancerlinq-llc-and-u-s-food-and-drug-administration-on-checkpoint-inhibitors/ https://www.tempus.com/news/pr/tempus-to-host-inaugural-investor-day-on-may-29-2026/ https://www.tempus.com/news/pr/tempus-to-launch-largest-clinically-available-liquid-biopsy-panel-xf/ https://www.tempus.com/news/pr/tempus-to-participate-in-morgan-stanleys-23nd-annual-global-healthcare-conference/ https://www.tempus.com/news/pr/tempus-to-participate-in-td-cowens-4th-annual-tools-dx-revolution-conference/ https://www.tempus.com/news/pr/tempus-to-participate-in-the-morgan-stanley-technology-media-and-telecom-conference/ https://www.tempus.com/news/pr/tempus-to-participate-in-the-morgan-stanley-technology-media-telecom-conference/ https://www.tempus.com/news/pr/tempus-to-participate-in-the-nci-match-clinical-trial/ https://www.tempus.com/news/pr/tempus-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference/ https://www.tempus.com/news/pr/tempus-to-participate-in-the-piper-sandler-37th-annual-healthcare-conference/ https://www.tempus.com/news/pr/tempus-to-participate-in-the-stifel-2025-healthcare-conference/ https://www.tempus.com/news/pr/tempus-to-present-at-43rd-annual-j-p-morgan-healthcare-conference/ https://www.tempus.com/news/pr/tempus-to-present-at-44th-annual-j-p-morgan-healthcare-conference/ https://www.tempus.com/news/pr/tempus-to-present-at-td-cowens-45th-annual-health-care-conference/ https://www.tempus.com/news/pr/tempus-to-present-at-the-24th-annual-needham-virtual-healthcare-conference/ https://www.tempus.com/news/pr/tempus-to-present-at-the-25th-annual-needham-virtual-healthcare-conference/ https://www.tempus.com/news/pr/tempus-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference/ https://www.tempus.com/news/pr/tempus-to-present-at-the-morgan-stanley-22nd-annual-global-healthcare-conference/ https://www.tempus.com/news/pr/tempus-to-present-at-the-william-blair-45th-annual-growth-stock-conference/ https://www.tempus.com/news/pr/tempus-to-report-first-quarter-2025-financial-results-on-may-6/ https://www.tempus.com/news/pr/tempus-to-report-first-quarter-2026-financial-results-on-may-5/ https://www.tempus.com/news/pr/tempus-to-report-fourth-quarter-and-full-year-2024-financial-results-on-february-24/ https://www.tempus.com/news/pr/tempus-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-24/ https://www.tempus.com/news/pr/tempus-to-report-second-quarter-2024-financial-results-on-august-6/ https://www.tempus.com/news/pr/tempus-to-report-second-quarter-2025-financial-results-on-august-8/ https://www.tempus.com/news/pr/tempus-to-report-third-quarter-2024-financial-results-on-november-7/ https://www.tempus.com/news/pr/tempus-to-report-third-quarter-2025-financial-results-on-november-4/ https://www.tempus.com/news/pr/tempus-unveils-a-breakthrough-in-ai-for-oncologists-tempus-one/ https://www.tempus.com/news/pr/tempus-unveils-advisory-board-featuring-leading-physicians-from-across-the-u-s/ https://www.tempus.com/news/pr/tempus-unveils-ai-enabled-smart-tests-across-disease-types/ https://www.tempus.com/news/pr/tempus-unveils-its-lens-platform-offering-unparalleled-access-to-one-of-the-worlds-largest-de-identified-clinical-and-molecular-datasets/ https://www.tempus.com/news/pr/tempus-unveils-its-scalable-tumor-organoid-screening-platform-in-cell-reports-study/ https://www.tempus.com/news/pr/tempus-unveils-tempus-o-a-platform-to-structure-and-annotate-clinical-data-at-scale/ https://www.tempus.com/news/pr/tempus-unveils-tempus-xt-595-gene-panel-aimed-at-empowering-data-driven-cancer-care/ https://www.tempus.com/news/pr/tempus-welcomes-city-of-hope-comprehensive-cancer-center-to-tempus-plus-community/ https://www.tempus.com/news/pr/tempus-welcomes-rush-university-medical-center-to-tempus-plus-community/ https://www.tempus.com/news/pr/tempus-welcomes-unc-lineberger-comprehensive-cancer-center-to-tempus-plus-community/ https://www.tempus.com/news/pr/tempus-xf-liquid-biopsy-assay-demonstrates-extensive-analytical-and-clinical-validity-in-npj-precision-oncology-study/ https://www.tempus.com/news/pr/tempus-xo-assay-validation/ https://www.tempus.com/news/smoking-has-a-very-broad-long-lasting-impact-on-the-human-genome/ https://www.tempus.com/newsletter-signup/ https://www.tempus.com/oncology/ https://www.tempus.com/order/ https://www.tempus.com/patients-clinical-trials/ https://www.tempus.com/patients-neuro-psych/ https://www.tempus.com/patients-oncology/ https://www.tempus.com/pit-program-update/ https://www.tempus.com/policy-center/ https://www.tempus.com/policy-center/california-compliance-statement/ https://www.tempus.com/policy-center/consumer-health-data-privacy-policy/ https://www.tempus.com/policy-center/cookie-policy/ https://www.tempus.com/policy-center/info-security-requirements/ https://www.tempus.com/policy-center/notice-of-privacy-practices/ https://www.tempus.com/policy-center/ny-or-ak-privacy/ https://www.tempus.com/policy-center/patient-good-faith-estimate/ https://www.tempus.com/policy-center/patient-protection-billing/ https://www.tempus.com/policy-center/patient-terms-of-use/ https://www.tempus.com/policy-center/pixel-sla/ https://www.tempus.com/policy-center/privacy/ https://www.tempus.com/policy-center/responsible-disclosure/ https://www.tempus.com/policy-center/software-terms-of-use/ https://www.tempus.com/policy-center/terms-of-use/ https://www.tempus.com/publications/ https://www.tempus.com/publications/4d-flow-image-quality-with-blood-pool-contrast-a-comparison-of-gadofosveset-trisodium-and-ferumoxytol/ https://www.tempus.com/publications/4d-flow-mri-quantification-of-mitral-and-tricuspid-regurgitation-reproducibility-and-consistency-relative-to-conventional-mri/ https://www.tempus.com/publications/4d-flow-vs-2d-cardiac-mri-for-the-evaluation-of-pulmonary-regurgitation-and-ventricular-volume-in-repaired-tetralogy-of-fallot-a-retrospective-case-control-study/ https://www.tempus.com/publications/9413-2/ https://www.tempus.com/publications/a-10-year-old-male-with-four-genetic-diagnoses-and-a-complex-multisystem-presentation/ https://www.tempus.com/publications/a-canadian-cancer-trials-group-liquid-biopsy-informed-platform-trial-to-evaluate-treatment-in-cdk4-6-inhibitor-resistant-er-her2-metastatic-breast/ https://www.tempus.com/publications/a-canadian-cancer-trials-group-liquid-biopsy-informed-platform-trial-to-evaluate-treatment-in-cdk4-6-inhibitor-resistant-er-her2-metastatic-breast-cancer/ https://www.tempus.com/publications/a-case-of-sequential-alpelisib-and-capivasertib-in-a-patient-with-metastatic-breast-cancer-harboring-both-a-pik3ca-and-akt-mutations/ https://www.tempus.com/publications/a-circulating-tumor-fraction-dna-biomarker-response-stratified-by-esr1-mutation-status-correlates-with-overall-survival-in-patients-with-hr-her2-metastatic-breast-cancer/ https://www.tempus.com/publications/a-comparison-of-data-processing-methods-to-support-patient-matching-to-oncology-clinical-trials/ https://www.tempus.com/publications/a-comprehensive-analysis-of-clinical-and-polygenic-germline-influences-on-somatic-mutational-burden/ https://www.tempus.com/publications/a-comprehensive-analysis-of-pole-pold1-genomic-alterations-in-colorectal-cancer/ https://www.tempus.com/publications/a-comprehensive-whole-genome-sequencing-assay-provides-robust-characterization-of-clinically-relevant-genomic-alterations-across-myeloid-malignancies-concordant-with-matched-results-from-targeted-dna/ https://www.tempus.com/publications/a-concordance-study-among-26-ngs-laboratories-participating-in-the-national-cancer-institute-molecular-analysis-for-therapy-choice-nci-match-clinical-trial/ https://www.tempus.com/publications/a-deep-learning-based-rna-seq-germline-variant-caller/ https://www.tempus.com/publications/a-deep-learning-based-rna-seq-germline-variant-caller-2/ https://www.tempus.com/publications/a-diagnostic-dilemma-and-classification-conundrum-atypical-histiocytic-neoplasm-presenting-as-a-calvarial-mass/ https://www.tempus.com/publications/a-feasibility-study-of-biologically-focused-therapy-for-myelodysplastic-syndrome-patients-refractory-to-hypomethylating-agents/ https://www.tempus.com/publications/a-foundation-model-for-clinical-grade-computational-pathology-and-rare-cancers-detection/ https://www.tempus.com/publications/a-longitudinal-circulating-tumor-molecular-response-biomarker-as-a-predictor-of-clinical-outcomes-in-a-real-world-cohort-of-patients-with-advanced-solid-tumors-treated-with-tyrosine-kinase-inhibitors/ https://www.tempus.com/publications/a-methylation-based-covid-19-classification-model-to-predict-severe-disease-in-vaccinated-individuals/ https://www.tempus.com/publications/a-molecular-biomarker-for-early-and-longitudinal-treatment-response-monitoring-in-a-real-world-cohort-of-advanced-solid-tumors-treated-with-targeted-therapies/ https://www.tempus.com/publications/a-multi-institutional-study-assessing-prevalence-of-deleterious-germline-mutations-in-pancreatic-cancer/ https://www.tempus.com/publications/a-multi-modal-pan-cancer-atlas-of-tumor-immune-states-across-primary-and-metastatic-disease-using-a-large-real-world-database/ https://www.tempus.com/publications/a-multi-omic-immune-profile-score-ips-stratifies-real-world-outcomes-of-microsatellite-stable-mss-advanced-colorectal-cancer-patients-treated-with-immune-checkpoint-inhibitors/ https://www.tempus.com/publications/a-natural-language-processing-nlp-approach-for-optical-character-recognition-ocr-resilient-extraction-correction-and-structuring-of-karyotype-data-in-oncology-clinical-notes/ https://www.tempus.com/publications/a-new-hla-genotyping-algorithm-shows-extremely-high-accuracy-and-concordance-between-tumor-and-normal-samples/ https://www.tempus.com/publications/a-novel-approach-to-define-ctdna-molecular-response-to-immunotherapy/ https://www.tempus.com/publications/a-novel-combination-of-tissue-informed-comprehensive-genomic-profiling-cgp-and-non-bespoke-blood-based-profiling-for-quantifying-circulating-tumor-dna-ctdna/ https://www.tempus.com/publications/a-novel-multi-omic-algorithm-to-predict-real-world-outcomes-among-patients-with-rare-advanced-solid-cancers-treated-with-off-label-immune-checkpoint-inhibitors/ https://www.tempus.com/publications/a-novel-phenotyping-pipeline-to-improve-identification-of-patients-with-pulmonary-hypertension-in-electronic-health-records/ https://www.tempus.com/publications/a-pan-cancer-organoid-platform-for-precision-medicine/ https://www.tempus.com/publications/a-patient-derived-fragmented-tumor-assay-for-detailed-evaluation-of-drug-response-in-the-tumor-microenvironment-tme-using-scrnaseq/ https://www.tempus.com/publications/a-phase-2-single-arm-study-of-nivolumab-and-ipilimumab-nivo-ipi-in-previously-treated-classical-kaposi-sarcoma-cks/ https://www.tempus.com/publications/a-phase-i-open-label-multicentre-first-in-human-study-to-evaluate-safety-pharmacokinetics-and-efficacy-of-amg-404-a-pd-1-inhibitor-in-patients-with-advanced-solid-tumours/ https://www.tempus.com/publications/a-phase-ii-randomized-double-blind-study-of-the-use-of-rucaparib-versus-placebo-maintenance-therapy-in-metastatic-and-recurrent-endometrial-cancer/ https://www.tempus.com/publications/a-phase-ii-randomized-double-blind-study-of-the-use-of-rucaparib-vs-placebo-maintenance-therapy-in-metastatic-and-recurrent-endometrial-cancer/ https://www.tempus.com/publications/a-phase-ii-single-arm-study-of-nivolumab-and-ipilimumab-nivo-ipi-in-previously-treated-classic-kaposi-sarcoma-cks/ https://www.tempus.com/publications/a-phase-ii-study-of-pembrolizumab-plus-fulvestrant-in-er-positive-her2-negative-advanced-metastatic-breast-cancer-patients/ https://www.tempus.com/publications/a-platform-of-cdk4-6-inhibitor-resistant-patient-derived-breast-cancer-organoids-illuminates-mechanisms-of-resistance-and-therapeutic-vulnerabilities/ https://www.tempus.com/publications/a-probabilistic-approach-for-building-disease-phenotypes-across-electronic-health-records/ https://www.tempus.com/publications/a-quantitative-bayesian-informed-approach-to-gene-specific-variant-classification-updated-expert-panel-recommendations-improve-classification-of-tp53-germline-variants-for-li-fraumeni-syndrome/ https://www.tempus.com/publications/a-quantitative-bayesian-informed-approach-to-gene-specific-variant-classification-updated-expert-panel-recommendations-improve-classification-of-tp53-germline-variants-for-li-fraumeni-syndrome-2/ https://www.tempus.com/publications/a-randomized-trial-evaluating-automated-notifications-for-the-identification-and-treatment-of-aortic-stenosis-and-mitral-regurgitation-the-alert-study/ https://www.tempus.com/publications/a-randomized-trial-evaluating-the-impact-of-automated-notifications-on-the-identification-and-treatment-of-patients-with-aortic-stenosis-and-mitral-regurgitation-design-of-the-alert-trial/ https://www.tempus.com/publications/a-real-world-study-of-claudin-18-2-cldn18-2-association-with-molecular-subtypes-mutations-biomarkers-immune-landscapes-and-gene-signatures-and-prognostic-value-in-pancreatic-ductal-adenocarcinoma/ https://www.tempus.com/publications/a-review-of-evidence-supporting-nccn-category-2b-off-label-recommendations-for-determination-of-medicare-reimbursement-eligibility/ https://www.tempus.com/publications/a-self-supervised-framework-for-laboratory-data-imputation-in-electronic-health-records/ https://www.tempus.com/publications/a-technology-enabled-clinical-trial-programs-impact-on-patient-screening-and-trial-enrollment-in-2024/ https://www.tempus.com/publications/a-tumor-intrinsic-signature-involving-immunosuppression-via-mif-cd74-signaling-is-associated-with-overall-survival-in-ict-treated-lung-adenocarcinoma/ https://www.tempus.com/publications/a-tumor-naive-ctdna-assay-detects-minimal-residual-disease-in-resected-stage-ii-or-iii-colorectal-cancer-and-predicts-recurrence-subset-analysis-from-the-galaxy-study-in-circulate-japan/ https://www.tempus.com/publications/a-tumor-uninformed-ctdna-assay-detecting-mrd-in-patients-with-resected-stage-ii-or-iii-colorectal-cancer-predicts-recurrence-subset-analysis-from-the-galaxy-study-in-circulate-japan/ https://www.tempus.com/publications/accelerated-cardiac-magnetic-resonance-imaging-using-deep-learning-for-volumetric-assessment-in-children/ https://www.tempus.com/publications/accurate-estimation-of-circulating-tumor-dna-fraction-from-ultra-low-pass-whole-genome-sequencing/ https://www.tempus.com/publications/accurate-genotyping-of-ugt1a1-dinucleotide-repeat-polymorphism-from-targeted-ngs-data-for-the-assessment-of-irinotecan-chemotherapy-adverse-events/ https://www.tempus.com/publications/acquired-rufy1-ret-rearrangement-as-a-mechanism-of-resistance-to-lorlatinib-in-a-patient-with-cd74-ros1-rearranged-non-small-cell-lung-cancer-a-case-report/ https://www.tempus.com/publications/actionable-genomic-alterations-and-outcomes-in-lung-squamous-and-adenosquamous-cell-carcinoma/ https://www.tempus.com/publications/actionable-genomic-landscapes-from-a-real-world-cohort-of-localized-urothelial-carcinoma-patients/ https://www.tempus.com/publications/actionable-genomic-landscapes-from-a-real-world-cohort-of-urothelial-carcinoma-patients/ https://www.tempus.com/publications/actionable-germline-findings-in-endometrial-cancer-from-a-large-multigene-panel-tested-cohort/ https://www.tempus.com/publications/actionable-mutation-profiles-and-survival-outcomes-in-invasive-mucinous-adenocarcinoma-of-the-lung/ https://www.tempus.com/publications/actionable-structural-variant-detection-via-rna-ngs-and-dna-ngs-in-patients-with-advanced-non-small-cell-lung-cancer/ https://www.tempus.com/publications/activating-structural-alterations-in-mapk-genes-are-distinct-genetic-drivers-in-a-unique-subgroup-of-spitzoid-neoplasms/ https://www.tempus.com/publications/addressing-racial-disparities-in-valvular-heart-disease-the-role-of-echo-driven-ehr-alerts-in-improving-care-access/ https://www.tempus.com/publications/advanced-age-in-humans-and-mouse-models-of-glioblastoma-show-decreased-survival-from-extratumoral-influence/ https://www.tempus.com/publications/advanced-pancreatic-adenocarcinoma-outcomes-in-patients-with-ddr-deficiencies-outside-of-brca1-2-and-palb2/ https://www.tempus.com/publications/advancing-evidence-generation-for-circulating-tumor-dna-lessons-learned-from-a-multi-assay-study-of-baseline-circulating-tumor-dna-levels-across-cancer-types-and-stages/ https://www.tempus.com/publications/adverse-myocardial-remodeling-in-repaired-tetralogy-of-fallot/ https://www.tempus.com/publications/ai-augmented-histopathologic-review-using-image-analysis-to-optimize-dna-yield-and-tumor-purity-from-ffpe-slides/ https://www.tempus.com/publications/ai-based-prediction-of-microsatellite-instability-in-solid-tumors-a-cost-effective-screening-strategy-for-cancer-immunotherapy/ https://www.tempus.com/publications/ai-based-predictive-and-diagnostic-electrocardiography/ https://www.tempus.com/publications/ai-driven-multimodal-algorithm-predicts-immunotherapy-and-targeted-therapy-outcomes-in-clear-cell-renal-cell-carcinoma/ https://www.tempus.com/publications/ai-driven-predictive-biomarker-discovery-with-contrastive-learning-to-improve-clinical-trial-outcomes/ https://www.tempus.com/publications/ai-driven-rna-based-homologous-recombination-deficiency-algorithm-predicts-first-line-platinum-response-in-metastatic-pancreatic-cancer/ https://www.tempus.com/publications/alk-fusion-detection-by-rna-next-generation-sequencing-ngs-compared-to-dna-in-a-large-real-world-non-small-cell-lung-cancer-nsclc-dataset/ https://www.tempus.com/publications/alleviation-of-low-ph-induced-immunosuppression-through-antagonism-of-the-ph-sensor-gpr65-in-highly-glycolytic-nsclc-tumors/ https://www.tempus.com/publications/an-agentic-ai-workflow-for-automated-high-fidelity-curation-of-cancer-diagnosis-and-staging-from-unstructured-patient-records/ https://www.tempus.com/publications/an-ecg-based-machine-learning-model-for-predicting-new-onset-atrial-fibrillation-is-superior-to-age-and-clinical-features-in-identifying-patients-at-high-stroke-risk/ https://www.tempus.com/publications/an-ecg-based-machine-learning-model-for-predicting-new-onset-atrial-fibrillation-is-superior-to-age-and-clinical-variables-in-selecting-a-population-at-high-stroke-risk/ https://www.tempus.com/publications/an-ehr-based-machine-learning-model-predicts-myocardial-infarction-better-than-an-ecg-based-machine-learning-model-and-the-pooled-cohort-equations/ https://www.tempus.com/publications/an-independent-assessment-of-an-artificial-intelligence-system-for-prostate-cancer-detection-shows-strong-diagnostic-accuracy/ https://www.tempus.com/publications/an-integrative-molecular-framework-to-predict-homologous-recombination-deficiency/ https://www.tempus.com/publications/an-ntrk-1-associated-soft-tissue-tumor-showing-distinctive-nodules-with-peripheral-accentuation-of-cellularity/ https://www.tempus.com/publications/an-rna-based-survival-model-predicting-real-world-response-to-trastuzumab-deruxtecan/ https://www.tempus.com/publications/analysis-of-advanced-quantitative-computed-tomography-imaging-features-in-predicting-progression-free-survival-of-advanced-epithelial-ovarian-cancer/ https://www.tempus.com/publications/analysis-of-cfdna-fragmentomics-metrics-and-commercial-targeted-sequencing-panels/ https://www.tempus.com/publications/analysis-of-gene-expression-signatures-in-prostate-cancer-prior-to-liver-metastases/ https://www.tempus.com/publications/analysis-of-her2-prevalence-by-rna-expression-across-solid-tumors/ https://www.tempus.com/publications/analysis-of-multimodal-real-world-data-from-1248-breast-cancer-patients-reveals-distinct-novel-consensus-molecular-segments-associated-with-cdk4-6-inhibitor-resistance/ https://www.tempus.com/publications/analysis-of-prame-in-advanced-metastatic-solid-tumors-shows-homogeneous-expression-and-stability-between-lesions-across-treatment-lines-and-upon-exposure-to-checkpoint-inhibitors/ https://www.tempus.com/publications/analysis-on-real-world-chemotherapy-outcomes-in-patients-pts-with-tyrosine-kinase-inhibitor-tki-resistant-advanced-egfr-mutant-non-small-cell-lung-cancer-nsclc-in-the-united-states/ https://www.tempus.com/publications/analytical-validation-of-next-generation-sequencing-based-comprehensive-liquid-biopsy-assay-for-therapy-selection/ https://www.tempus.com/publications/ancestry-associated-differences-in-somatic-mutation-rates-from-tumor-profiling-data-of-a-pan-cancer-cohort-of-100000-patients/ https://www.tempus.com/publications/ancestry-driven-recalibration-of-tumor-mutational-burden-and-disparate-clinical-outcomes-in-response-to-immune-checkpoint-inhibitors/ https://www.tempus.com/publications/ancestry-inference-from-targeted-ngs-tests-to-enable-precision-medicine-and-improve-racial-ethnic-representation-in-clinical-trials/ https://www.tempus.com/publications/ancestry-inference-from-targeted-ngs-tests-to-enable-precision-medicine-and-improve-racial-ethnic-representation-in-clinical-trials-2/ https://www.tempus.com/publications/anti-tumor-activity-of-bdtx-1535-an-irreversible-cns-penetrant-inhibitor-of-multiple-egfr-extracellular-domain-alterations-in-preclinical-glioblastoma-models/ https://www.tempus.com/publications/applying-machine-vision-to-empower-preclinical-development-of-cell-engager-and-adoptive-cell-therapeutics-in-patient-derived-organoid-models-of-solid-tumors/ https://www.tempus.com/publications/applying-machine-vision-to-empower-preclinical-development-of-immunotherapies-in-patient-derived-organoid-models-of-solid-tumors/ https://www.tempus.com/publications/aquarius-a-longitudinal-multi-center-molecular-biomarker-discovery-registry-for-patients-with-hematologic-malignancies/ https://www.tempus.com/publications/artificial-intelligence-assisted-cancer-diagnosis-improves-the-efficiency-of-pathologists-in-prostatic-biopsies/ https://www.tempus.com/publications/artificial-intelligence-augmented-histopathologic-review-using-image-analysis-to-optimize-dna-yield-from-formalin-fixed-paraffin-embedded-slides/ https://www.tempus.com/publications/artificial-intelligence-helps-pathologists-increase-diagnostic-accuracy-and-efficiency-in-the-detection-of-breast-cancer-lymph-node-metastases/ https://www.tempus.com/publications/asco-temp/ https://www.tempus.com/publications/aspscr1tfe3-type-1-vs-type-2-fusions-in-alveolar-soft-part-sarcoma-asps-display-a-differential-tumor-immune-microenvironment-time-influencing-response-to-immune-checkpoint-inhibitors-icis/ https://www.tempus.com/publications/assessing-the-completeness-of-oncology-treatment-data-from-administrative-claims-a-benchmarking-study-against-abstracted-ehrs-using-patient-level-linkages/ https://www.tempus.com/publications/assessing-the-reliability-accuracy-and-utility-of-clinical-abstraction-methods-from-unstructured-electronic-health-records-ehrs/ https://www.tempus.com/publications/assessing-the-role-of-bcor-bcorl1-and-other-historically-low-frequency-somatic-mutations-in-myelodysplastic-syndromes/ https://www.tempus.com/publications/assessing-the-utility-of-molecular-diagnostic-classification-for-cancers-of-unknown-primary/ https://www.tempus.com/publications/assessing-variability-across-hrd-assays-findings-from-the-friends-hrd-harmonization-project/ https://www.tempus.com/publications/assessment-of-the-adequacy-of-the-fast-healthcare-interoperability-resources-fhir-genomics-standard-for-the-representation-of-somatic-testing-reports/ https://www.tempus.com/publications/assessment-of-the-precision-and-reproducibility-of-ventricular-volume-function-and-mass-measurements-with-ferumoxytol-enhanced-4d-flow-mri/ https://www.tempus.com/publications/assessment-of-tumor-mutational-burden-and-outcomes-in-patients-with-diverse-advanced-cancers-treated-with-immunotherapy/ https://www.tempus.com/publications/association-between-ex-vivo-pharmacotyping-of-patient-derived-tumor-organoids-and-personalized-therapeutic-options-for-patients-with-biliary-tract-cancer/ https://www.tempus.com/publications/association-between-her-family-expression-and-clinical-outcomes-with-trastuzumab-deruxtecan-t-dxd-in-patients-with-hormone-receptor-positive-her2-negative-hr-her2-metastatic-breast-cancer-mbc/ https://www.tempus.com/publications/association-between-lag3-expression-and-immune-checkpoint-inhibitor-ici-efficacy-in-advanced-melanoma/ https://www.tempus.com/publications/association-between-mobile-based-patient-reported-sleep-questionnaires-and-passive-wearable-sleep-sensors-in-psychiatry-patients/ https://www.tempus.com/publications/association-between-patient-reported-sleep-quality-and-passive-sleep-measurements-in-patients-with-psychiatric-disorders-using-mobile-based-questionnaires-and-wearable-sensors/ https://www.tempus.com/publications/association-of-a-ctdna-biomarker-of-treatment-response-with-clinical-outcomes-in-a-real-world-pan-cancer-cohort-treated-with-tyrosine-kinase-inhibitors/ https://www.tempus.com/publications/association-of-a-novel-circulating-tumor-fraction-dna-biomarker-of-treatment-response-monitoring-and-clinical-outcomes-in-a-real-world-diverse-pan-cancer-cohort-treated-with-immunotherapy/ https://www.tempus.com/publications/association-of-genetic-ancestry-with-molecular-tumor-profiles-in-colorectal-cancer/ https://www.tempus.com/publications/association-of-molecular-profiles-of-head-and-neck-squamous-cell-carcinoma-with-heterogeneity-across-racial-ethnic-groups-in-the-united-states/ https://www.tempus.com/publications/association-of-renal-cell-carcinoma-rcc-metastatis-to-pancreas-with-a-distinct-molecular-profile-and-immune-cell-population/ https://www.tempus.com/publications/association-of-tumor-homologous-recombination-deficiency-hrd-score-with-immune-checkpoint-inhibitor-benefit-in-metastatic-clear-cell-renal-cell-carcinoma/ https://www.tempus.com/publications/associations-between-androgen-directed-treatments-and-ar-mutational-landscapes-in-the-circulating-tumor-dna-of-a-real-world-metastatic-prostate-cancer-cohort/ https://www.tempus.com/publications/associations-between-circulating-tumor-dna-genomic-profiles-and-serum-thymidine-kinase-patterns-in-patients-with-advanced-hormone-receptor-positive-her2-negative-hr-her-breast-cancer-initiating/ https://www.tempus.com/publications/associations-between-multimodal-immune-biomarkers-and-clinical-outcomes-in-a-real-world-non-small-cell-lung-cancer-cohort/ https://www.tempus.com/publications/associations-of-genetic-ancestry-to-the-somatic-mutational-landscape-from-tumor-profiling-data-of-100000-cancer-patients/ https://www.tempus.com/publications/asymptomatic-aortic-coarctation-diagnosed-because-of-large-abdominal-arterial-collateral/ https://www.tempus.com/publications/automated-alerts-to-improve-timely-evaluation-and-treatment-of-valvular-heart-disease-the-alert-trial/ https://www.tempus.com/publications/avelumab-first-line-maintenance-1lm-for-locally-advanced-or-metastatic-urothelial-carcinoma-la-muc-treatment-tx-patterns-and-real-world-rw-outcomes-in-the-us/ https://www.tempus.com/publications/basecamp-1-a-master-prescreening-study-to-identify-patients-with-high-risk-or-metastatic-solid-tumors-with-hla-loss-of-heterozygosity-loh-in-preparation-for-tmod-car-t-cell-therapy-trials/ https://www.tempus.com/publications/basecamp-1-an-approach-to-improve-patient-screening-efficiency-and-to-provide-large-datasets-for-precision-medicine-clinical-trials/ https://www.tempus.com/publications/basecamp-1-an-observational-study-to-identify-relapsed-solid-tumor-patients-with-human-leukocyte-antigen-hla-loss-of-heterozygosity-loh-and-leukapheresis-for-future-car-t-cell-therapy/ https://www.tempus.com/publications/basecamp-1-is-an-efficient-pre-screening-study-that-identifies-patients-with-hla-loh-and-provides-mutational-rna-seq-and-microbiome-data-for-precision-logic-gated-car-t-therapeutic-trials/ https://www.tempus.com/publications/basecamp-1-leveraging-human-leukocyte-antigen-a-hla-a-loss-of-heterozygosity-loh-in-solid-tumors-by-next-generation-sequencing-ngs-to-identify-patients-with-relapsed-solid-tumors-for-carcinoemb/ https://www.tempus.com/publications/basecamp-1-screening-study-a-model-for-efficient-enrolment-in-precision-oncology-clinical-trials/ https://www.tempus.com/publications/baseline-biomarker-analyses-of-patients-with-chemorefractory-kras-g12c-mutated-metastatic-colorectal-cancer-mcrc-from-the-phase-3-codebreak-300-study/ https://www.tempus.com/publications/baseline-biomarker-analysis-and-clinical-outcomes-of-the-pd-1-tgf-r2-bispecific-antibody-inca33890-in-patients-with-non-msi-h-metastatic-colorectal-cancer-mcrc/ https://www.tempus.com/publications/benchmarking-of-germline-copy-number-variant-callers-from-whole-genome-sequencing-data-for-clinical-applications/ https://www.tempus.com/publications/beyond-hla-loh-alternative-modes-of-hla-loss-are-common-and-vary-by-cancer-type/ https://www.tempus.com/publications/biology-informed-predictive-modeling-and-resistance-monitoring-in-trastuzumab-deruxtecan-treated-metastatic-breast-cancer/ https://www.tempus.com/publications/biomarkers-of-immunotherapy-response-in-neuro-oncology/ https://www.tempus.com/publications/blood-ctdna-vs-tumor-tissue-screening-for-the-detection-of-kras-mutations-in-low-grade-serous-ovarian-cancer/ https://www.tempus.com/publications/bloodpac-data-commons-for-liquid-biopsy-data/ https://www.tempus.com/publications/braf-copy-number-alterations-and-ultralow-braf-mrna-expression-are-prognostic-for-poor-overall-survival-in-prostate-cancer/ https://www.tempus.com/publications/braf-mutations-and-fusions-in-a-real-world-cohort-of-nsclc-patients/ https://www.tempus.com/publications/breast-cancer-intrinsic-subtypes-predict-outcomes-in-primary-and-metastatic-samples/ https://www.tempus.com/publications/calibrating-observational-health-record-data-against-a-randomized-trial/ https://www.tempus.com/publications/calibrating-observational-health-record-data-against-a-randomized-trial-2/ https://www.tempus.com/publications/cancer-mutations-converge-on-a-collection-of-protein-assemblies-to-predict-resistance-to-replication-stress-2/ https://www.tempus.com/publications/case-of-relapsed-metastatic-cutaneous-squamous-cell-carcinoma-with-her2-mutation-treated-with-trastuzumab/ https://www.tempus.com/publications/case-report-awake-craniotomy-during-pregnancy-for-resection-of-glioblastoma/ https://www.tempus.com/publications/case-report-with-biallelic-variants-in-gcnt2-implicates-exon-1b-in-congenital-cataracts/ https://www.tempus.com/publications/cathepsin-protease-expression-and-therapeutic-outcomes-to-trastuzumab-deruxtecan-t-dxd-in-metastatic-breast-cancer/ https://www.tempus.com/publications/cd34-positive-acral-chondromyxoid-mesenchymal-neoplasm-harboring-a-novel-tcf4erg-fusion/ https://www.tempus.com/publications/cdk12-pathogenic-mutations-in-african-american-and-white-patients-with-prostate-cancer/ https://www.tempus.com/publications/cell-free-dna-molecular-response-predicts-clinical-efficacy-in-hgsoc-patients-treated-with-azenosertib/ https://www.tempus.com/publications/cell-free-testing-reliably-detects-dpyd-and-ugt1a1-pgx-alterations-improving-chemotherapy-dosing-and-clinical-yield/ https://www.tempus.com/publications/challenges-and-opportunities-associated-with-the-md-anderson-impact2-randomized-study-in-precision-oncology/ https://www.tempus.com/publications/changes-in-non-small-cell-lung-cancer-nsclc-next-generation-sequencing-ngs-rates-after-electronic-health-record-ehr-integration-using-large-scale-multi-institutional-real-world-data/ https://www.tempus.com/publications/changes-in-segmental-pulse-wave-velocity-of-the-thoracic-aorta-with-age-and-left-ventricular-remodelling-an-mri-4d-flow-study/ https://www.tempus.com/publications/characterisation-of-the-immunogenomic-landscape-of-ovarian-cancer-uncovers-a-distinct-subset-of-endometroid-tumours-associated-with-high-cst2-expression-and-a-favourable-prognosis/ https://www.tempus.com/publications/characteristics-of-patients-receiving-immune-checkpoint-inhibitors-ici-in-ascos-cancerlinq/ https://www.tempus.com/publications/characterization-of-dna-damage-repair-ddr-alterations-and-the-tumor-immune-microenvironment-time-in-advanced-non-small-cell-lung-cancer-nsclc/ https://www.tempus.com/publications/characterization-of-the-immune-landscape-of-primary-vs-metastatic-breast-cancer-in-a-real-world-data-cohort/ https://www.tempus.com/publications/characterization-of-the-tumor-immune-microenvironment-time-and-somatic-landscape-in-gastrointestinal-gi-malignancies-with-mtap-deletions-del/ https://www.tempus.com/publications/characterization-of-the-tumor-immune-microenvironment-time-and-somatic-landscape-of-metaplastic-breast-cancer-mpbc/ https://www.tempus.com/publications/characterization-of-tmem127-related-tumor-predisposition-in-a-hereditary-cancer-cohort/ https://www.tempus.com/publications/characterization-of-tumor-infiltrating-t-cell-repertoire-in-human-cancers/ https://www.tempus.com/publications/characterizing-demographics-clinical-and-genomic-characteristics-for-u-s-patients-with-hr-her2-metastatic-breast-cancer-following-progression-on-a-cdk4-and-6-inhibitor/ https://www.tempus.com/publications/characterizing-differences-in-checkpoint-inhibitor-biomarkers-in-a-real-world-cohort-of-stage-iii-and-iv-non-small-cell-lung-cancer-patients/ https://www.tempus.com/publications/characterizing-genomic-variants-defining-a-plasma-cell-disorder-patient-cohort-using-a-broad-next-generation-multi-gene-dna-sequencing-panel/ https://www.tempus.com/publications/characterizing-the-genomic-and-immune-landscape-of-serous-borderline-tumors-and-low-grade-serous-ovarian-cancer/ https://www.tempus.com/publications/characterizing-the-genomic-landscape-of-pole-pold1-mutated-colorectal-adenocarcinoma/ https://www.tempus.com/publications/characterizing-the-landscape-of-ring-type-e3-ubiquitin-transferase-altered-rnf43-alt-colorectal-cancer-crc-and-defining-unique-subsets-with-potential-therapeutic-vulnerabilities-in-microsatellite/ https://www.tempus.com/publications/chemoradiation-induced-molecular-alterations-and-associated-outcomes-in-patients-with-rectal-cancer/ https://www.tempus.com/publications/chromosome-3p-mutations-drive-unique-and-non-redundant-transcriptional-programs-in-primary-ccrcc/ https://www.tempus.com/publications/circulating-tumor-dna-and-tissue-testing-for-pancreatobiliary-tumors/ https://www.tempus.com/publications/circulating-tumor-dna-as-a-prognostic-biomarker-for-cdk-4-6-inhibitor-therapy-in-metastatic-breast-cancer/ https://www.tempus.com/publications/circulating-tumor-dna-ctdna-dynamics-in-liver-limited-metastatic-colorectal-cancer-mcrc-patients-resected-after-fi-rst-linesystemic-treatment/ https://www.tempus.com/publications/circulating-tumor-dna-ctdna-dynamics-predict-clinical-recurrence-in-liver-limited-metastatic-colorectal-cancer-mcrc-patients-resected-after-first-line-systemic-treatment/ https://www.tempus.com/publications/circulating-tumor-dna-ctdna-mutations-associate-with-response-in-patients-pts-with-extensive-stage-small-cell-lung-cancer-es-sclc-treated-with-talazoparib-tala-and-temozolomide-tmz/ https://www.tempus.com/publications/circulating-tumor-dna-dynamics-in-patients-with-liver-limited-metastatic-colorectal-cancer-resected-after-first-line-systemic-treatment/ https://www.tempus.com/publications/circulating-tumor-dna-for-early-risk-stratification-of-oligometastatic-lung-cancer/ https://www.tempus.com/publications/circulating-tumor-dna-predicts-venous-thromboembolism-in-minority-patients-with-cancers/ https://www.tempus.com/publications/circulating-tumor-dna-predicts-venous-thromboembolism-in-patients-with-cancers/ https://www.tempus.com/publications/circulating-tumor-dna-tumor-fraction-as-a-precision-biomarker-for-radiotherapy-in-oligometastatic-nsclc/ https://www.tempus.com/publications/clinical-and-genomic-characteristics-of-patients-with-hr-her2-metastatic-breast-cancer-following-progression-on-a-cdk4-and-6-inhibitor/ https://www.tempus.com/publications/clinical-and-molecular-landscape-of-esr1-and-pik3ca-co-mutated-hormone-receptor-positive-metastatic-breast-cancer-hr-mbc-insights-from-8626-patients-including-polyclonality-and-tp53-alterations/ https://www.tempus.com/publications/clinical-echocardiographic-and-socioeconomic-predictors-of-progression-and-outcomes-in-patients-with-moderate-aortic-stenosis/ https://www.tempus.com/publications/clinical-echocardiographic-and-socioeconomic-predictors-of-progression-and-outcomes-in-patients-with-moderate-aortic-stenosis-2/ https://www.tempus.com/publications/clinical-genomic-and-transcriptomic-data-profiling-of-biliary-tract-cancer-reveals-subtype-specific-immune-signatures/ https://www.tempus.com/publications/clinical-impact-of-next-generation-sequencing-guided-targeted-therapies-in-advanced-cancer-a-systematic-review-and-meta-analysis/ https://www.tempus.com/publications/clinical-implications-of-her3-overexpression-in-a-diverse-patient-cohort-with-prostate-cancer/ https://www.tempus.com/publications/clinical-morphologic-and-molecular-findings-in-ntrk3-fusion-spitz-neoplasms/ https://www.tempus.com/publications/clinical-outcomes-among-patients-with-advanced-non-small-cell-lung-cancer-who-received-targeted-therapy-in-a-real-world-setting/ https://www.tempus.com/publications/clinical-outcomes-and-longitudinal-circulating-tumor-dna-changes-after-treatment-with-nivolumab-and-olaparib-in-immunotherapy-relapsed-melanoma-with-detected-homologous-recombination-deficiency/ https://www.tempus.com/publications/clinical-outcomes-with-erbb2-gene-amplification-and-activating-mutations-in-muscle-invasive-bladder-cancer-patients-treated-with-neoadjuvant-chemotherapy/ https://www.tempus.com/publications/clinical-rna-sequencing-improves-the-detection-of-actionable-fusions-over-dna-sequencing-alone/ https://www.tempus.com/publications/clinical-use-of-4d-flow-mri-for-quantification-of-aortic-regurgitation/ https://www.tempus.com/publications/clinical-utility-and-cost-effectiveness-of-a-molecular-biomarker-for-immune-checkpoint-inhibitor-response-monitoring-and-treatment-decisions/ https://www.tempus.com/publications/clinical-validation-of-a-novel-multi-omic-algorithm-for-stratifying-outcomes-in-a-real-world-cohort-of-metastatic-solid-cancer-patients-treated-with-immune-checkpoint-inhibitors/ https://www.tempus.com/publications/clinical-validation-of-artificial-intelligence-augmented-pathology-diagnosis-demonstrates-significant-gains-in-diagnostic-accuracy-in-prostate-cancer-detection/ https://www.tempus.com/publications/clinical-validation-of-the-tempus-xo-assay/ https://www.tempus.com/publications/clinical-validation-of-the-tempus-xt-next-generation-targeted-oncology-sequencing-assay/ https://www.tempus.com/publications/clinico-molecular-real-world-data-demonstrates-prognostic-significance-of-a-three-gene-biomarker-for-colorectal-liver-oligometastases/ https://www.tempus.com/publications/clinicogenomic-and-immune-profiles-of-male-breast-cancer-by-race-insights-from-a-large-real-world-cohort/ https://www.tempus.com/publications/clinicogenomic-landscape-and-outcomes-of-metastatic-colorectal-cancer-patients-with-pathogenic-gnas-variants/ https://www.tempus.com/publications/clinicopathologic-and-molecular-genetic-features-of-spindle-cell-rhabdomyosarcoma-harboring-zfp64ncoa2-3-fusions-a-series-of-14-cases/ https://www.tempus.com/publications/clinicopathologic-and-molecular-landscape-of-invasive-mucinous-adenocarcinoma-of-the-lung/ https://www.tempus.com/publications/cloud-processed-4d-cmr-flow-imaging-for-pulmonary-flow-quantification/ https://www.tempus.com/publications/clsp-1025-a-first-in-class-precision-t-cell-engager-for-the-treatment-of-p53-mutant-cancers/ https://www.tempus.com/publications/co-occurrence-of-gene-fusions-and-microsatellite-instability-msi-defines-a-clinically-distinct-subtype-of-colorectal-cancer/ https://www.tempus.com/publications/cohort-builder-in-tempus-lens-querying-a-large-oncology-database-with-generative-ai/ https://www.tempus.com/publications/comparative-analysis-of-genomic-landscape-reveals-heterogeneity-in-her2-positive-primary-breast-cancers-and-residual-disease-following-neoadjuvant-therapy/ https://www.tempus.com/publications/comparative-analysis-of-microsatellite-instability-high-msi-h-braf-v600e-mutated-versus-msi-h-brafwild-type-colorectal-cancers-crc-including-tumor-microenvironment-tme-associated-genom/ https://www.tempus.com/publications/comparative-analysis-of-the-targetable-landscape-in-kras-mutated-and-wild-type-pancreatic-adenocarcinoma/ https://www.tempus.com/publications/comparative-analysis-of-the-tumor-immune-microenvironment-time-and-primary-and-metastatic-tissue-in-hr-her2-and-triple-negative-breast-cancer-tnbc/ https://www.tempus.com/publications/comparative-analysis-of-the-tumor-immune-microenvironment-time-in-primary-and-metastatic-sites-of-microsatellite-stable-mss-and-microsatellite-instability-high-msi-colorectal-cancer/ https://www.tempus.com/publications/comparative-analysis-of-tumor-immune-microenvironment-in-primary-tumors-vs-metastatic-tissue-in-microsatellite-stable-metastatic-colorectal-cancer/ https://www.tempus.com/publications/comparative-genomic-analysis-of-pik3r1-mutated-and-wild-type-breast-cancers/ https://www.tempus.com/publications/comparing-the-somatic-germline-and-immune-landscapes-of-upper-tract-urothelial-carcinoma-utuc-and-uc-of-the-bladder-ucb/ https://www.tempus.com/publications/comparison-of-demographics-and-clinical-characteristics-using-real-world-data-from-tempus-multimodal-database-and-seer-cancer-registry-across-17-solid-cancer-cohorts/ https://www.tempus.com/publications/comparison-of-ihc-to-he-registration-vs-he-only-ground-truth-methodologies-for-evaluating-lymphocyte-detection-ai-models-on-he-images-of-non-small-cell-lung-cancer/ https://www.tempus.com/publications/comparison-of-interassay-similarity-and-cellular-deconvolution-in-spatial-transcriptomics-data-using-visum-cytassist/ https://www.tempus.com/publications/comparison-of-pulmonary-versus-extra-pulmonary-small-cell-neuroendocrine-carcinomas-demonstrate-distinct-genomic-alterations/ https://www.tempus.com/publications/comparison-of-the-tumor-immune-microenvironment-and-checkpoint-blockade-biomarkers-between-stage-iii-and-iv-non-small-cell-lung-cancer/ https://www.tempus.com/publications/comparison-of-tissue-and-liquid-biopsy-cgp-in-advanced-solid-tumors-insights-from-a-community-cancer-center/ https://www.tempus.com/publications/comparison-of-tumor-immune-microenvironments-between-primary-and-metastatic-sites-in-non-small-cell-lung-cancer/ https://www.tempus.com/publications/comparison-of-tumor-immune-microenvironments-times-between-primary-and-metastatic-sites-mets-in-triple-negative-breast-cancer-tnbc/ https://www.tempus.com/publications/complete-response-in-a-patient-with-chemorefractory-egfr-amplified-pd-l1-positive-metastatic-gastric-cancer-treated-by-dual-anti-egfr-and-anti-pd-1-monoclonal-antibody-therapy/ https://www.tempus.com/publications/composite-deep-learning-ecg-algorithm-trained-to-identify-structural-heart-diseases-can-identify-clinically-ascertained-hypertrophic-cardiomyopathy/ https://www.tempus.com/publications/comprehensive-characterization-of-kras-mutations-and-inter-relation-with-primary-tumor-location-in-colorectal-cancers/ https://www.tempus.com/publications/comprehensive-comparison-of-somatic-germline-and-immune-cell-profiles-in-upper-tract-and-bladder-urothelial-carcinoma/ https://www.tempus.com/publications/comprehensive-genomic-and-transcriptomic-profiling-of-molecular-subtypes-reveal-ancestral-differences-in-the-activity-of-signaling-pathways-between-patients-with-african-and-european-ancestry/ https://www.tempus.com/publications/comprehensive-genomic-and-transcriptomic-profiling-of-pediatric-malignancies-using-the-tempus-xt-next-generation-sequencing-assay-to-identify-clinically-meaningful-alterations/ https://www.tempus.com/publications/comprehensive-genomic-profiling-in-advanced-metastatic-colorectal-cancer-number-needed-to-test-and-budget-impact-of-expanded-first-line-use/ https://www.tempus.com/publications/comprehensive-genomic-profiling-in-advanced-metastatic-colorectal-cancer-number-needed-to-test-and-budget-impact-of-expanded-first-line-use-2/ https://www.tempus.com/publications/comprehensive-genomic-profiling-provides-patients-access-to-novel-matched-therapies-in-a-diverse-real-world-cohort-of-advanced-lung-cancer-patients/ https://www.tempus.com/publications/comprehensive-molecular-characterization-of-patients-with-metastatic-invasive-lobular-carcinoma-ilc-using-real-world-data-to-describe-this-unique-clinical-entity/ https://www.tempus.com/publications/comprehensive-motion-compensated-highly-accelerated-4d-flow-mri-with-ferumoxytol-enhancement-for-pediatric-congenital-heart-disease/ https://www.tempus.com/publications/comprehensive-validation-of-rna-sequencing-for-clinical-ngs-fusion-genes-and-rna-expression-reporting/ https://www.tempus.com/publications/comprehensive-whole-genome-sequencing-wgs-assay-provides-diagnostic-insight-into-clinically-relevant-genomic-alterations-across-myeloid-malignancies/ https://www.tempus.com/publications/concordance-analysis-of-tissue-and-circulating-tumor-dna-ctdna-in-renal-cell-carcinoma-rcc-insights-from-a-multimodal-real-world-database/ https://www.tempus.com/publications/concordance-and-use-patterns-of-tissue-and-cell-free-based-genomic-testing-in-metastatic-breast-cancer/ https://www.tempus.com/publications/concordance-between-human-epidermal-growth-factor-receptor-2-her2-status-by-immunohistochemistry-ihc-and-next-generation-sequencing-ngs-in-tissue-and-blood-samples-from-gastric-and-gastroesophag/ https://www.tempus.com/publications/concurrent-dna-and-rna-ngs-testing-to-characterize-rare-fusions-in-advanced-nsclc-patients/ https://www.tempus.com/publications/concurrent-glucocorticoid-taper-enables-reintroduction-of-alectinib-after-drug-induced-rash/ https://www.tempus.com/publications/concurrent-rna-and-dna-ngs-testing-for-the-detection-of-clinically-relevant-fusions-in-pediatric-solid-tumor-patients/ https://www.tempus.com/publications/concurrent-tissue-and-circulating-tumor-dna-analysis-in-renal-cell-carcinoma-insights-from-a-multimodal-database/ https://www.tempus.com/publications/concurrent-tissue-and-circulating-tumor-dna-molecular-profiling-to-detect-guideline-based-targeted-mutations-in-a-multicancer-cohort/ https://www.tempus.com/publications/contrived-materials-and-a-data-set-for-the-evaluation-of-liquid-biopsy-tests-a-blood-profiling-atlas-in-cancer-bloodpac-community-study/ https://www.tempus.com/publications/correlation-of-mesothelin-msln-expression-measured-by-rna-sequencing-rnaseq-and-immunohistochemistry-ihc-in-msln-expressing-tumors/ https://www.tempus.com/publications/correlation-of-mutational-changes-in-circulating-tumor-dna-with-clinical-outcomes-in-her2-positive-metastatic-breast-cancer/ https://www.tempus.com/publications/cost-effectiveness-of-a-circulating-tumor-fraction-molecular-biomarker-for-treatment-response-monitoring/ https://www.tempus.com/publications/coupling-tumor-genomics-whole-transcriptome-sequencing-and-patient-outcomes-to-define-the-tumor-microenvironment-in-receptor-tyrosine-amplified-gastrointestinal-cancers-analysis-from-24598-cases/ https://www.tempus.com/publications/crestone-initial-efficacy-and-safety-of-seribantumab-in-solid-tumors-harboring-nrg1-fusions/ https://www.tempus.com/publications/crizotinib-in-patients-with-tumors-harboring-alk-or-ros1-rearrangements-in-the-nci-match-trial/ https://www.tempus.com/publications/cytotoxic-cd4-t-cells-contribute-to-anti-tumor-immune-responses-in-nsclc/ https://www.tempus.com/publications/deciphering-resistance-mechanisms-to-fam-trastuzumab-deruxtecan-nxki-in-metastatic-breast-cancer-using-real-world-data/ https://www.tempus.com/publications/deep-learning-enabled-dynamic-infiltration-and-response-to-nk-therapies-in-solid-tumor-organoids/ https://www.tempus.com/publications/deep-learning-identifies-fgfr-alterations-from-he-whole-slide-images-in-bladder-cancer/ https://www.tempus.com/publications/deep-learning-identifies-microsatellite-instability-in-he-whole-slide-images-from-prostate-esophageal-and-gastric-cancers-and-generalizes-across-cancer-types/ https://www.tempus.com/publications/deep-learning-prediction-of-new-onset-atrial-fibrillation-using-echocardiography-videos/ https://www.tempus.com/publications/deep-learning-single-frame-and-multiframe-super-resolution-for-cardiac-mri/ https://www.tempus.com/publications/deep-multimodal-fusion-for-the-discovery-of-prognostic-biomarkers-integrating-radiology-histology-and-molecular-information/ https://www.tempus.com/publications/deep-neural-networks-can-predict-new-onset-atrial-fibrillation-from-the-12-lead-electrocardiogram-and-help-identify-those-at-risk-of-af-related-stroke/ https://www.tempus.com/publications/deep-orthogonal-fusion-multimodal-prognostic-biomarker-discovery-integrating-radiology-pathology-genomic-and-clinical-data/ https://www.tempus.com/publications/defining-non-small-cell-lung-cancer-tumor-microenvironment-changes-at-primary-and-acquired-immune-checkpoint-inhibitor-resistance-using-clinical-and-real-world-data/ https://www.tempus.com/publications/defining-non-small-cell-lung-cancer-tumor-microenvironment-changes-at-primary-and-acquired-immune-checkpoint-inhibitor-resistance-using-clinical-and-real-world-data-2/ https://www.tempus.com/publications/describing-the-genomic-landscape-of-bladder-cancer-histologic-subtypes/ https://www.tempus.com/publications/design-and-development-of-the-molecular-analysis-for-therapy-choice-nci-match-designated-laboratory-network/ https://www.tempus.com/publications/detecting-hla-loss-of-heterozygosity-within-a-standard-diagnostic-sequencing-workflow-for-prognostic-and-therapeutic-opportunities/ https://www.tempus.com/publications/detection-of-human-leukocyte-antigen-class-i-loss-of-heterozygosity-in-solid-tumor-types-by-next-generation-dna-sequencing/ https://www.tempus.com/publications/detection-of-kmt2a-partial-tandem-duplication-ptd-in-aml-by-whole-genome-sequencing-wgs-addressing-limitations-of-traditional-techniques-in-the-era-of-revumenib-approval/ https://www.tempus.com/publications/detection-of-pancreatic-ductal-adenocarcinoma-basal-like-and-classical-subtypes-from-he-whole-slide-images/ https://www.tempus.com/publications/detection-of-rare-oncogenic-fusions-through-concurrent-dna-and-rna-next-generation-sequencing-in-a-pan-cancer-clinical-setting/ https://www.tempus.com/publications/determining-clinical-relevance-of-genomic-heterogeneity-in-an-ethnically-diverse-cohort-of-newly-diagnosed-patients-with-breast-cancer/ https://www.tempus.com/publications/determining-parp-inhibition-as-a-treatment-strategy-in-melanoma-based-on-homologous-recombination-deficiency-related-loss-of-heterozygosity/ https://www.tempus.com/publications/development-and-characterization-of-patient-derived-xenografts-from-non-small-cell-lung-cancer-brain-metastases/ https://www.tempus.com/publications/development-and-clinical-utility-of-an-he-based-tumor-origin-prediction-model/ https://www.tempus.com/publications/development-and-validation-of-a-deep-learning-based-microsatellite-instability-predictor-from-prostate-cancer-whole-slide-images/ https://www.tempus.com/publications/development-and-validation-of-a-moderate-aortic-stenosis-disease-progression-model/ https://www.tempus.com/publications/development-and-validation-of-an-ngs-assay-for-the-detection-of-clinically-actionable-genetic-variants-in-dpyd-and-ugt1a1/ https://www.tempus.com/publications/development-and-validation-of-the-immune-profile-score-ips-a-novel-multi-omic-algorithmic-assay-for-stratifying-outcomes-in-a-real-world-cohort-of-advanced-solid-cancer-patients-treated-with-immune/ https://www.tempus.com/publications/development-and-validation-of-the-immune-profile-score-ips-a-novel-multiomic-algorithmic-assay-for-stratifying-outcomes-in-a-real-world-cohort-of-patients-with-advanced-solid-cancer-treated-with-im/ https://www.tempus.com/publications/development-of-machine-learning-models-for-prediction-of-left-ventricular-systolic-dysfunction-in-patients-with-isolated-left-ventricular-dilation/ https://www.tempus.com/publications/development-of-machine-learning-models-incorporating-clinical-demographic-and-echocardiography-variables-for-predicting-left-ventricular-systolic-dysfunction-in-patients-with-isolated-left-ventricul/ https://www.tempus.com/publications/differential-gene-expression-and-pathway-analysis-of-invasive-mucinous-adenocarcinoma/ https://www.tempus.com/publications/digital-profiling-of-gene-expression-from-histology-images-with-linearized-attention/ https://www.tempus.com/publications/discoidin-domain-receptor-driven-gene-signatures-as-markers-of-patient-response-to-anti-pd-l1-immune-checkpoint-therapy/ https://www.tempus.com/publications/distinct-and-convergent-effects-of-sf3b1-mutations-in-human-breast-cancer/ https://www.tempus.com/publications/distinct-genomic-features-in-a-retrospective-cohort-of-mucosal-acral-and-vulvovaginal-melanomas/ https://www.tempus.com/publications/distinct-genomic-patterns-in-pigmented-epithelioid-melanocytoma-a-molecular-and-histologic-analysis-of-16-cases/ https://www.tempus.com/publications/distinct-transcriptional-and-immunosuppressive-microenvironment-signatures-in-pik3ca-and-esr1-mutant-hormone-receptor-positive-hr-her2-metastatic-breast-cancer-mbc/ https://www.tempus.com/publications/dna-damage-repair-gene-alterations-influence-the-tumor-immune-microenvironment-in-advanced-non-small-cell-lung-cancer/ https://www.tempus.com/publications/dora-a-phase-ii-multicenter-international-study-of-olaparib-with-or-without-durvalumab-as-a-chemotherapy-free-maintenance-strategy-in-platinum-pretreated-advanced-triple-negative-breast-cancer-tnb/ https://www.tempus.com/publications/dual-ctdna-and-tissue-sequencing-improves-detection-of-actionable-variants-in-patients-with-breast-cancer/ https://www.tempus.com/publications/dual-tissue-and-plasma-testing-improves-detection-of-actionable-variants-in-patients-with-solid-cancers/ https://www.tempus.com/publications/durable-clinical-response-to-the-multidisciplinary-management-of-neurosurgery-radiation-and-chemoimmunotherapy-in-a-patient-with-pd-l1-pd-l2-jak2-pdj-amplified-refractory-triple-negative-breast-ca/ https://www.tempus.com/publications/dynamic-changes-in-circulating-tumor-fraction-as-a-predictor-of-real-world-clinical-outcomes-in-solid-tumor-malignancy-patients-treated-with-immunotherapy/ https://www.tempus.com/publications/early-ctdna-quantification-by-ctfe-outperforms-max-vaf-for-survival-stratification-across-locally-advanced-and-oligometastatic-nsclc-treated-with-radiotherapy/ https://www.tempus.com/publications/early-introductions-and-transmission-of-sars-cov-2-variant-b-1-1-7-in-the-united-states/ https://www.tempus.com/publications/early-stage-endometrioid-endometrial-cancer-recurrence-risk-stratification-using-a-machine-learning-rna-seq-gene-expression-signature/ https://www.tempus.com/publications/ecg-based-machine-learning-model-identifies-patients-at-high-risk-for-incident-pulmonary-hypertension/ https://www.tempus.com/publications/echocardiographic-and-socioeconomic-predictors-of-progression-of-moderate-tricuspid-regurgitation-a-single-center-study/ https://www.tempus.com/publications/economic-impact-of-concurrent-tissue-and-circulating-tumor-dna-molecular-profiling-in-advanced-breast-cancer-patients/ https://www.tempus.com/publications/effect-of-germline-mutations-on-somatic-alteration-landscapes-in-brca-associated-cancers/ https://www.tempus.com/publications/effects-of-color-calibration-via-icc-profile-on-inter-scanner-generalization-of-ai-models/ https://www.tempus.com/publications/effects-of-socioeconomic-status-on-access-to-next-generation-sequencing-in-patients-with-metastatic-breast-cancer/ https://www.tempus.com/publications/efficacy-of-cabozantinib-and-nivolumab-in-cluster-1-2-metastatic-clear-cell-renal-cell-carcinoma-results-from-optic-rcc-a-phase-ii-trial-of-a-novel-rnaseq-based-biomarker/ https://www.tempus.com/publications/efficient-and-generalizable-prediction-of-molecular-alterations-in-multiple-cancer-cohorts-using-hematoxylin-and-eosin-whole-slide-images/ https://www.tempus.com/publications/egfr-s442-mutation-confers-cetuximab-resistance-that-can-be-overcome-by-erbb2-blockade-by-trastuzumab-deruxtecan/ https://www.tempus.com/publications/ehr-based-machine-learning-model-predicts-drug-induced-qt-prolongation-with-superior-performance-compared-to-clinical-risk-predictors/ https://www.tempus.com/publications/elevating-bulk-sequencing-with-high-resolution-spatial-transcriptomics-a-paired-data-analysis-of-clinically-relevant-spatial-niches-in-crc-and-nsclc/ https://www.tempus.com/publications/enhanced-detection-of-heart-valve-disease-using-integrated-artificial-intelligence-at-scale/ https://www.tempus.com/publications/enhancing-clonal-hematopoiesis-variant-detection-in-tumor-normal-matched-sequencing-using-machine-learning/ https://www.tempus.com/publications/enhancing-diagnostic-accuracy-and-treatment-appropriateness-in-cardiac-transthyretin-amyloidosis-through-natural-language-processing-a-retrospective-analysis/ https://www.tempus.com/publications/enhancing-tcr-t-with-a-fas-based-switch-receptor-boosts-t-cell-engraftment-persistence-and-anti-tumor-activity-in-models-of-hard-to-treat-prame-solid-tumor-indications/ https://www.tempus.com/publications/enhancing-team-efficiency-for-genetic-risk-assessment-medical-oncology-led-germline-testing-for-pancreatic-cancer/ https://www.tempus.com/publications/erbb3-overexpression-is-enriched-in-diverse-patient-populations-with-castration-sensitive-prostate-cancer-and-is-associated-with-a-unique-ar-activity-signature/ https://www.tempus.com/publications/esr1-mutation-longitudinal-dynamics-in-rwd-cohort-of-hr-her2-metastatic-breast-cancer-patients-treated-with-standard-of-care-hormonal-therapy/ https://www.tempus.com/publications/esr1-mutations-and-associated-alterations-in-patients-with-estrogen-receptor-er-her2-positive-her2-breast-cancers-at-diagnosis-of-metastatic-disease-mbc/ https://www.tempus.com/publications/esr1-mutations-drive-resistance-to-cdk4-6-inhibitors-in-er-breast-cancer/ https://www.tempus.com/publications/esr1-y537s-and-d538g-mutations-drive-resistance-to-cdk4-6-inhibitors-in-estrogen-receptor-positive-breast-cancer/ https://www.tempus.com/publications/establishing-cerebral-arterial-blood-flow-baselines-in-healthy-individuals-using-non-contrast-4d-flow-mri/ https://www.tempus.com/publications/evaluating-biomarkers-of-immunotherapy-response-in-a-real-world-metastatic-nsclc-cohort/ https://www.tempus.com/publications/evaluating-clinical-features-and-prognostic-factors-associated-with-response-to-immune-checkpoint-blockade-in-mnsclc-patients/ https://www.tempus.com/publications/evaluating-prognostic-biomarkers-in-advanced-epithelial-ovarian-carcinoma-using-machine-learning-on-real-world-data/ https://www.tempus.com/publications/evaluating-the-clinical-environmental-genetic-and-genomic-profile-of-men-with-early-onset-aggressive-prostate-cancer-pca/ https://www.tempus.com/publications/evaluating-the-clinical-significance-of-clonal-hematopoiesis-of-indeterminate-potential-chip-in-patients-with-non-small-cell-lung-cancer-nsclc/ https://www.tempus.com/publications/evaluation-of-atrial-septal-defects-with-4d-flow-mri-multilevel-and-inter-reader-reproducibility-for-quantification-of-shunt-severity/ https://www.tempus.com/publications/evaluation-of-cardiac-shunts-with-4d-flow-cardiac-magnetic-resonance-intra-and-interobserver-variability/ https://www.tempus.com/publications/evaluation-of-homologous-recombination-deficiency-hrd-in-gastric-cancer-real-world-prevalence-and-outcomes-with-first-line-1l-platinum-based-therapy/ https://www.tempus.com/publications/evaluation-of-large-language-model-llm-based-clinical-abstraction-of-electronic-health-records-ehrs-for-non-small-cell-lung-cancer-nsclc-patients/ https://www.tempus.com/publications/evaluation-of-microsatellite-instability-status-a-definitive-predictive-biomarker-for-immune-checkpoint-inhibitors-ici-in-underrepresented-minorities-urm-with-gastrointestinal-gi-cancers/ https://www.tempus.com/publications/evaluation-of-real-world-tumor-response-derived-from-electronic-health-record-data-sources-a-feasibility-analysis-in-patients-with-metastatic-non-small-cell-lung-cancer-treated-with-chemother/ https://www.tempus.com/publications/evaluation-of-the-1021-hrd-assay-compared-to-established-hrd-testing-platforms-in-ovarian-cancer/ https://www.tempus.com/publications/evaluation-of-the-somatic-and-immunologic-landscapes-of-primary-and-metastatic-cervical-cancer-to-better-inform-future-clinical-trial-development/ https://www.tempus.com/publications/everest-1-a-seamless-phase-1-2-study-of-a2b530-a-carcinoembryonic-antigen-cea-logic-gated-tmod-car-t-cell-therapy-in-patients-with-solid-tumors-associated-with-cea-expression-also-exhibiting-huma/ https://www.tempus.com/publications/everest-1-a-seamless-phase-1-2-study-of-cea-logic-gated-tmod-car-t-cell-therapy-a2b530-in-patients-with-solid-tumors-associated-with-cea-expression-also-exhibiting-hla-loss-of-heterozygosity-loh/ https://www.tempus.com/publications/everest-1-initial-safety-data-from-a-seamless-phase-1-2-study-of-a2b530-a-logic-gated-tmod-car-t-cell-therapy-in-patients-with-solid-tumors-associated-with-cea-expression-also-exhibiting-hla-loh/ https://www.tempus.com/publications/everest-2-a-seamless-phase-1-2-study-of-a2b694-a-logic-gated-tmod-car-t-cell-therapy-in-patients-with-mesothelin-expressing-solid-tumors-with-human-leukocyte-antigen-a02-loss-of-heterozygosity/ https://www.tempus.com/publications/everest-2-a-seamless-phase-1-2-study-of-a2b694-a-mesothelin-msln-logic-gated-tmod-car-t-cell-therapy-in-patients-with-solid-tumors-that-show-msln-expression-and-human-leukocyte-antigen-hla-a02/ https://www.tempus.com/publications/evolving-from-discrete-molecular-data-integrations-to-actionable-molecular-insights-within-the-electronic-health-record/ https://www.tempus.com/publications/evolving-from-discrete-molecular-data-integrations-to-actionable-molecular-insights-within-the-electronic-health-record-2/ https://www.tempus.com/publications/examining-tp53-mutated-plasma-cell-disorders-across-the-disease-spectrum-using-broad-next-generation-sequencing/ https://www.tempus.com/publications/exceptional-response-in-a-patient-with-mrcc-through-precision-guided-treatment-involving-immunotherapy-rechallenge-with-temsirolimus-and-bevacizumab/ https://www.tempus.com/publications/exchanging-genomics-reports-between-pathology-labs-and-medical-centers-using-the-minimal-clinical-oncology-data-element-mcode-fhir-implementation-guide/ https://www.tempus.com/publications/expanded-studies-of-a-methylation-based-covid-19-classification-model-to-predict-severity-of-disease-and-its-ability-to-differentiate-from-other-respiratory-viruses/ https://www.tempus.com/publications/expanding-the-molecular-taxonomy-of-nut-midline-carcinomas-with-multiomic-analyses/ https://www.tempus.com/publications/exploratory-evaluation-of-the-somatic-and-immunologic-landscape-of-primary-and-metastatic-cervical-cancer-to-better-inform-future-clinical-trial-development/ https://www.tempus.com/publications/exploring-barriers-to-pediatric-cancer-clinical-trials-the-role-of-a-networked-just-in-time-study-program/ https://www.tempus.com/publications/false-lumen-ejection-fraction-predicts-growth-in-type-b-aortic-dissection-preliminary-results/ https://www.tempus.com/publications/fc-ri-negative-nk-cells-and-association-with-improved-outcomes-in-trastuzumab-treated-patients/ https://www.tempus.com/publications/fibroblast-growth-factor-receptor-fgfr-aberrations-in-metastatic-non-small-cell-lung-cancer-mnsclc-an-analysis-of-prevalence-and-a-potential-therapeutic-target-for-resistance-to-epidermal-growth/ https://www.tempus.com/publications/fibroblasts-as-paracrine-targets-of-the-oncometabolite-d-2-hg-in-the-idh1-mutant-cholangiocarcinoma-tumor-microenvironment/ https://www.tempus.com/publications/findings-from-the-friends-hrd-harmonization-project/ https://www.tempus.com/publications/first-in-human-phase-1b-trial-of-quinacrine-plus-capecitabine-in-patients-with-refractory-metastatic-colorectal-cancer/ https://www.tempus.com/publications/first-line-lenvatinib-versus-dabrafenib-plus-trametinib-dt-in-braf-mutated-differentiated-thyroid-cancer-dtc-insights-from-real-world-data/ https://www.tempus.com/publications/fluid-structure-interaction-simulations-of-patient-specific-aortic-dissection/ https://www.tempus.com/publications/fractional-clues-decoding-nf1-variant-pathogenicity-through-low-variant-allele-fraction/ https://www.tempus.com/publications/free-breathing-pediatric-chest-mri-performance-of-self-navigated-golden-angle-ordered-conical-ultrashort-echo-time-acquisition/ https://www.tempus.com/publications/frequency-of-common-and-uncommon-braf-alterations-among-colorectal-and-non-colorectal-gastrointestinal-malignancies/ https://www.tempus.com/publications/functional-precision-medicine-profiling-of-patient-derived-organoids-identifies-effective-targeted-therapies-for-patients-with-low-grade-serous-ovarian-carcinoma/ https://www.tempus.com/publications/functional-precision-medicine-uncovering-high-actionability-in-rare-cancers-beyond-genomics/ https://www.tempus.com/publications/gdf15-mrna-expression-in-biliary-tract-cancer-btc-a-multiomic-analysis-of-its-prognostic-relevance-and-association-with-tumor-immune-states-in-a-large-real-world-cohort/ https://www.tempus.com/publications/gemini-breast-evaluating-minimal-residual-disease-mrd-through-longitudinal-circulating-tumor-dna-ctdna-profiling-in-breast-malignancies/ https://www.tempus.com/publications/gemini-nsclc-multiomics-and-single-cell-spatial-profiling-to-benchmark-back-translate-and-build-digital-twins-of-io-response/ https://www.tempus.com/publications/gemini-nsclc-study-integrated-longitudinal-multi-omic-biomarker-profiling-study-of-non-small-cell-lung-cancer-nsclc-patients/ https://www.tempus.com/publications/gene-expression-and-mutation-profiles-in-her2-mutated-metastatic-breast-cancer/ https://www.tempus.com/publications/gene-specific-criteria-for-pten-variant-curation-recommendations-from-the-clingen-pten-expert-panel/ https://www.tempus.com/publications/generalizability-of-radiomics-based-progression-risk-models-in-immunotherapy-treated-mnsclc-subjects/ https://www.tempus.com/publications/generic-protocols-for-analytical-validation-of-tumor-informed-circulating-tumor-dna-assays-for-molecular-residual-disease-the-blood-profiling-atlas-in-cancers-molecular-residual-disease-analytical/ https://www.tempus.com/publications/genetic-alterations-in-tumor-tissue-and-cell-free-dna-in-patients-with-papillary-thyroid-carcinoma-at-initial-surgery/ https://www.tempus.com/publications/genetic-ancestry-and-somatic-mutations-in-lung-adenocarcinoma-insights-from-real-world-clinico-genomic-data/ https://www.tempus.com/publications/genetic-ancestry-associations-with-actionable-somatic-mutations-from-tumor-profiling-data-of-100000-cancer-patients/ https://www.tempus.com/publications/genetic-ancestry-associations-with-pancreatic-cancer-mutational-profiles-from-a-diverse-9274-patient-real-world-cohort/ https://www.tempus.com/publications/genetic-ancestry-associations-with-prostate-adenocarcinoma-mutational-profiles-new-insights-from-a-diverse-5959-patient-real-world-cohort/ https://www.tempus.com/publications/genetic-ancestry-associations-with-somatic-mutations-in-a-real-world-cohort-of-over-3000-patients-with-prostate-cancer/ https://www.tempus.com/publications/genetic-ancestry-correlates-of-the-cancer-somatic-mutational-landscape-from-tumor-profiling-data-of-50000-cancer-patients/ https://www.tempus.com/publications/genetic-ancestry-differences-in-tumor-mutation-and-expression-in-early-and-average-onset-colorectal-cancer/ https://www.tempus.com/publications/genetic-ancestry-differences-in-tumor-mutation-between-early-and-average-onset-colorectal-cancer/ https://www.tempus.com/publications/genetic-ancestry-inference-from-tumor-profiling-data-of-100000-cancer-patients/ https://www.tempus.com/publications/genetic-and-clinical-landscape-of-nutm1-structural-variants/ https://www.tempus.com/publications/genetic-and-histologic-spatiotemporal-evolution-of-recurrent-multifocal-multicentric-and-metastatic-glioblastoma/ https://www.tempus.com/publications/genetic-and-oncogenic-features-of-rasgrf-fusions/ https://www.tempus.com/publications/genetic-configurations-and-liver-niche-drive-tumor-intrinsic-state-plasticity-in-metastatic-mss-crc/ https://www.tempus.com/publications/genetic-profiling-of-mammary-periductal-stromal-tumors-with-histologic-correlation-highlights-high-grade-and-low-grade-groups-and-similarities-to-phyllodes-tumors/ https://www.tempus.com/publications/genome-wide-analysis-of-glioblastoma-patients-with-unexpectedly-long-survival/ https://www.tempus.com/publications/genomic-alterations-and-pathologic-responses-to-neoadjuvant-androgen-receptor-pathway-inhibitor-arpi-doublets-vs-docetaxel-triplets-in-the-genomic-umbrella-neoadjuvant-study-guns/ https://www.tempus.com/publications/genomic-and-immune-landscape-comparison-of-met-exon-14-skipping-and-met-amplified-non-small-cell-lung-cancer/ https://www.tempus.com/publications/genomic-and-immune-landscape-of-biliary-tract-cancers-with-arid1a-pbrm1-and-bap1-alterations/ https://www.tempus.com/publications/genomic-and-immune-landscape-of-erbb2-erbb3-alterations-in-gastroesophageal-adenocarcinoma/ https://www.tempus.com/publications/genomic-and-transcriptomic-analysis-to-uncover-potential-biomarkers-of-response-and-primary-resistance-to-mirvetuximab-soravtansine-in-patients-with-ovarian-cancer/ https://www.tempus.com/publications/genomic-and-transcriptomic-comparison-between-breast-cancers-from-patients-of-african-and-european-genetically-determined-ancestries-demonstrates-potential-for-ancestry-specific-biomarker-informed-the/ https://www.tempus.com/publications/genomic-and-transcriptomic-correlates-of-deep-psa-response-in-patients-with-metastatic-hormone-sensitive-prostate-cancer-mhspc/ https://www.tempus.com/publications/genomic-and-transcriptomic-mediators-of-resistance-to-antibody-drug-conjugates-adcs-in-metastatic-breast-cancer-mbc-a-comprehensive-multi-center-study/ https://www.tempus.com/publications/genomic-characteristics-clinical-profiling-and-outcomes-of-advanced-pancreatic-ductal-adenocarcinoma-pdac-with-mtap-deletion-mtap-del-analyses-from-a-multimodal-real-world-dataset/ https://www.tempus.com/publications/genomic-characterization-and-molecular-taxonomy-of-sarcomatoid-variant-prostate-cancer/ https://www.tempus.com/publications/genomic-characterization-and-monitoring-molecular-response-to-treatment-in-african-american-aa-advanced-prostate-cancer-pc-patients-pts-via-next-generation-sequencing-ngs-real-world-experienc/ https://www.tempus.com/publications/genomic-characterization-of-chondrosarcoma-a-rare-sarcoma-with-clinical-responses-to-immune-checkpoint-inhibition/ https://www.tempus.com/publications/genomic-characterization-of-chondrosarcoma-reveals-potential-therapeutic-targets/ https://www.tempus.com/publications/genomic-characterization-of-lung-cancer-errfi1-and-nkx2-1-mutations-and-clu-expression/ https://www.tempus.com/publications/genomic-characterization-of-sporadic-met-amplified-non-small-cell-lung-cancer-nsclc-and-association-with-real-world-outcomes/ https://www.tempus.com/publications/genomic-characterization-of-upper-tract-urothelial-carcinoma-utuc-with-or-without-sarcomatoid-differentiation/ https://www.tempus.com/publications/genomic-characterization-of-vulvar-squamous-cell-carcinoma/ https://www.tempus.com/publications/genomic-characterization-of-vulvar-squamous-cell-carcinoma-reveals-differential-gene-expression-based-on-clinical-outcome/ https://www.tempus.com/publications/genomic-characterization-of-vulvar-squamous-cell-carcinoma-to-reveal-differential-gene-expression-based-on-clinical-outcome/ https://www.tempus.com/publications/genomic-comparison-of-met-exon-14-skipping-and-met-amplified-non-small-cell-lung-cancer/ https://www.tempus.com/publications/genomic-fusions-in-pigmented-spindle-cell-nevus-of-reed/ https://www.tempus.com/publications/genomic-landscape-analysis-of-ctdna-alterations-in-cholangiocarcinoma/ https://www.tempus.com/publications/genomic-landscape-and-clinical-characteristics-of-patients-pts-with-neuroendocrine-prostate-cancer-nepc-with-or-without-aggressive-variant-prostate-cancer-characterized-by-molecular-signature-avp/ https://www.tempus.com/publications/genomic-landscape-and-outcomes-of-renal-cell-carcinoma-with-metastases-to-the-pancreas/ https://www.tempus.com/publications/genomic-landscape-of-advanced-prostate-cancer-in-racial-minority-populations-real-world-experience-in-a-safety-net-hospital-oncology-clinic/ https://www.tempus.com/publications/genomic-landscape-of-er-her2-metastatic-breast-cancer-as-a-function-of-prior-treatment-with-a-cdk4-6-inhibitor/ https://www.tempus.com/publications/genomic-landscape-of-erbb2-3-alterations-in-colorectal-cancer-comutations-immuno-oncology-biomarkers-and-consensus-molecular-subtype/ https://www.tempus.com/publications/genomic-landscape-of-her2-negative-advanced-or-metastatic-breast-cancer-with-pik3ca-gain-of-function-mutations/ https://www.tempus.com/publications/genomic-landscape-of-smarca4-deficient-lung-tumors-by-clinical-rna-sequencing/ https://www.tempus.com/publications/genomic-landscapes-of-early-onset-versus-average-onset-colorectal-cancer-populations/ https://www.tempus.com/publications/genomic-landscapes-of-early-onset-versus-average-onset-colorectal-cancer-populations-2/ https://www.tempus.com/publications/genomic-markers-of-cdk-4-6-inhibitor-resistance-in-hormone-receptor-positive-metastatic-breast-cancer/ https://www.tempus.com/publications/genomic-profiles-of-early-progressors-vs-exceptional-responders-on-cdk4-6i-in-er-her2-advanced-breast-cancer/ https://www.tempus.com/publications/genomic-profiling-of-epithelial-neoplasms-of-the-appendix-insights-across-histological-subtypes-and-histological-grades/ https://www.tempus.com/publications/genomic-profiling-of-residual-tumor-after-neoadjuvant-chemotherapy-for-breast-cancer/ https://www.tempus.com/publications/genomic-profiling-reveals-molecular-heterogeneity-in-patients-with-richter-transformation-rt-and-chronic-lymphocytic-leukemia-cll/ https://www.tempus.com/publications/geospatial-and-molecular-characterization-of-tumor-immune-cell-infiltration-in-nsclc/ https://www.tempus.com/publications/germline-alterations-in-patients-with-lung-cancer/ https://www.tempus.com/publications/germline-alterations-in-patients-with-lung-cancer-2/ https://www.tempus.com/publications/germline-atm-mutation-and-somatic-pik3ca-and-bcor-mutations-found-in-an-infant-with-aggressive-orbital-embryonal-rhabdomyosarcoma/ https://www.tempus.com/publications/germline-dna-repair-gene-mutations-and-clonal-hematopoiesis-ch-in-24849-patients-with-brca-associated-cancers/ https://www.tempus.com/publications/germline-mutations-and-the-presence-of-clonal-hematopoiesis-of-indeterminate-potential-chip-in-20963-patients-with-brca-associated-cancers/ https://www.tempus.com/publications/germline-pathogenic-likely-pathogenic-p-lp-variants-in-epithelial-neuroendocrine-neoplasms-the-case-for-universal-germline-genetic-testing/ https://www.tempus.com/publications/germline-somatic-interactions-in-brca-associated-cancers-unique-molecular-profiles-and-clinical-outcomes-linking-atm-to-tp53-synthetic-essentiality/ https://www.tempus.com/publications/germline-testing-in-asian-american-and-pacific-islander-women-with-breast-cancer/ https://www.tempus.com/publications/global-activation-of-oncogenic-pathways-underlies-therapy-resistance-in-diffuse-midline-glioma/ https://www.tempus.com/publications/greater-than-two-coexisting-mutations-in-kras-and-nras-identified-in-the-circulating-tumor-dna-fraction-of-liquid-biopsies-by-ngs-and-confirmed-with-ddpcr/ https://www.tempus.com/publications/he-based-deep-learning-model-predicts-immune-phenotypes-in-nsclc/ https://www.tempus.com/publications/he-based-msi-predictor-generalizes-to-external-site-stain-and-scanner-characteristics/ https://www.tempus.com/publications/he-image-based-consensus-molecular-subtype-classification-of-colorectal-cancer-using-weak-labeling/ https://www.tempus.com/publications/her2-expression-and-associated-real-world-overall-survival-rwos-in-patients-with-select-solid-tumors/ https://www.tempus.com/publications/hifi-long-read-wgs-sequencing-performance-of-buccal-saliva-samples-and-estimation-of-non-human-dna-contamination-from-unaligned-hifi-reads/ https://www.tempus.com/publications/high-and-stable-muc16-expression-in-endometrial-cancer-highlights-potential-for-targeted-antibody-drug-conjugate-development/ https://www.tempus.com/publications/high-grade-angiosarcoma-transformation-in-schwannoma-and-smarcb1-mutation-a-case-report/ https://www.tempus.com/publications/high-prmt5-expression-is-associated-with-decreased-immune-infiltrate-and-worse-outcomes-to-immune-checkpoint-inhibitors-in-non-small-cell-lung-cancer/ https://www.tempus.com/publications/homologous-recombination-deficiency-concepts-definitions-and-assays/ https://www.tempus.com/publications/homologous-recombination-deficiency-hrd-in-non-small-cell-lung-cancer-genomic-analysis-using-an-rna-based-hrd-algorithm/ https://www.tempus.com/publications/homologous-recombination-deficiency-is-detectable-from-he-whole-slide-images-in-real-world-prostate-needle-core-biopsies/ https://www.tempus.com/publications/homologous-recombination-repair-hrr-mutation-concordance-between-liquid-biopsy-lb-and-tumor-tissue-by-ngs-in-a-real-world-prostate-cancer-pc-database/ https://www.tempus.com/publications/homologous-recombination-repair-pathway-alterations-and-their-relationship-to-homologous-recombination-deficiency-in-advanced-pancreatic-cancer-patients/ https://www.tempus.com/publications/hypofractionated-radiation-therapy-for-subcutaneous-rosai-dorfman-disease-a-case-report/ https://www.tempus.com/publications/identification-of-a-novel-class-of-early-exon-alk-rearrangements-across-two-pan-tumor-sequencing-databases/ https://www.tempus.com/publications/identification-of-a-novel-role-for-pd-1-signaling-in-promotion-tumor-proliferation-in-b-cell-lymphoma/ https://www.tempus.com/publications/identification-of-novel-druggable-fusions-enabled-through-the-use-of-an-automated-rna-fusion-prioritization-pipeline/ https://www.tempus.com/publications/identification-of-poor-responders-to-trastuzumab-deruxtecan-with-a-multi-modal-her2-status-predictor/ https://www.tempus.com/publications/identification-of-predictive-biomarkers-of-response-to-adcs-by-hts-of-highly-molecularly-characterized-panels-of-patient-derived-organoids-pdos/ https://www.tempus.com/publications/identifying-biomarkers-associated-with-disease-free-survival-in-early-stage-lung-cancer/ https://www.tempus.com/publications/identifying-biomarkers-of-response-in-braf-p-v600e-mutant-colorectal-cancers-mcrc/ https://www.tempus.com/publications/identifying-fit-for-emulation-data-adaptation-of-a-structured-data-feasibility-assessment-process-for-real-world-oncology-trial-emulations/ https://www.tempus.com/publications/imaging-based-histological-features-are-predictive-of-met-alterations-in-non-small-cell-lung-cancer/ https://www.tempus.com/publications/immune-related-rna-seq-biomarker-based-clustering-reveals-heterogeneous-immunotherapy-responses-and-guides-subtype-specific-strategies-in-metastatic-nsclc/ https://www.tempus.com/publications/immune-related-rna-seq-biomarker-based-clustering-reveals-heterogeneous-immunotherapy-responses-and-guides-subtype-specific-strategies-in-metastatic-nsclc-2/ https://www.tempus.com/publications/immunodriver-1-driver-alterations-dalts-and-their-immunological-implications-in-early-and-metastatic-non-small-cell-lung-cancer-nsclc/ https://www.tempus.com/publications/immunodriver-2-cd8-t-cell-and-pd-l1-levels-associate-with-first-line-1l-overall-survival-os-in-immune-checkpoint-inhibition-ici-treated-non-small-cell-lung-cancer-nsclc/ https://www.tempus.com/publications/impact-of-adverse-event-definitions-on-real-world-detection-of-oncology-immune-related-adverse-events/ https://www.tempus.com/publications/impact-of-ai-augmented-histopathology-review-on-next-generation-sequencing-ngs-success/ https://www.tempus.com/publications/impact-of-ai-clinical-trial-program-on-screening-matching-and-enrollment-of-patients-over-6-months/ https://www.tempus.com/publications/impact-of-androgen-receptor-mutations-on-immune-infiltration-in-castration-resistant-prostate-cancer/ https://www.tempus.com/publications/impact-of-braf-v600e-mutation-on-immunologic-characteristics-of-the-tumor-microenvironment-tme-and-associated-genomic-alterations-in-patients-with-microsatellite-instability-high-msi-h-or-mismatch-2/ https://www.tempus.com/publications/impact-of-claudin-1-cldn1-expression-on-molecular-correlates-and-clinical-outcomes-in-patients-with-advanced-biliary-tract-cancers-btcs/ https://www.tempus.com/publications/impact-of-coverage-policy-complexity-and-restrictiveness-on-supportive-care-receipt-in-a-real-world-cohort-of-patients-with-cancer/ https://www.tempus.com/publications/impact-of-exigent-research-networks-partnership-with-the-tempus-ai-time-program-on-the-screening-and-matching-of-patients-for-clinical-trials/ https://www.tempus.com/publications/impact-of-fgfr3-pathway-activation-in-patients-with-muscle-invasive-bladder-cancer-treated-with-neoadjuvant-chemotherapy/ https://www.tempus.com/publications/impact-of-her2-status-dynamics-on-fam-trastuzumab-deruxtecan-nxki-treatment-outcomes-in-metastatic-breast-cancer-real-world-insights/ https://www.tempus.com/publications/impact-of-intratumor-heterogeneity-ith-on-survival-outcomes-in-patients-with-non-small-cell-lung-cancer-nsclc-with-high-tumor-mutational-burden-tmb-h/ https://www.tempus.com/publications/impact-of-kras-codon-specific-mutations-on-survival-in-metastatic-crc-on-trifluridine-tipiracil-with-without-bevacizumab/ https://www.tempus.com/publications/impact-of-kras-codon-specific-mutations-on-survival-of-patients-with-metastatic-crc-mcrc-treated-with-trifluridine-tipiracil-tas-plus-bevacizumab-bev-a-real-world-analysis/ https://www.tempus.com/publications/impact-of-large-language-models-on-trial-to-patient-matching-efficiency/ https://www.tempus.com/publications/impact-of-next-generation-sequencing-on-interobserver-agreement-and-diagnosis-of-spitzoid-neoplasms/ https://www.tempus.com/publications/impact-of-ngs-testing-timing-on-real-world-treatment-patterns-and-clinical-outcomes-in-colorectal-cancer-a-retrospective-observational-study/ https://www.tempus.com/publications/impact-of-psa-nadir-on-long-term-survival-in-metastatic-hormone-sensitive-prostate-cancer-final-10-year-analysis-of-the-ecog-acrin-e3805-chaarted-trial/ https://www.tempus.com/publications/impact-of-ras-and-brafv600e-mutations-on-tumor-immune-microenvironment-and-associated-genomic-alterations-in-patients-with-microsatellite-instability-msi-or-dna-mismatch-repair-deficient-dmmr-colo/ https://www.tempus.com/publications/impact-of-ras-braf-v600e-mutations-on-the-tumor-immune-microenvironment-in-mismatch-repair-deficient-microsatellite-instability-colorectal-cancers/ https://www.tempus.com/publications/impact-of-ras-mutations-on-immunologic-characteristics-of-the-tumor-microenvironment-tme-in-patients-with-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colorect/ https://www.tempus.com/publications/impact-of-structural-biology-assessment-on-variant-interpretation-and-patient-outcomes-over-ten-years-in-a-clinical-diagnostic-laboratory/ https://www.tempus.com/publications/impact-of-the-taylor-cancer-research-center-tcrc-and-tempus-ai-time-partnership-on-clinical-trial-start-up-and-accrual/ https://www.tempus.com/publications/impact-of-timing-of-real-world-ct-imaging-on-cost-effectiveness-of-a-molecular-biomarker-for-treatment-response-monitoring-of-immunotherapy/ https://www.tempus.com/publications/impact-of-tumor-mutational-burden-on-clinical-outcomes-in-muscle-invasive-bladder-cancer-patients-treated-with-neoadjuvant-chemotherapy/ https://www.tempus.com/publications/impact-of-tumor-suppressor-gene-tsg-alteration-alt-burden-on-outcomes-in-patients-pts-with-metastatic-castration-sensitive-prostate-cancer-mcspc/ https://www.tempus.com/publications/implementation-of-ehr-integrated-notifications-on-patients-at-risk-for-sudden-cardiac-arrest/ https://www.tempus.com/publications/improving-ethnic-and-racial-diversity-in-biomarker-driven-clinical-trials-a-proof-of-concept-with-the-basecamp-1-master-prescreening-study-of-patients-with-high-risk-solid-tumors-with-human-leukocyte/ https://www.tempus.com/publications/imputation-of-race-and-ethnicity-categories-using-genetic-ancestry-from-real-world-genomic-testing-data/ https://www.tempus.com/publications/in-silico-tumor-immune-microenvironment-time-analysis-of-non-small-cell-lung-cancer-nsclc-to-inform-clinical-development-of-cdr404-a-first-of-its-kind-mage-a4-targeted-t-cell-engager/ https://www.tempus.com/publications/incidence-of-molecular-alterations-in-kras-and-other-known-cancer-genes-in-patients-with-pancreatic-cancer-assessed-with-a-commercial-genomic-profiling-panel-compared-to-tcga-results/ https://www.tempus.com/publications/incorporating-real-world-clinico-genomic-insights-to-inform-diversity-enrollment-targets-in-oncology-trials/ https://www.tempus.com/publications/independent-real-world-application-of-a-clinical-grade-automated-prostate-cancer-detection-system/ https://www.tempus.com/publications/index-of-suspicion-predictors-of-tricuspid-regurgitation-progression-and-follow-up-echo-imaging-an-artificial-intelligence-enhanced-study/ https://www.tempus.com/publications/integrated-clinical-pathologic-and-genetic-data-in-a-racially-diverse-hereditary-breast-cancer-cohort/ https://www.tempus.com/publications/integrated-clinicopathologic-genomic-and-transcriptomic-characterization-of-gastric-cancer-by-race-ethnicity-in-a-national-multi-institutional-cohort/ https://www.tempus.com/publications/integrated-genomic-profiling-expands-clinical-options-for-patients-with-cancer/ https://www.tempus.com/publications/integrated-transcriptomic-analysis-of-cicdux4-fusion-sarcomas-reveals-elevated-proliferation-signaling-and-implicates-dna-repair-gene-pole/ https://www.tempus.com/publications/integrating-genomics-and-real-world-data-to-predict-fam-trastuzumab-deruxtecan-response-in-metastatic-breast-cancer-across-her2-subtypes/ https://www.tempus.com/publications/integrating-next-generation-sequencing-ehr-and-claims-data-to-extend-follow-up-in-a-real-world-advanced-lung-adenocarcinoma-biomarker-treatment-landscape/ https://www.tempus.com/publications/integrating-next-generation-sequencing-with-morphology-improves-prognostic-and-biologic-classification-of-spitz-neoplasms/ https://www.tempus.com/publications/integrating-rna-expression-and-visual-features-for-immune-infiltrate-prediction/ https://www.tempus.com/publications/integration-of-patient-derived-tumor-organoids-and-patient-clinical-multimodal-data-to-investigate-the-role-of-organoids-in-predicting-treatment-response/ https://www.tempus.com/publications/integration-of-tumor-extrinsic-and-intrinsic-features-associates-with-immunotherapy-response-in-non-small-cell-lung-cancer/ https://www.tempus.com/publications/integrative-modeling-of-multimodal-real-world-data-for-improved-risk-stratification-of-first-line-cdk4-6-inhibitor-outcomes-in-patients-with-estrogen-receptor-er-positive-human-epidermal-growth-fact/ https://www.tempus.com/publications/integrin-beta-6-ib6-in-focus-contemporary-real-world-evidence-on-prevalence-in-non-small-cell-lung-cancer-nsclc/ https://www.tempus.com/publications/interrelation-of-functional-homologous-recombination-deficiency-and-hrr-pathway-alterations-in-prostate-cancer/ https://www.tempus.com/publications/interrogating-real-world-tumor-infiltrating-t-cell-repertoires-to-identify-antigen-enriched-tcrs-in-a-large-pan-cancer-clinical-cohort/ https://www.tempus.com/publications/intersection-of-black-race-and-carbohydrate-antigen-19-9-nonproduction-underpins-worse-pathologic-response-to-neoadjuvant-therapy-in-pancreatic-cancer/ https://www.tempus.com/publications/intrinsic-subtype-distributions-across-inherited-breast-cancer-genes-an-opportunity-to-refine-treatment/ https://www.tempus.com/publications/investigating-fibroblast-activation-protein-alpha-fap-as-a-therapeutic-target-for-delivery-of-precision-cancer-medicines-expression-spatial-localization-and-functional-insights/ https://www.tempus.com/publications/investigating-the-clinical-landscape-and-biological-impact-of-sf3b1-hotspot-mutations-in-breast-cancer/ https://www.tempus.com/publications/investigating-the-impact-of-ngs-data-availability-on-clinical-decision-making-in-brain-cancer/ https://www.tempus.com/publications/investigation-of-liver-specific-gene-expression-signatures-in-prostate-cancers-prior-to-liver-metastases/ https://www.tempus.com/publications/kmt2c-mutation-identifies-an-immunotherapy-sensitive-subset-of-gastrointestinal-cancers-a-large-real-world-analysis/ https://www.tempus.com/publications/laboratory-development-test-validation-of-an-he-based-deep-learning-histogenomic-model-to-predict-biomarkers-in-endometrial-cancer/ https://www.tempus.com/publications/laboratory-development-test-validation-of-deep-learning-histogenomic-models-to-predict-msi-status-in-multiple-cancer-types/ https://www.tempus.com/publications/landscape-of-krasg12c-associated-genomic-alterations-and-interrelation-with-immuno-oncology-biomarkers-in-kras-mutated-cancers/ https://www.tempus.com/publications/landscape-of-krasg12c-associated-genomic-alterations-and-interrelation-with-immuno-oncology-io-biomarkers/ https://www.tempus.com/publications/landscape-of-somatic-genetic-alterations-and-pam50-intrinsic-subtypes-in-breast-cancer-associated-with-germline-pathogenic-variants-in-dna-repair-genes/ https://www.tempus.com/publications/large-language-models-with-retrieval-augmented-generation-for-zero-shot-disease-phenotyping-2/ https://www.tempus.com/publications/large-scale-analysis-reveals-distinct-molecular-subtypes-in-real-world-gastric-cancer-data/ https://www.tempus.com/publications/large-scale-dna-alteration-prediction-from-he-images-across-different-cancer-types-generalizing-to-external-images/ https://www.tempus.com/publications/large-scale-ultradeep-phenotypic-analysis-of-patient-derived-tumor-organoids-unveils-intra-and-inter-tumor-heterogeneity-of-drug-response/ https://www.tempus.com/publications/lauren-subtype-classification-in-gastric-cancer-using-deep-learning-on-real-world-he-images/ https://www.tempus.com/publications/learning-relevant-he-slide-morphologies-for-prediction-of-colorectal-cancer-tumor-mutational-burden-using-weakly-supervised-deep-learning/ https://www.tempus.com/publications/leveraging-a-comprehensive-genomic-data-library-for-detecting-clonal-hematopoiesis-in-liquid-biopsy/ https://www.tempus.com/publications/leveraging-machine-learning-technology-to-efficiently-identify-and-match-patients-for-precision-oncology-clinical-trials/ https://www.tempus.com/publications/leveraging-real-world-genomic-data-to-characterize-immunotherapy-response-in-cancers-with-germline-chek2-cancer-risk-variants/ https://www.tempus.com/publications/leveraging-rna-sequencing-for-scalable-tumor-immune-repertoire-profiling/ https://www.tempus.com/publications/leveraging-scale-in-precision-oncology-to-measure-pathway-activation-and-detect-genetic-drivers-in-a-large-real-world-pan-cancer-cohort/ https://www.tempus.com/publications/lexicon-for-clonal-hematopoiesis-in-liquid-biopsy/ https://www.tempus.com/publications/liberty-liquid-biopsy-for-relapsed-refractory-neuroblastoma-a-pilot-study-of-characterization-of-circulating-tumor-dna-alterations-in-patients-with-relapsed-and-refractory-neuroblastoma-usi/ https://www.tempus.com/publications/lipid-metabolic-gene-expression-is-associated-with-decreased-overall-survival-and-immunogenicity-in-kras-stk11-nsclc/ https://www.tempus.com/publications/long-term-breast-cancer-response-to-cdk4-6-inhibition-defined-by-tp53-mediated-geroconversion/ https://www.tempus.com/publications/long-term-survival-in-newly-diagnosed-ovarian-cancer-patients/ https://www.tempus.com/publications/longitudinal-and-multi-tissue-molecular-diagnostics-track-somatic-brca2-reversion-mutations-that-correct-the-open-reading-frame-of-germline-alteration-upon-clinical-relapse/ https://www.tempus.com/publications/longitudinal-changes-in-circulating-tumor-dna-in-a-phase-i-dose-escalation-study-of-micvotabart-pelidotin-a-first-in-human-adc-targeting-edbfn/ https://www.tempus.com/publications/longitudinal-clinical-performance-of-a-novel-tumor-naive-minimal-residual-disease-assay-in-patients-with-resected-stage-ii-and-iii-colorectal-cancer-a-subset-analysis-from-the-galaxy-study-in-circula/ https://www.tempus.com/publications/longitudinal-shifts-of-solid-tumor-and-liquid-biopsy-sequencing-concordance-in-metastatic-breast-cancer/ https://www.tempus.com/publications/loss-of-asxl1-tumor-suppressor-promotes-resistance-to-cdk4-6-inhibitors-in-er-breast-cancer/ https://www.tempus.com/publications/loss-of-stk11-suppresses-lipid-metabolism-to-attenuate-kras-induced-immunogenicity-in-patients-with-non-small-cell-lung-cancer/ https://www.tempus.com/publications/low-interferon-expression-coupled-with-9p21-loss-in-non-small-cell-lung-cancer-nsclc-patients-associated-with-distinct-somatic-landscape-altered-immune-population-and-poorer-response-to-immune-che/ https://www.tempus.com/publications/low-level-aurora-kinase-a-aurka-amplification-as-a-novel-personalized-biomarker-of-cdk4-6-inhibitor-cdk4-6i-resistance-in-patients-with-hormone-receptor-positive-hr-metastatic-breast-cancer/ https://www.tempus.com/publications/lower-checkpoint-gene-expression-is-associated-with-primary-resistance-to-nivolumab-ipilimumab-combination-in-advanced-renal-cell-carcinoma/ https://www.tempus.com/publications/lower-checkpoint-gene-expression-is-associated-with-primary-resistance-to-nivolumab-ipilimumab-combination-in-advanced-renal-cell-carcinoma-2/ https://www.tempus.com/publications/lymphocyte-activation-gene-3-lag3-expression-patterns-and-immunotherapy-io-response-in-metastatic-renal-cell-carcinoma-mrcc/ https://www.tempus.com/publications/machine-learning-analysis-including-social-determinants-of-health-for-predication-of-mortality-following-transcatheter-aortic-valve-implantation-a-single-center-experience/ https://www.tempus.com/publications/machine-learning-analysis-of-progression-from-moderate-to-severe-tricuspid-regurgitation/ https://www.tempus.com/publications/machine-learning-based-cluster-analysis-of-patients-with-significant-tricuspid-regurgitation-reveals-distinct-population-with-different-phenotypes-and-clinical-outcomes/ https://www.tempus.com/publications/machine-learning-enabled-assessment-of-risk-for-drug-induced-qt-prolongation-at-the-time-of-prescribing/ https://www.tempus.com/publications/machine-learning-predicts-retinoblastoma-rb-function-in-real-world-small-cell-lung-cancer-patients/ https://www.tempus.com/publications/mait-cell-abundance-within-solid-tumors-is-associated-with-key-clinical-characteristics/ https://www.tempus.com/publications/map2k1-mutated-melanocytic-tumors-have-reproducible-histopathologic-features-and-share-similarities-with-melanocytic-tumors-with-braf-v600e-mutations/ https://www.tempus.com/publications/matched-tissue-and-circulating-tumor-dna-ctdna-analysis-in-renal-cell-carcinoma-rcc-results-from-a-multimodal-real-world-database/ https://www.tempus.com/publications/matched-whole-genome-sequencing-wgs-and-whole-exome-sequencing-wes-of-tumor-tissue-with-circulating-tumor-dna-ctdna-analysis-complementary-modalities-in-clinical-practice/ https://www.tempus.com/publications/metabolic-and-tumor-immune-cell-landscapes-are-significantly-different-amongst-kras-mutational-variants-in-non-small-cell-lung-cancer/ https://www.tempus.com/publications/microsatellite-instability-detection-with-cell-free-dna-next-generation-sequencing/ https://www.tempus.com/publications/microsatellite-stable-tumors-with-high-tumor-mutational-burden-in-association-with-tumor-response-to-immune-checkpoint-inhibitor-therapy-across-solid-tumors-and-correlation-with-specific-oncogenic-alt/ https://www.tempus.com/publications/mid-treatment-ctdna-to-predict-outcomes-in-stage-iib-iiic-nsclc-treated-with-mri-adapted-chemoradiation-2/ https://www.tempus.com/publications/milademetan-in-advanced-solid-tumors-with-mdm2-amplification-and-wild-type-tp53-pre-clinical-and-phase-2-clinical-trial-results/ https://www.tempus.com/publications/minimum-technical-preanalytical-patient-and-clinical-context-data-elements-for-cerebrospinal-fluid-liquid-biopsy-recommendations-for-public-database-submissions/ https://www.tempus.com/publications/modular-validation-of-lymphocyte-detection-and-tumor-and-stroma-segmentation-models-to-accurately-predict-tumor-infiltrating-lymphocytes-from-he-images-in-metastatic-non-small-cell-lung-cancer/ https://www.tempus.com/publications/molecular-alterations-in-adult-histiocytic-neoplasms/ https://www.tempus.com/publications/molecular-analysis-of-atypical-deep-penetrating-nevus-progressing-to-melanoma/ https://www.tempus.com/publications/molecular-and-clinical-correlates-of-early-onset-clear-cell-renal-cell-carcinoma-eorcc-a-real-world-multi-omics-analysis/ https://www.tempus.com/publications/molecular-and-immune-landscape-of-early-onset-versus-average-onset-well-differentiated-enteropancreatic-neuroendocrine-tumors/ https://www.tempus.com/publications/molecular-and-immune-landscape-of-her2-amplified-colorectal-cancer/ https://www.tempus.com/publications/molecular-and-immune-landscape-of-invasive-mucinous-adenocarcinoma-ima-of-the-lung-and-its-survival-outcome/ https://www.tempus.com/publications/molecular-characteristics-and-clinical-outcomes-of-gastroesophageal-cancer-diagnosed-at-age/ https://www.tempus.com/publications/molecular-characteristics-of-advanced-clear-cell-renal-cell-carcinoma-ccrcc-harboring-tert-mutations/ https://www.tempus.com/publications/molecular-characteristics-of-early-onset-versus-average-onset-gastroesophageal-adenocarcinoma/ https://www.tempus.com/publications/molecular-characteristics-of-tnbc-and-pathologic-response-to-chemoimmunotherapy-a-focus-on-racial-disparities/ https://www.tempus.com/publications/molecular-characterization-of-her-2-low-patients-identifies-basal-enriched-subset-with-poor-clinical-outcomes-in-real-world-data/ https://www.tempus.com/publications/molecular-characterization-of-microsatellite-stable-mss-colorectal-cancer-crc-patients-with-a-braf-v600e-mutation/ https://www.tempus.com/publications/molecular-characterization-of-oncogenic-gene-fusions-in-a-large-real-world-cohort-of-solid-tumors/ https://www.tempus.com/publications/molecular-characterization-of-patients-with-metastatic-invasive-lobular-carcinoma-ilc-using-real-world-data-to-describe-this-unique-clinical-entity/ https://www.tempus.com/publications/molecular-characterization-of-resected-non-metastatic-pancreatic-cancer-pc-based-on-kras-status/ https://www.tempus.com/publications/molecular-characterization-of-resistance-to-immune-checkpoint-inhibitor-and-chemotherapy-treatment-in-advanced-non-small-cell-lung-cancer/ https://www.tempus.com/publications/molecular-classification-of-cancers-of-unknown-primary-expands-and-refines-treatment-options/ https://www.tempus.com/publications/molecular-classification-of-neuroendocrine-carcinoma-of-the-bladder/ https://www.tempus.com/publications/molecular-diagnostic-classification-for-cancers-of-unknown-primary-cup-post-testing-diagnosis-and-treatment-impact-analysis-from-real-world-claims-data/ https://www.tempus.com/publications/molecular-differences-in-pancreatic-ductal-adenocarcinomas-from-black-versus-white-patients/ https://www.tempus.com/publications/molecular-landscape-of-extra-pulmonary-small-cell-neuroendocrine-carcinomas-based-on-site-of-origin/ https://www.tempus.com/publications/molecular-landscape-of-patients-pts-with-metastatic-breast-cancer-mbc-who-progressed-on-second-line-2l-selective-estrogen-receptor-degraders-serds/ https://www.tempus.com/publications/molecular-portraits-of-metastatic-breast-cancer-using-tissue-next-generation-sequencing/ https://www.tempus.com/publications/molecular-profiling-of-a-real-world-breast-cancer-cohort-with-genetically-inferred-ancestries-reveals-actionable-tumor-biology-differences-between-european-ancestry-and-african-ancestry-patient-popula/ https://www.tempus.com/publications/molecular-profiling-of-advanced-non-small-cell-lung-cancer-in-response-to-first-line-immune-checkpoint-inhibitors-and-or-chemotherapy-using-multimodal-real-world-data/ https://www.tempus.com/publications/molecular-subtypes-identified-in-lung-adenocarcinoma-using-a-large-scale-real-world-dataset/ https://www.tempus.com/publications/molecular-subtypes-nectin4-her2-expression-and-clinical-outcomes-in-patients-pts-with-advanced-urothelial-carcinoma-auc-or-muscle-invasive-bladder-cancer-mibc-exploratory-analyses-from-javeli/ https://www.tempus.com/publications/molecular-testing-care-gap-analysis-of-egfr-mutation-for-early-stage-nsclc-patients-in-community-practices/ https://www.tempus.com/publications/mondo-integrating-disease-terminology-across-communities/ https://www.tempus.com/publications/mouse-intraductal-mind-an-in-vivo-model-for-studying-the-underlying-mechanisms-of-dcis-malignancy/ https://www.tempus.com/publications/mouse-intraductal-mind-an-in-vivo-model-for-studying-the-underlying-mechanisms-of-dcis-malignancy-2/ https://www.tempus.com/publications/msi-colon-adenocarcinoma-transcriptomic-subtypes-are-biomarkers-of-response-to-immunotherapy/ https://www.tempus.com/publications/muc16-as-a-therapeutic-target-advancing-antibody-drug-conjugates-for-ovarian-cancer-treatment/ https://www.tempus.com/publications/muc16-in-ovarian-cancer-high-stable-expression-across-histologic-subtypes-disease-stages-and-platinum-sensitivity-status-supports-antibody-drug-conjugate-development/ https://www.tempus.com/publications/multi-center-prospective-study-evaluating-an-ai-enabled-clinical-decision-support-tool-to-improve-biomarker-testing-in-early-stage-nsclc/ https://www.tempus.com/publications/multi-field-of-view-deep-learning-model-predicts-non-small-cell-lung-cancer-programmed-death-ligand-1-status-from-whole-slide-hematoxylin-and-eosin-images/ https://www.tempus.com/publications/multi-institutional-study-of-the-frequency-genomic-landscape-and-outcome-of-idh-mutant-glioma-in-pediatrics/ https://www.tempus.com/publications/multi-modal-large-language-models-for-metastatic-breast-cancer-prognosis/ https://www.tempus.com/publications/multi-omic-analysis-of-1001-gist-tumors-reveals-immune-enriched-subtypes/ https://www.tempus.com/publications/multi-omic-profiling-of-simultaneous-ductal-carcinoma-in-situ-and-invasive-breast-cancer/ https://www.tempus.com/publications/multi-platform-classification-of-idh-wild-type-glioblastoma-based-on-erk-mapk-pathway-diagnostic-prognostic-and-therapeutic-implications/ https://www.tempus.com/publications/multi-state-modeling-of-tricuspid-regurgitation-disease-progression-rate-using-an-ehr-integrated-natural-language-processing-platform/ https://www.tempus.com/publications/multicenter-retrospective-cohort-study-of-the-sequential-use-of-antibody-drug-conjugates-trastuzumab-deruxtecan-sacituzumab-govitecan-in-patients-with-her2-low-metastatic-breast-cancer-a-subgroup-a/ https://www.tempus.com/publications/multimodal-ai-correlates-of-glucose-spikes-in-people-with-normal-glucose-regulation-pre-diabetes-and-type-2-diabetes/ https://www.tempus.com/publications/multimodal-ai-for-patient-subtype-discovery-in-lusc-using-real-world-data/ https://www.tempus.com/publications/multimodal-immune-profile-score-ips-signature-as-a-predictive-response-biomarker-to-immune-checkpoint-inhibitors-in-tumor-mutational-burden-high-tmb-h-advanced-pancancer-cohorts/ https://www.tempus.com/publications/multimodal-prediction-of-diagnosis-for-cancers-of-unknown-primary-2/ https://www.tempus.com/publications/multimodal-profiling-of-biliary-tract-cancers-to-detect-potentially-actionable-biomarkers-and-differences-in-immune-signatures-between-subtypes/ https://www.tempus.com/publications/multimodal-real-world-data-reveals-immunogenomic-drivers-of-acquired-and-primary-resistance-to-immune-checkpoint-blockade/ https://www.tempus.com/publications/multimodal-real-world-data-reveals-immunogenomic-drivers-of-acquired-and-primary-resistance-to-immune-checkpoint-blockade-2/ https://www.tempus.com/publications/multiomic-analysis-and-oncologic-outcomes-in-pancreatic-cancer-by-pin1-expression/ https://www.tempus.com/publications/multiomic-characterization-of-early-and-metastatic-biliary-tract-cancer-btc/ https://www.tempus.com/publications/multiomic-machine-learning-integration-of-dna-and-rna-features-to-predict-immunotherapy-benefit-in-mss-crc-and-other-rare-cancers/ https://www.tempus.com/publications/multiple-variant-men1-haplotypes-observed-in-multiple-endocrine-neoplasia-type-1/ https://www.tempus.com/publications/multiplex-qpcr-discriminates-variants-of-concern-to-enhance-global-surveillance-of-sars-cov-2/ https://www.tempus.com/publications/mutant-and-wild-type-ras-crosstalk-and-stoichiometric-deficiencies-are-determinants-of-sensitivity-to-targeted-therapies-in-krasg12r-2-pancreatic-ductal-adenocarcinoma/ https://www.tempus.com/publications/mutation-status-and-epithelial-differentiation-stratify-recurrence-risk-in-chordoid-meningioma-a-multicenter-study-with-high-prognostic-relevance/ https://www.tempus.com/publications/mutational-analysis-of-cfdna-to-identify-predictive-biomarkers-in-previously-untreated-patients-with-metastatic-pancreatic-cancer-receiving-the-gsk-3-inhibitor-elraglusib-9-ing-41-in-combination-wit/ https://www.tempus.com/publications/mutational-analysis-of-primary-and-advanced-chordoma-tissue-using-next-generation-sequencing/ https://www.tempus.com/publications/mutations-of-the-mapk-tsc-mtor-pathway-characterize-periventricular-glioblastoma-with-epithelioid-sega-like-morphology-morphological-and-therapeutic-implications/ https://www.tempus.com/publications/mutations-of-the-mapk-tsc-mtor-pathway-characterize-periventricular-glioblastoma-with-epithelioid-sega-like-morphology-morphological-and-therapeutic-implications-2/ https://www.tempus.com/publications/natural-language-processing-models-can-be-trained-to-accurately-recognize-the-presence-of-disease-within-clinical-notes/ https://www.tempus.com/publications/natural-language-processing-optimized-case-selection-for-real-world-evidence-studies/ https://www.tempus.com/publications/neoadjuvant-chemotherapy-induces-genomic-and-transcriptomic-changes-in-ovarian-cancer/ https://www.tempus.com/publications/neopulmonary-outflow-tract-obstruction-assessment-by-4d-flow-mri-in-adults-with-transposition-of-the-great-arteries-after-arterial-switch-operation/ https://www.tempus.com/publications/neratinib-fulvestrant-trastuzumab-for-hr-positive-her2-negative-her2-mutant-metastatic-breast-cancer-outcomes-and-biomarker-analysis-from-the-summit-trial/ https://www.tempus.com/publications/neural-network-based-framework-to-integrating-rna-seq-imaging-features-to-predict-tumor-immune-infiltration-score/ https://www.tempus.com/publications/neurofibromatosis-and-schwannomatosis-associated-tumors-approaches-to-genetic-testing-and-counseling-considerations/ https://www.tempus.com/publications/never-stop-looking-dual-diagnoses-due-to-updated-gene-disease-relationships-in-exome-patients/ https://www.tempus.com/publications/next-generation-sequencing-ngs-in-older-adults-with-breast-cancer-using-tissue-based-and-circulating-tumor-dna-ctdna-assays/ https://www.tempus.com/publications/next-generation-sequencing-ngs-testing-for-cancer-patients-at-a-safety-net-hospital/ https://www.tempus.com/publications/next-generation-sequencing-ngs-to-identify-relapsed-gastrointestinal-gi-solid-tumor-patients-with-human-leukocyte-antigen-hla-loss-of-heterozygosity-loh-for-future-logic-gated-car-t-therapy-to/ https://www.tempus.com/publications/next-generation-sequencing-of-intraoperatively-acquired-cerebrospinal-fluid-and-matched-tumor-tissue-in-patients-undergoing-surgical-resection-for-glioblastoma/ https://www.tempus.com/publications/noninterventional-cohort-study-of-biomarker-testing-and-treatment-patterns-in-patients-with-advanced-gastric-or-gastroesophageal-junction-g-gej-cancer/ https://www.tempus.com/publications/notch-mutations-in-subjects-with-recurrent-or-metastatic-adenoid-cystic-carcinoma-treated-with-rivoceranib-from-study-rm-202/ https://www.tempus.com/publications/novel-associations-between-clonal-hematopoiesis-and-therapeutic-exposures-revealed-in-patients-with-solid-tumors-using-real-world-evidence/ https://www.tempus.com/publications/novel-genomic-variants-and-pathways-associated-with-baseline-serum-thymidine-kinase-1-levels-in-hr-positive-her2-negative-mbc-patients-commencing-palbociclib-and-letrozole/ https://www.tempus.com/publications/novel-targetable-fgfr2-and-fgfr3-alterations-in-glioblastoma-associate-with-aggressive-phenotype-and-distinct-gene-expression-programs/ https://www.tempus.com/publications/ntrk-expression-is-common-in-xanthogranuloma-and-is-associated-with-the-solitary-variant/ https://www.tempus.com/publications/obesity-among-patients-with-chromosome-22q11-duplication-syndrome/ https://www.tempus.com/publications/olaparib-pembrolizumab-and-carboplatin-as-first-line-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-a-phase-ii-trial/ https://www.tempus.com/publications/oncology-trial-emulation-using-real-world-electronic-health-record-data-results-of-the-coalition-to-advance-real-world-evidence-through-randomized-controlled-trial-emulation-care-initiative/ https://www.tempus.com/publications/ongoing-partial-response-at-6-months-to-olaparib-for-metastatic-melanoma-with-somatic-palb2-mutation-after-failure-of-immunotherapy-a-case-report/ https://www.tempus.com/publications/onvansertib-in-combination-with-chemotherapy-and-bevacizumab-in-second-line-treatment-of-kras-mutant-metastatic-colorectal-cancer-a-single-arm-phase-ii-trial/ https://www.tempus.com/publications/opening-the-black-box-biologic-pathways-underlying-multimodal-digital-pathology-artificial-intelligence-in-metastatic-prostate-cancer/ https://www.tempus.com/publications/operational-metrics-for-the-elaine-2-study-combining-a-traditional-approach-with-a-just-in-time-model/ https://www.tempus.com/publications/operational-metrics-for-the-elaine-ii-study-combining-a-traditional-approach-with-a-just-in-time-model/ https://www.tempus.com/publications/optimizing-clinical-trial-subject-selection-insights-from-exigent-research-network-and-the-tempus-ai-time-program-collaboration/ https://www.tempus.com/publications/outcomes-following-first-line-immune-checkpoint-inhibitors-with-or-without-chemotherapy-stratified-by-kras-mutational-status-a-real-world-analysis-in-patients-with-advanced-nsclc/ https://www.tempus.com/publications/outcomes-following-first-line-immunotherapy-with-or-without-chemotherapy-stratified-by-kras-mutational-status-a-real-world-analysis-in-patients-with-advanced-nsclc/ https://www.tempus.com/publications/outcomes-for-patients-with-spop-mutated-castration-resistant-prostate-cancer-crpc-treated-with-an-androgen-receptor-pathway-inhibitor-arpi/ https://www.tempus.com/publications/outcomes-for-patients-with-spop-mutated-castration-resistant-prostate-cancer-crpc-treated-with-an-androgen-receptor-pathway-inhibitor-arpi-2/ https://www.tempus.com/publications/outcomes-with-avelumab-maintenance-treatment-for-advanced-urothelial-cancer-in-a-us-patient-cohort/ https://www.tempus.com/publications/overall-survival-os-in-advanced-non-small-cell-lung-cancer-ansclc-patients-treated-with-frontline-chemotherapy-or-immunotherapy-by-comorbidity-a-real-world-data-rwd-collaboration/ https://www.tempus.com/publications/overcoming-the-challenges-of-variant-calling-in-pms2-high-homology-regions-for-improved-lynch-syndrome-diagnosis-using-whole-genome-sequencing/ https://www.tempus.com/publications/overcoming-tumor-heterogeneity-clinical-trial-assays-to-prospectively-assign-patients-customized-multiplexed-tcr-t-cell-therapy-in-phase-1/ https://www.tempus.com/publications/overestimation-of-tumor-mutational-burden-tmb-using-algorithms-compared-to-germline-subtraction/ https://www.tempus.com/publications/paired-tumor-normal-sequencing-reduces-apparent-racial-differences-in-tumor-mutational-burden-tmb/ https://www.tempus.com/publications/pan-cancer-assessment-of-an-rna-based-signature-of-hrd/ https://www.tempus.com/publications/pan-cancer-multi-omic-erbb2-her2-characterization-using-next-generation-sequencing-and-quantitative-proteomics/ https://www.tempus.com/publications/pan-cancer-nuclei-segmentation-in-hematoxylin-and-eosin-whole-slide-images/ https://www.tempus.com/publications/pancreatic-cancer-action-networks-spark-a-cloud-based-patient-health-data-and-analytics-platform-for-pancreatic-cancer/ https://www.tempus.com/publications/pathogenic-braf-mutations-in-prostate-cancer-frequency-and-distribution/ https://www.tempus.com/publications/pathogenicity-assessment-of-a-tsc2-c-29661ga-splice-site-variant-in-vaginal-adenocarcinoma/ https://www.tempus.com/publications/pathway-enrichment-analysis-in-tumors-with-high-mutation-burdens-and-interferon-g-signature-expression-a-pan-cancer-analysis/ https://www.tempus.com/publications/patient-characteristics-treatment-patterns-and-clinical-outcomes-among-patients-with-de-novo-advanced-or-metastatic-stage-iiib-iv-non-small-cell-lung-cancer-in-a-real-world-setting/ https://www.tempus.com/publications/patient-records-to-timelines-a-llm-based-approach-for-summarizing-oncology-patient-history/ https://www.tempus.com/publications/patient-similarity-network-of-multiple-myeloma-identifies-patient-subgroups-with-distinct-genetic-and-clinical-features/ https://www.tempus.com/publications/pavo-a-phase-ii-open-label-single-arm-study-of-niraparib-in-patients-with-locally-advanced-metastatic-palb2-mutated-tumors/ https://www.tempus.com/publications/pd-1-blockade-plus-cisplatin-based-chemotherapy-in-patients-with-small-cell-neuroendocrine-bladder-and-prostate-cancers/ https://www.tempus.com/publications/pediatric-rectal-adenocarcinoma-with-mismatch-repair-deficiency-responds-to-immunotherapy/ https://www.tempus.com/publications/pelvic-blood-flow-predicts-fibroid-volume-and-embolic-required-for-uterine-fibroid-embolization-a-pilot-study-with-4d-flow-mr-angiography/ https://www.tempus.com/publications/performance-of-copy-number-variant-detection-from-short-read-whole-genome-sequencing-for-clinical-gene-panel-applications/ https://www.tempus.com/publications/performance-of-copy-number-variant-detection-tools-in-clinical-applications-a-comparative-benchmark-for-short-read-whole-genome-sequencing/ https://www.tempus.com/publications/peroxisome-proliferator-activated-receptor-gamma-pparg-status-defines-the-luminal-lineage-in-molecular-profiles-of-advanced-urothelial-cancer-uc-tumors/ https://www.tempus.com/publications/pharmacogenomic-actionability-in-15000-patients-with-next-generation-sequencing-enabled-copy-number-variation-and-novel-haplotype-detection/ https://www.tempus.com/publications/pharmacogenomic-insights-in-psychiatric-care-uncovering-novel-actionability-allele-specific-cyp2d6-copy-number-variation-and-phenoconversion-in-15000-patients-2/ https://www.tempus.com/publications/pharmacogenomic-testing-and-depressive-symptom-remission-a-systematic-review-and-meta-analysis-of-prospective-controlled-clinical-trials-2/ https://www.tempus.com/publications/phase-2-single-arm-study-of-nivolumab-and-ipilimumab-nivo-ipi-in-previously-treated-classical-kaposi-sarcoma-cks/ https://www.tempus.com/publications/phase-ii-dora-study-of-olaparib-with-or-without-durvalumab-as-a-chemotherapy-free-maintenance-strategy-in-platinum-pretreated-advanced-triple-negative-breast-cancer/ https://www.tempus.com/publications/pilot-study-parp1-imaging-in-advanced-prostate-cancer/ https://www.tempus.com/publications/piloting-the-forthcoming-acmg-amp-cap-clingen-standards-for-sequence-variant-classification/ https://www.tempus.com/publications/pin1-cholesterol-biosynthesis-and-clinical-outcomes-in-urothelial-carcinoma-uc-a-propensity-weighted-real-world-clinicogenomic-analysis/ https://www.tempus.com/publications/pin1-mrna-expression-in-biliary-tract-cancer-a-multiomic-analysis-of-its-prognostic-relevance-and-association-with-tumor-immune-states-in-a-large-real-world-cohort/ https://www.tempus.com/publications/pitfalls-in-machine-learning-based-assessment-of-tumor-infiltrating-lymphocytes-in-breast-cancer-a-report-of-the-international-immuno-oncology-biomarker-working-group-on-breast-cancer/ https://www.tempus.com/publications/plasma-tmb-ptmb-and-circulating-tumor-fraction-ctf-dynamics-as-biomarkers-of-benefit-from-the-addition-of-atezolizumab-to-first-line-folfoxiri-bevacizumab-in-metastatic-colorectal-cancer-mcrc-a/ https://www.tempus.com/publications/pole-pold1-mutations-as-predictive-biomarkers-for-immunotherapy-response-insights-from-a-pan-cancer-real-world-dataset/ https://www.tempus.com/publications/poly-adp-ribose-polymerase-inhibitors-parpi-therapy-response-in-an-acral-melanoma-patient-with-emsy-gene-amplification/ https://www.tempus.com/publications/pparg-amplification-is-associated-with-lack-of-response-to-anti-pd1-in-muscle-invasive-urothelial-cancer/ https://www.tempus.com/publications/pre-radiotherapy-ctdna-liquid-biopsy-for-risk-stratification-of-oligometastatic-non-small-cell-lung-cancer/ https://www.tempus.com/publications/pre-radiotherapy-ctdna-risk-stratifies-non-small-cell-lung-cancer-patients-with-oligometastatic-disease/ https://www.tempus.com/publications/precision-health-diagnostic-and-surveillance-network-uses-s-gene-target-failure-sgtf-combined-with-sequencing-technologies-to-track-emerging-sars-cov-2-variants/ https://www.tempus.com/publications/precision-oncology-for-high-grade-gliomas-a-tumor-organoid-model-for-adjuvant-treatment-selection/ https://www.tempus.com/publications/precision-oncology-improvements-in-follow-up-and-confirmation-of-potential-germline-variants-identified-from-tumor-next-generation-sequencing/ https://www.tempus.com/publications/preclinical-activity-of-kb-0742-an-oral-highly-selective-cdk9-inhibitor-in-cell-lines-and-in-myc-high-expressing-patient-derived-models-of-multiple-breast-cancer-subtypes/ https://www.tempus.com/publications/preclinical-evaluation-of-artesunate-as-an-antineoplastic-agent-in-ovarian-cancer-treatment/ https://www.tempus.com/publications/predicting-chemosensitivity-in-epithelial-ovarian-cancer-using-patient-derived-tissue-organoids/ https://www.tempus.com/publications/predicting-oncogenic-viral-status-using-rna-signatures/ https://www.tempus.com/publications/prediction-of-drug-induced-qtc-prolongation-with-an-ecg-based-machine-learning-model/ https://www.tempus.com/publications/prediction-of-incident-af-with-deep-learning-can-identify-patients-at-high-risk-for-af-related-stroke/ https://www.tempus.com/publications/prediction-of-met-overexpression-in-lung-adenocarcinoma-from-hematoxylin-and-eosin-images/ https://www.tempus.com/publications/prediction-of-mortality-from-12-lead-electrocardiogram-voltage-data-using-a-deep-neural-network/ https://www.tempus.com/publications/prediction-of-sotorasib-response-duration-and-identification-of-clinically-actionable-resistance-mechanisms-using-an-rna-and-machine-learning-based-patient-classifier/ https://www.tempus.com/publications/predictors-of-disease-progression-and-adverse-clinical-outcomes-in-patients-with-moderate-aortic-stenosis-using-an-artificial-intelligence-based-software-platform/ https://www.tempus.com/publications/predictors-of-inpatient-cost-of-care-in-patients-with-cardiovascular-disease-enrolled-in-the-centers-for-medicare-and-medicaid-cms-bundled-payments-for-care-improvement-advanced-bpci-a-initiative/ https://www.tempus.com/publications/predictors-of-tricuspid-regurgitation-progression-and-follow-up-echo-imaging-an-artificial-intelligence-enhanced-study/ https://www.tempus.com/publications/presence-of-chip-mutated-autologous-hematopoietic-cells-in-mobilized-peripheral-blood-products-is-associated-with-shorter-progression-free-survival-after-autologous-transplants-for-multiple-myeloma/ https://www.tempus.com/publications/prevalence-and-association-of-clonal-hematopoiesis-with-cardiovascular-health-in-patients-of-the-avera-sequencing-and-analytics-protocol-asap-study/ https://www.tempus.com/publications/prevalence-of-germline-findings-among-tumors-from-cancer-types-lacking-hereditary-testing-guidelines/ https://www.tempus.com/publications/prevalence-of-germline-mutations-and-homologous-recombination-deficiency-hrd-in-a-real-world-biliary-tract-cancer-btc-cohort/ https://www.tempus.com/publications/prevalence-of-high-tumor-mutational-burden-tmb-h-and-microsatellite-instability-high-msi-h-status-in-neuroendocrine-neoplasms/ https://www.tempus.com/publications/prevalence-of-kras-subtype-alterations-in-non-small-cell-lung-cancer-nsclc-with-brain-metastases/ https://www.tempus.com/publications/prevalence-of-microsatellite-instability-and-monitoring-response-to-immune-checkpoint-inhibition-utilizing-liquid-biopsy-among-african-american-men-with-advanced-prostate-cancer/ https://www.tempus.com/publications/prevalence-of-pharmacogenomic-actionability-in-11000-patients-receiving-psychiatric-care/ https://www.tempus.com/publications/primary-pancreatic-adenocarcinoma-ppda-and-metastatic-pancreatic-adenocarcinoma-mpda-are-they-genomically-distinct/ https://www.tempus.com/publications/privacy-preserving-validation-for-multiomic-prediction-models/ https://www.tempus.com/publications/private-payers-and-cancer-care-revisiting-the-land-of-opportunity/ https://www.tempus.com/publications/profiling-membrane-antigen-expression-of-select-antibody-drug-conjugate-adc-targets-in-egfr-altered-non-small-cell-lung-cancer-treated-with-osimertinib/ https://www.tempus.com/publications/profiling-the-splicing-landscape-in-solid-tumors-in-a-large-real-world-dataset/ https://www.tempus.com/publications/prognostic-impact-of-brca-mutation-on-metastasis-free-survival-in-a-localized-locoregional-high-risk-real-world-prostate-cancer-population/ https://www.tempus.com/publications/prognostic-value-of-portec-3-molecular-markers-by-disease-risk-in-a-real-world-early-endometrial-cancer-cohort/ https://www.tempus.com/publications/prolonged-response-to-treatment-based-on-cell-free-dna-analysis-and-molecular-profiling-in-three-patients-with-metastatic-cancer-a-case-series/ https://www.tempus.com/publications/prospective-basecamp-1-experience-in-patients-with-gastrointestinal-gi-cancer-identifying-patients-with-human-leukocyte-antigen-hla-loss-of-heterozygosity-loh-for-a-future-therapeutic-trial-exp/ https://www.tempus.com/publications/prospective-clinical-implementation-of-paige-prostate-detect-artificial-intelligence-assistance-in-the-detection-of-prostate-cancer-in-prostate-biopsies-confident-p-trial-implementation-of-artificial/ https://www.tempus.com/publications/prospective-evaluation-of-circulating-tumor-dna-using-next-generation-sequencing-as-a-biomarker-during-neoadjuvant-chemotherapy-in-localized-pancreatic-cancer/ https://www.tempus.com/publications/prospective-organoid-drug-profiling-and-clinical-response-correlation-for-patients-with-primary-or-recurrent-ovarian-carcinoma-oc-in-the-prosperity-study/ https://www.tempus.com/publications/proteomic-evaluation-of-her-2-expression-and-activation-in-tumors-that-are-rna-overexpressed-but-not-dna-amplified/ https://www.tempus.com/publications/protocol-for-drug-screening-of-patient-derived-tumor-organoids-using-high-content-fluorescent-imaging/ https://www.tempus.com/publications/provider-insights-and-utilization-of-psychiatric-pharmacogenomics-for-patients-with-comorbid-breast-cancer-and-emotional-distress/ https://www.tempus.com/publications/ptch1-and-axin2-modulation-of-ar-copy-number-effects-on-ar-gene-overexpression-in-metastatic-castration-resistant-prostate-cancer-mcrpc/ https://www.tempus.com/publications/pten-pathogenic-variants-are-associated-with-poor-prognosis-in-patients-with-advanced-soft-tissue-sarcoma/ https://www.tempus.com/publications/purity-independent-subtyping-of-tumor-purist-real-world-data-validation-of-a-pancreatic-ductal-adenocarcinoma-pdac-gene-expression-classifier-and-its-prognostic-implications/ https://www.tempus.com/publications/pursuit-of-novel-first-in-class-medicines-with-a-suite-of-ai-enabled-platform-technologies/ https://www.tempus.com/publications/qualitative-grading-of-aortic-regurgitation-a-pilot-study-comparing-cmr-4d-flow-and-echocardiography/ https://www.tempus.com/publications/quantifying-clinical-actionability-of-updated-tumor-profiling-reports-through-electronic-health-record-ehr-enabled-on-demand-ordering-and-resulting/ https://www.tempus.com/publications/quantifying-the-impact-of-immune-history-and-variant-on-sars-cov-2-viral-kinetics-and-infection-rebound-a-retrospective-cohort-study/ https://www.tempus.com/publications/racial-and-genetic-ancestry-associations-with-gene-expression-patterns-in-a-real-world-cohort-of-colorectal-cancer-patients/ https://www.tempus.com/publications/racial-differences-in-alk-gene-alterations-detected-by-tissue-and-liquid-biopsy-across-patients-with-lung-cancer/ https://www.tempus.com/publications/racial-differences-in-tmb-measures-between-paired-tumor-normal-and-tumor-only-sequencing-across-endometrial-bladder-and-non-small-cell-lung-cancers/ https://www.tempus.com/publications/racial-differences-in-ugt1a1-allele-frequencies-and-its-potential-impact-in-pharmacogenetic-testing-for-cancer-chemotherapy-drugs/ https://www.tempus.com/publications/racial-disparities-in-comprehensive-cancer-tumor-profiling-testing-from-real-world-data-of-100000-cancer-patient-records/ https://www.tempus.com/publications/racial-disparities-in-pathological-complete-response-among-patients-receiving-neoadjuvant-chemotherapy-for-early-stage-breast-cancer/ https://www.tempus.com/publications/racial-disparities-in-tumor-profiling-testing-inferred-from-continental-genetic-ancestry-determination-of-100000-cancer-patients/ https://www.tempus.com/publications/racial-diversity-and-co-mutational-analysis-of-biologically-relevant-alterations-in-egfr-mutant-lung-cancers/ https://www.tempus.com/publications/racial-diversity-and-co-mutational-analysis-of-biologically-relevant-alterations-in-egfr-mutant-lung-cancers-2/ https://www.tempus.com/publications/radiogenomics-for-egfr-mutation-status-prediction-in-ct-images-impact-of-model-design-on-performance-and-prospective-generalizability/ https://www.tempus.com/publications/rapid-detection-of-somatic-variants-in-human-leukocyte-antigen-class-1-genes-from-solid-tumor-samples/ https://www.tempus.com/publications/rate-of-incidental-germline-findings-detected-by-tumor-normal-matched-sequencing-in-cancer-types-lacking-hereditary-cancer-testing-guidelines/ https://www.tempus.com/publications/real-world-adherence-patterns-of-comprehensive-genomic-profiling-to-biomarker-recommended-therapies-in-patients-with-advanced-non-small-cell-lung-cancer/ https://www.tempus.com/publications/real-world-analyses-of-braf-alterations-in-patients-with-non-colorectal-gastrointestinal-cancers/ https://www.tempus.com/publications/real-world-analyses-to-evaluate-the-role-of-tigit-as-a-target-in-first-line-1l-gastric-gastroesophageal-junction-and-esophageal-adenocarcinomas-gc-gejc-eac/ https://www.tempus.com/publications/real-world-analyses-to-evaluate-the-role-of-tigit-as-a-target-in-first-line-1l-metastatic-non-small-cell-lung-cancer-mnsclc/ https://www.tempus.com/publications/real-world-characteristics-and-outcomes-of-patients-with-advanced-non-small-cell-lung-cancer-ansclc-receiving-immune-checkpoint-inhibitor/ https://www.tempus.com/publications/real-world-characterization-of-ptk7-an-oncofetal-pseudokinase-expressed-in-multiple-solid-tumors/ https://www.tempus.com/publications/real-world-characterization-of-sez6-a-transmembrane-protein-expressed-in-various-solid-tumors/ https://www.tempus.com/publications/real-world-clinical-genomic-analysis-of-patients-with-braf-mutated-cancers-identifies-braf-class-ii-and-iii-as-a-population-of-unmet-medical-need/ https://www.tempus.com/publications/real-world-clinical-genomics-study-of-hr-her2-metastatic-breast-cancers-treated-by-cdk4-6i-plus-endocrine-therapies-revealed-a-drug-resistant-tumor-segment-characterized-by-er-independence/ https://www.tempus.com/publications/real-world-clinical-genomics-study-of-hr-her2-metastatic-breast-cancers-treated-by-cdk4-6i-plus-endocrine-therapies-revealed-a-drug-resistant-tumor-segment-characterized-by-er-independence-2/ https://www.tempus.com/publications/real-world-clinical-multi-omics-analyses-reveal-bifurcation-of-er-independent-and-er-dependent-drug-resistance-to-cdk4-6-inhibitors/ https://www.tempus.com/publications/real-world-clinical-outcome-analyses-in-head-and-neck-squamous-cell-carcinoma-hnscc-to-uncover-tigit-biology-in-patients-treated-with-first-line-immune-checkpoint-inhibitors/ https://www.tempus.com/publications/real-world-clinical-outcomes-of-patients-with-her2-brcam-early-breast-cancer-treated-with-adjuvant-capecitabine/ https://www.tempus.com/publications/real-world-comparative-efficacy-of-cdk4-6-inhibitors-in-first-line-treatment-of-hr-her2-metastatic-breast-cancer/ https://www.tempus.com/publications/real-world-conditional-survival-analysis-of-women-with-newly-diagnosed-ovarian-cancer/ https://www.tempus.com/publications/real-world-data-analysis-of-genomic-profiling-matched-targeted-therapy-outcomes-in-patients-with-fusion-positive-nsclc/ https://www.tempus.com/publications/real-world-data-enables-large-scale-assessment-of-who-cns5-glioma-classification/ https://www.tempus.com/publications/real-world-data-rwd-outcome-analysis-of-esr1-mutation-emergence-in-hr-her2-metastatic-breast-cancer-through-the-continuum-of-standard-of-care-hormonal-therapy/ https://www.tempus.com/publications/real-world-data-validation-of-the-purist-pancreatic-ductal-adenocarcinoma-gene-expression-classifier-and-its-prognostic-implications/ https://www.tempus.com/publications/real-world-evaluation-of-racial-and-socioeconomic-disparities-in-patients-with-nsclc-treated-with-immunotherapy/ https://www.tempus.com/publications/real-world-evaluation-of-the-reduction-in-complexity-of-ordering-dna-sequencing-tests-through-the-adoption-of-fast-healthcare-interoperability-resources-fhir-standards/ https://www.tempus.com/publications/real-world-evidence-of-diagnostic-testing-and-treatment-patterns-in-us-patients-with-breast-cancer-with-implications-for-treatment-biomarkers-from-rna-sequencing-data/ https://www.tempus.com/publications/real-world-evidence-of-kmt2c-mutation-as-a-biomarker-of-sensitivity-to-platinum-based-therapy-in-solid-cancers/ https://www.tempus.com/publications/real-world-evidence-on-predictors-of-survival-for-hormone-positive-and-triple-negative-advanced-breast-cancer-by-treatment-and-brca-status-in-the-united-states/ https://www.tempus.com/publications/real-world-experience-of-ntrk-fusion-positive-thyroid-cancer/ https://www.tempus.com/publications/real-world-experience-of-the-clinical-correlation-between-arid-gene-alterations-rna-expression-levels-and-treatment-benefit-of-immunotherapy-in-malignant-solid-tumors/ https://www.tempus.com/publications/real-world-experience-of-the-clinical-correlation-between-arid-gene-alterations-rna-expression-levels-and-treatment-benefit-of-immunotherapy-in-malignant-solid-tumors-2/ https://www.tempus.com/publications/real-world-genomic-analysis-of-chemerin-in-prostate-cancer-pca-and-correlation-with-markers-of-immune-infiltration-and-activation/ https://www.tempus.com/publications/real-world-molecular-epidemiology-study-of-select-biomarkers-in-extensive-stage-small-cell-lung-cancer-es-sclc/ https://www.tempus.com/publications/real-world-outcome-analysis-of-patients-with-advanced-gastric-and-gastroesophageal-adenocarcinoma-with-her2-low-expression-treated-with-first-line-therapy/ https://www.tempus.com/publications/real-world-outcomes-of-alk-fusion-types-and-treatment-patterns-in-alk-positive-nsclc-insights-from-a-retrospective-cohort-study/ https://www.tempus.com/publications/real-world-outcomes-of-first-line-immune-checkpoint-inhibitors-with-or-without-chemotherapy-in-kras-g12c-altered-nsclc-according-to-pd-l1-status/ https://www.tempus.com/publications/real-world-outcomes-of-patients-with-advanced-non-small-cell-lung-cancer-ansclc-and-autoimmune-disease-ad-receiving-immune-checkpoint-inhibitors-icis/ https://www.tempus.com/publications/real-world-prevalence-of-autoimmune-disease-ad-among-patients-pts-receiving-immune-checkpoint-inhibitors-ici-in-ascos-cancerlinq-database/ https://www.tempus.com/publications/real-world-response-endpoints-in-patients-with-mnsclc-treated-with-chemotherapy-across-real-world-datasets/ https://www.tempus.com/publications/real-world-rw-treatment-tx-patterns-sequencing-and-outcomes-in-us-patients-pts-with-locally-advanced-or-metastatic-urothelial-cancer-la-muc-treated-with-avelumab-first-line-maintenance-1lm/ https://www.tempus.com/publications/real-world-second-line-treatment-use-and-clinical-outcomes-in-patients-with-hr-positive-her2-negative-metastatic-breast-cancer-mbc-and-an-esr1-mutation-esr1m/ https://www.tempus.com/publications/real-world-treatment-patterns-and-outcomes-reveal-distinct-clinical-trajectories-of-patients-with-cyclin-e1-positive-ovarian-cancer/ https://www.tempus.com/publications/real-world-treatment-patterns-and-sequencing-in-patients-with-locally-advanced-or-metastatic-urothelial-cancer-la-muc-in-the-us/ https://www.tempus.com/publications/real-world-utilization-of-comprehensive-genomic-profiling-cgp-in-head-and-neck-squamous-cell-carcinoma-scchn/ https://www.tempus.com/publications/real-world-validation-of-the-purist-classifier-demonstrates-enhanced-therapy-selection-for-pancreatic-ductal-adenocarcinoma-pdac-patients/ https://www.tempus.com/publications/real-world-validation-of-the-purity-independent-subtyping-of-tumors-classifier-for-informing-therapy-selection-in-pancreatic-ductal-adenocarcinoma/ https://www.tempus.com/publications/reasoning-guided-retrieval-improves-oncology-trial-eligibility-matching-from-clinical-notes/ https://www.tempus.com/publications/rechommend-an-ecg-based-machine-learning-approach-for-identifying-patients-at-high-risk-of-undiagnosed-structural-heart-disease-detectable-by-echocardiography/ https://www.tempus.com/publications/reclassification-of-a-spindle-cell-sarcoma-after-identification-of-a-tfg-ros1-fusion-a-case-demonstrating-the-clinical-benefit-of-next-generation-sequencing-in-sarcoma/ https://www.tempus.com/publications/recommendations-for-reporting-of-secondary-findings-in-clinical-exome-and-genome-sequencing/ https://www.tempus.com/publications/recurrent-glioblastoma-treated-with-recombinant-poliovirus/ https://www.tempus.com/publications/recurrent-transcriptionally-active-esr1-fusions-render-therapeutic-vulnerabilities-to-kinase-inhibition-in-advanced-breast-cancer/ https://www.tempus.com/publications/reducing-manual-chart-review-in-oncology-validation-of-an-ai-based-monitoring-tool-for-lung-cancer-staging-and-biomarker-tracking/ https://www.tempus.com/publications/refining-colorectal-cancer-classification-and-clinical-stratification-through-a-single-cell-atlas/ https://www.tempus.com/publications/regulation-of-oncogenic-transcription-and-tumor-growth-in-pediatric-cancers-by-the-cdk9-inhibitor-kb-0742/ https://www.tempus.com/publications/relationship-between-dynamic-changes-in-circulating-tumor-fraction-and-real-world-imaging-with-real-world-survival-in-patients-with-solid-tumors-treated-with-immunotherapy/ https://www.tempus.com/publications/renal-cell-carcinoma-with-metastasis-to-the-pancreas-genomic-signatures-and-clinical-outcomes/ https://www.tempus.com/publications/resolving-classification-of-pten-variants-using-gene-specific-acmg-amp-guidelines-a-first-review-of-curation-efforts-by-the-clingen-pten-variant-curation-expert-panel/ https://www.tempus.com/publications/response-to-selpercatinib-in-a-patient-with-recurrent-glioblastoma-and-ret-amplification/ https://www.tempus.com/publications/retrospective-evaluation-of-an-ai-based-fusion-prioritization-agent-for-oncogenicity-assessment-in-clinical-sequencing/ https://www.tempus.com/publications/rna-based-homologous-recombination-deficiency-signature-detects-homologous-recombination-deficiency-rna-patients-with-and-without-homologous-recombination-repair-gene-pathogenic-alterations-in-men-wi/ https://www.tempus.com/publications/rna-pathway-enrichment-in-serum-based-mass-spectroscopy-prognostic-analyses/ https://www.tempus.com/publications/rna-sequencing-in-precision-cancer-immunotherapy/ https://www.tempus.com/publications/rna-sequencing-to-characterize-pathways-in-egfr-mutated-non-small-cell-lung-cancer/ https://www.tempus.com/publications/rna-sequencing-to-characterize-pathways-in-patients-with-egfr-mutated-non-small-cell-lung-cancer/ https://www.tempus.com/publications/robust-detection-of-sequencing-batch-effects-in-rna-through-low-dimensional-embedding-with-subtype-matched-reference-samples/ https://www.tempus.com/publications/robust-single-sample-consensus-molecular-subtype-classification-for-primary-and-metastatic-colorectal-cancer/ https://www.tempus.com/publications/robustness-of-deep-learning-histogenomic-models-to-tissue-area-tumor-purity-and-scanner-type/ https://www.tempus.com/publications/ros1-single-nucleotide-variants-predict-favorable-survival-outcomes-on-immunotherapy-regimens-in-non-small-cell-lung-cancer/ https://www.tempus.com/publications/safety-and-efficacy-of-a-randomized-phase-i-trial-to-evaluate-concurrent-or-sequential-ipilimumab-nivolumab-and-stereotactic-body-radiotherapy-in-patients-with-stage-iv-non-small-cell-lung-cancer-c/ https://www.tempus.com/publications/safety-tolerability-and-efficacy-of-agonist-anti-cd27-antibody-varlilumab-administered-in-combination-with-anti-pd-1-nivolumab-in-advanced-solid-tumors/ https://www.tempus.com/publications/sarcomatoid-transformation-rewires-the-immune-spatial-landscape-and-checkpoint-regulation-in-chromophobe-renal-cell-carcinoma/ https://www.tempus.com/publications/sarcomatoid-transformation-rewires-the-immune-spatial-landscape-and-checkpoint-regulation-in-chromophobe-renal-cell-carcinoma-2/ https://www.tempus.com/publications/sclerosing-melanocytic-tumors-with-map2k1-in-frame-deletions-and-15q-gains-a-distinctive-pathway-of-nevogenesis-with-reproducible-morphology/ https://www.tempus.com/publications/screening-for-intrinsic-and-acquired-resistance-mutations-to-anti-egfr-in-real-world-mss-colorectal-cancer-data/ https://www.tempus.com/publications/self-supervised-representation-learning-enables-genomic-prediction-at-single-organoid-resolution/ https://www.tempus.com/publications/shared-prame-epitopes-are-t-cell-targets-in-nut-carcinoma/ https://www.tempus.com/publications/signal-to-noise-ratio-in-4d-flow-cmr-sequence-determinants-and-impact-on-kinetic-energy-energy-loss-and-vorticity-insights-from-the-trek-study/ https://www.tempus.com/publications/smarc-b1-deficient-sinonasal-carcinoma-metastasis-to-the-brain-with-next-generation-sequencing-data-a-case-report-of-perineural-invasion-progressing-to-leptomeningeal-invasion/ https://www.tempus.com/publications/somatic-tumor-profile-analysis-in-a-patient-with-germline-pms2-mutation-and-synchronous-ovarian-and-uterine-carcinomas/ https://www.tempus.com/publications/spatial-and-temporal-heterogeneity-of-pd-l1-expression-and-tumor-mutational-burden-in-gastroesophageal-adenocarcinoma-at-baseline-diagnosis-and-after-chemotherapy/ https://www.tempus.com/publications/specifications-of-the-acmg-amp-variant-interpretation-guidelines-for-germline-tp53-variants/ https://www.tempus.com/publications/spinal-pleomorphic-xanthoastrocytoma-with-a-qki-raf1-fusion/ https://www.tempus.com/publications/stratification-based-on-prame-gene-expression-shows-inverse-survival-associations-among-histology-subtypes-in-a-first-line-non-small-cell-lung-cancer-real-world-cohort/ https://www.tempus.com/publications/stratification-of-cell-therapies-in-solid-tumor-organoids-using-deep-learning-derived-imaging-metrics/ https://www.tempus.com/publications/structured-ehr-data-underestimates-prevalence-and-misses-large-proportions-of-patients-with-pulmonary-hypertension/ https://www.tempus.com/publications/structured-evaluation-of-oncology-real-world-data-quality-for-practical-applications/ https://www.tempus.com/publications/successful-use-of-immunotherapy-to-treat-advanced-cutaneous-squamous-cell-carcinoma-in-recessive-dystrophic-epidermolysis-bullosa/ https://www.tempus.com/publications/summary-of-the-12-most-common-cancers-in-the-cancerlinq-discovery-clqd-database/ https://www.tempus.com/publications/survey-of-ctx-009-patient-selection-hypotheses-using-real-world-biliary-tract-cancer-data/ https://www.tempus.com/publications/survey-of-the-immunogenomic-landscape-of-solid-tumors-through-clinical-dna-and-rna-sequencing/ https://www.tempus.com/publications/symptom-tracking-using-tempuspro-in-patients-with-pharmacogenetic-testing-from-a-real-world-dataset/ https://www.tempus.com/publications/synthetic-lethality-mediated-precision-oncology-via-the-tumor-transcriptome/ https://www.tempus.com/publications/systematic-review-and-meta-analysis-of-l-methylfolate-augmentation-in-depressive-disorders/ https://www.tempus.com/publications/systemic-artery-to-pulmonary-vein-fistula-after-right-upper-lobectomy-demonstrated-by-4-dimensional-flow-magnetic-resonance-imaging/ https://www.tempus.com/publications/target-rna-expression-by-tumor-molecular-subtypes-in-patients-pts-with-advanced-urothelial-carcinoma-auc-or-muscle-invasive-bladder-cancer-mibc-exploratory-analyses-from-javelin-bladder-100-and/ https://www.tempus.com/publications/target-specific-therapy-for-actionable-and-approved-tumor-agnostic-biomarkers-associated-with-improved-survival-in-rare-cancers/ https://www.tempus.com/publications/targeted-next-generation-sequencing-ngs-of-105-cancer-related-genes-in-circulating-tumor-dna-ctdna-from-patients-with-advanced-cancers-treated-with-immune-checkpoint-inhibitors-icpi/ https://www.tempus.com/publications/targeted-next-generation-sequencing-ngs-of-temporally-matched-cerebrospinal-fluid-csf-and-tumor-tissue-in-patients-with-recurrent-glioblastoma-gbm/ https://www.tempus.com/publications/targeted-therapies-and-parpi-therapy-response-following-ici-therapy-failure-in-advanced-melanoma-a-case-series/ https://www.tempus.com/publications/targeting-b7-h3-in-prostate-cancer-phase-2-trial-in-localized-prostate-cancer-using-the-anti-b7-h3-antibody-enoblituzumab-with-biomarker-correlatives/ https://www.tempus.com/publications/targeting-her2-her3-co-mutations-in-metastatic-breast-cancer-case-reports-of-exceptional-responders-to-trastuzumab-and-pertuzumab-therapy/ https://www.tempus.com/publications/targetr-automated-multi-omics-report-framework-for-target-characterization-and-validation-of-immunotherapy-and-targeted-therapy-candidates-across-cancers/ https://www.tempus.com/publications/temporal-concordance-rates-of-pathogenic-variants-in-liquid-biopsies-taken-after-solid-tissue-ngs-profiling-in-a-real-world-pan-cancer-cohortcopy/ https://www.tempus.com/publications/the-association-between-tumor-immunogenomic-features-and-first-line-1l-therapeutic-outcomes-in-advanced-biliary-tract-cancer-btc/ https://www.tempus.com/publications/the-association-of-changes-in-circulating-tumor-fraction-and-in-actionable-variant-allele-frequencies-with-clinical-outcomes-in-real-world-diverse-cohort-of-advanced-patients-treated-with-tyrosine-kin/ https://www.tempus.com/publications/the-chromatin-remodeling-protein-arid1a-is-required-for-mll-af9-leukemogenesis/ https://www.tempus.com/publications/the-efficacy-and-use-of-artificial-intelligence-in-medical-data-management-and-decision-making-to-future-horizons/ https://www.tempus.com/publications/the-estimated-long-term-clinical-effects-of-brca-testing-and-olaparib-treatment-of-early-breast-cancer-in-the-us-population-a-population-impact-model/ https://www.tempus.com/publications/the-frequency-and-somatic-mutation-landscape-of-fibroblast-growth-factor-receptor-fgfr-alterations-in-breast-cancer/ https://www.tempus.com/publications/the-friends-of-cancer-research-real-world-data-collaboration-pilot-2-0-methodological-recommendations-from-oncology-case-studies/ https://www.tempus.com/publications/the-friends-of-cancer-research-real-world-data-rwd-pilot-2-0-collaboration-implementation-of-standardized-methodological-approaches-for-evaluation-of-oncology-rwd/ https://www.tempus.com/publications/the-genomic-and-immune-landscape-of-osteosarcoma/ https://www.tempus.com/publications/the-genomic-and-transcriptomic-landscape-of-pik3r1-mutated-breast-cancers/ https://www.tempus.com/publications/the-genomic-landscape-of-adolescent-and-young-adult-aya-malignancies-using-dna-and-rna-based-next-generation-sequencing/ https://www.tempus.com/publications/the-genomic-landscape-of-small-cell-lung-cancer-in-never-smoking-patients/ https://www.tempus.com/publications/the-genomic-transcriptomic-and-epigenomic-landscape-of-isocitrate-dehydrogenase-wild-type-glioblastoma-across-the-age-continuum/ https://www.tempus.com/publications/the-gundersen-precision-oncology-cohort-a-biospecimen-resource-for-mutation-characterization-and-target-discovery/ https://www.tempus.com/publications/the-impact-of-next-generation-sequencing-on-interobserver-agreement-and-diagnostic-accuracy-of-deep-penetrating-melanocytic-neoplasms/ https://www.tempus.com/publications/the-impact-of-time-censoring-on-machine-learning-models-which-identify-patients-with-undiagnosed-cardiac-amyloidosis/ https://www.tempus.com/publications/the-landscape-of-somatic-genetic-alterations-in-breast-cancers-from-carriers-of-germline-pathogenic-variants-in-dna-repair-gene/ https://www.tempus.com/publications/the-molecular-and-immune-landscape-of-her2-positive-breast-cancer/ https://www.tempus.com/publications/the-mutational-landscape-of-1172-patients-with-hormone-receptor-positive-her2-negative-metastatic-breast-cancer-treated-with-cdk4-6-inhibitors/ https://www.tempus.com/publications/the-other-half-of-the-story-high-rates-of-unique-parental-secondary-finding/ https://www.tempus.com/publications/the-tempus-time-trial-portal-and-clinical-trial-enrollment/ https://www.tempus.com/publications/the-time-trial-network-to-facilitate-rapid-clinical-trial-activation-patient-screening-and-enrollment-in-molecularly-targeted-trials/ https://www.tempus.com/publications/time-savings-from-integrating-discrete-genomic-data-into-the-electronic-health-record-using-the-epic-aura-network/ https://www.tempus.com/publications/timing-of-molecular-pet-imaging-after-salvage-radiation-therapy-for-recurrent-oligometastatic-castration-sensitive-prostate-cancer/ https://www.tempus.com/publications/to-fibroblast-or-not-to-fibroblast-outcomes-and-clinical-features-of-patients-pursuing-confirmatory-germline-testing-following-tp53-positive-results/ https://www.tempus.com/publications/toward-a-better-pan-tumor-predictive-signature-for-unleashing-precision-immuno-oncology/ https://www.tempus.com/publications/towards-cancer-mega-cohorts-a-novel-homogenization-algorithm-applied-to-diverse-breast-cancer-rna-seq-datasets/ https://www.tempus.com/publications/tracheal-chondrosarcoma-a-novel-presentation-of-lynch-syndrome/ https://www.tempus.com/publications/transcriptome-background-tissue-correction-in-metastatic-cancers-using-a-correlated-composition-admixture-model/ https://www.tempus.com/publications/transcriptome-based-cancer-type-prediction-for-tumors-of-unknown-origin/ https://www.tempus.com/publications/transcriptomic-analysis-of-homologous-recombination-repair-hrr-genes-in-brca1-2-and-palb2-wild-type-wt-metastatic-pancreatic-cancer-mpc-suggests-potential-platinum-sensitivity/ https://www.tempus.com/publications/transcriptomic-biomarkers-of-therapeutic-response-to-antibody-drug-conjugates-in-metastatic-breast-cancer-a-comprehensive-multi-center-study/ https://www.tempus.com/publications/transfer-learning-of-a-methylation-based-covid-19-severity-model-for-dna-viral-infection-by-eczema-herpeticum/ https://www.tempus.com/publications/transferring-diagnostic-and-prognostic-molecular-models-across-technological-platforms/ https://www.tempus.com/publications/translating-deep-learning-to-clinical-practice-external-validation-and-clinical-benefit-of-an-electrocardiogram-based-neural-network-for-detecting-low-ejection-fraction/ https://www.tempus.com/publications/treatment-outcomes-and-resource-utilization-among-patients-with-metastatic-breast-and-advanced-epithelial-ovarian-cancer-by-brca1-2-and-hrd-status/ https://www.tempus.com/publications/treatment-sequencing-in-hr-her2-metastatic-breast-cancer-and-associated-real-world-outcomes/ https://www.tempus.com/publications/tremelimumab-and-durvalumab-as-neoadjuvant-or-non-operative-management-strategy-of-patients-with-microsatellite-instability-high-resectable-gastric-or-gastroesophageal-junction-adenocarcinoma-the-inf/ https://www.tempus.com/publications/trends-in-immunotherapy-use-in-patients-with-advanced-non-small-cell-lung-cancer-ansclc-patients-analysis-of-real-world-data/ https://www.tempus.com/publications/trihealth-cancer-institutes-collaboration-with-the-tempus-ai-time-program-impact-on-clinical-trial-operations-and-enrollment/ https://www.tempus.com/publications/trop-2-expression-and-its-prognostic-impact-on-endometrial-cancer-a-real-world-data-analysis/ https://www.tempus.com/publications/tumor-derived-ccl2-drives-tumor-growth-and-immunosuppression-in-idh1-mutant-cholangiocarcinoma/ https://www.tempus.com/publications/tumor-mutational-burden-and-other-predictive-immunotherapy-markers-in-histiocytic-neoplasms/ https://www.tempus.com/publications/tumor-mutational-burden-corrected-for-human-leukocyte-antigen-somatic-defects-predicts-response-to-checkpoint-blockade-in-advanced-non-small-cell-lung-cancer/ https://www.tempus.com/publications/tumor-mutational-burden-from-tumor-only-sequencing-compared-with-germline-subtraction-from-paired-tumor-and-normal-specimens/ https://www.tempus.com/publications/tumor-neoantigen-burden-and-immune-environment-in-driver-alteration-positive-lung-adenocarcinoma/ https://www.tempus.com/publications/tumor-specific-lncrna-igf1r-as1-trans-regulates-chromatin-interactions-associated-with-oncogenic-myc-signaling/ https://www.tempus.com/publications/ultrahigh-tumor-mutational-burden-tmb-is-associated-with-improved-survival-outcomes-in-patients-pts-treated-with-immune-checkpoint-inhibitors-icis/ https://www.tempus.com/publications/uncovering-genomic-differences-between-small-and-large-cell-extra-pulmonary-neuroendocrine-carcinomas/ https://www.tempus.com/publications/uncovering-molecular-differences-in-pancreatic-ductal-adenocarcinoma-tissues-from-black-and-white-patients-in-the-us/ https://www.tempus.com/publications/uncovering-molecular-differences-in-pancreatic-ductal-adenocarcinoma-tissues-from-black-and-white-patients-in-the-us-2/ https://www.tempus.com/publications/unique-features-of-a-comprehensive-genomic-profiling-panel-expanding-treatment-options-in-a-value-based-community-oncology-network/ https://www.tempus.com/publications/unique-molecular-landscape-of-thyroid-cancer-in-african-americans-a-cross-institutional-large-cohort-genomic-analysis/ https://www.tempus.com/publications/universal-genetic-and-transcriptomic-concordance-metrics-to-validate-patient-derived-tumor-organoid-models/ https://www.tempus.com/publications/unstable-mutational-profile-and-heterogeneity-of-residual-breast-tumor-following-neoadjuvant-therapy-from-comprehensive-genomic-and-transcriptomic-sequencing/ https://www.tempus.com/publications/unveiling-integrin-beta-6-ib6-real-world-data-from-the-ib6-expression-and-clinical-outcomes-in-non-small-cell-lung-cancer-study/ https://www.tempus.com/publications/updated-clinical-results-and-associated-biomarkers-from-an-ongoing-phase-1-study-of-fx-909-a-first-in-class-peroxisome-proliferator-activated-receptor-gamma-pparg-inhibitor-in-patients-pts-with/ https://www.tempus.com/publications/upregulation-of-pole-and-proficient-dna-repair-are-features-of-cicdux4-sarcomas/ https://www.tempus.com/publications/use-of-a-deep-learning-model-on-he-slides-to-predict-nucleic-acid-yield-for-ngs-testing/ https://www.tempus.com/publications/use-of-pangenome-reference-improves-variant-calling-in-clinical-genome-sequencing/ https://www.tempus.com/publications/use-of-transcriptomic-signatures-of-rad51-and-gata6-predict-improved-real-world-overall-survival-with-platinum-therapy-in-brca-palb2-wild-type-metastatic-pancreatic-cancer/ https://www.tempus.com/publications/using-artificial-intelligence-to-prioritize-pathology-samples-report-of-a-test-drive/ https://www.tempus.com/publications/using-computer-vision-to-resolve-proliferative-dynamics-within-therapeutic-responses-in-large-scale-screens-of-patient-derived-models/ https://www.tempus.com/publications/using-real-world-evidence-to-evaluate-broad-panel-vs-sequential-single-and-narrow-panel-sequencing-in-members-with-non-small-cell-lung-cancer-nsclc/ https://www.tempus.com/publications/utility-of-rna-expression-to-determine-the-tissue-of-origin-of-malignancies-with-an-inconclusive-histopathology/ https://www.tempus.com/publications/utilizing-patient-derived-epithelial-ovarian-cancer-tumor-organoids-to-predict-carboplatin-resistance/ https://www.tempus.com/publications/validation-and-clinical-utility-of-a-pan-cancer-circulating-tumor-dna-assay-as-a-first-approach-test/ https://www.tempus.com/publications/validation-and-deployment-of-he-image-based-model-predicting-total-nucleic-acid-yield-in-multiple-cancer-types/ https://www.tempus.com/publications/validation-of-4d-flow-cmr-against-simultaneous-invasive-hemodynamic-measurements-a-swine-study/ https://www.tempus.com/publications/validation-of-a-composite-mortality-end-point-in-a-large-clinicogenomic-real-world-database-of-patients-with-advanced-cancer/ https://www.tempus.com/publications/validation-of-a-composite-mortality-endpoint-in-a-large-clinico-genomic-real-world-database-of-patients-with-advanced-cancer/ https://www.tempus.com/publications/validation-of-a-liquid-biopsy-assay-with-molecular-and-clinical-profiling-of-circulating-tumor-dna/ https://www.tempus.com/publications/validation-of-a-transcriptome-based-assay-for-classifying-cancers-of-unknown-primary-origin/ https://www.tempus.com/publications/validation-of-a-transcriptome-based-assay-for-classifying-cancers-of-unknown-primary-origin-2/ https://www.tempus.com/publications/validation-of-genomic-and-transcriptomic-models-of-homologous-recombination-deficiency-in-a-real-world-pan-cancer-cohort/ https://www.tempus.com/publications/validation-of-genomic-and-transcriptomic-models-of-homologous-recombination-deficiency-in-a-real-world-pan-cancer-cohort-2/ https://www.tempus.com/publications/validation-of-he-based-laboratory-development-test-predicting-molecular-alterations-in-non-small-cell-lung-cancer/ https://www.tempus.com/publications/validation-of-her2-trop2-and-nectin4-ihc-prediction-algorithms-for-the-adc-match-trial/ https://www.tempus.com/publications/variable-associations-between-humoral-immune-features-and-immune-checkpoint-blockade-related-outcomes-across-tissues-in-metastatic-lung-adenocarcinoma/ https://www.tempus.com/publications/very-low-mutation-burden-is-a-feature-of-inflamed-recurrent-glioblastomas-responsive-to-cancer-immunotherapy/ https://www.tempus.com/publications/viral-dynamics-and-duration-of-pcr-positivity-of-the-sars-cov-2-omicron-variant/ https://www.tempus.com/publications/viral-dynamics-of-sars-cov-2-variants-in-vaccinated-and-unvaccinated-persons/ https://www.tempus.com/publications/visium-hd-combined-with-deep-learning-based-cell-segmentation-on-he-images-yield-accurate-cell-annotation-at-single-cell-resolution/ https://www.tempus.com/publications/volumetric-segmentation-free-method-for-rapid-visualization-of-vascular-wall-shear-stress-using-4d-flow-mri/ https://www.tempus.com/publications/what-is-the-place-for-digital-health-and-artificial-intelligence-in-pediatric-primary-care-a-call-to-action-from-the-european-confederation-of-primary-care-paediatricians-ecpcp/ https://www.tempus.com/publications/whole-exome-sequencing-identifies-a-somatic-cell-mutation-signature-that-predicts-relapse-risk-and-survival-probability-in-multiple-myeloma/ https://www.tempus.com/publications/whole-genome-sequencing-reveals-novel-clinically-relevant-findings-missed-by-standard-of-care-for-patients-with-myelodysplastic-syndrome/ https://www.tempus.com/publications/whole-genome-sequencing-uncovers-novel-bcrabl1-breakpoints-and-variants-in-leukemia-implications-for-personalized-medicine/ https://www.tempus.com/radiology/ https://www.tempus.com/research/ https://www.tempus.com/ship/ https://www.tempus.com/solutions/ https://www.tempus.com/solutions/biological-modeling/ https://www.tempus.com/solutions/cdx/ https://www.tempus.com/solutions/cdx-and-lab-services/ https://www.tempus.com/solutions/clinical-trial-matching/ https://www.tempus.com/solutions/clinical-trial-recruitment/ https://www.tempus.com/solutions/compass/ https://www.tempus.com/solutions/cro-services/ https://www.tempus.com/solutions/data-and-ai/ https://www.tempus.com/solutions/digital-pathology/ https://www.tempus.com/solutions/discover/ https://www.tempus.com/solutions/ecg-ai/ https://www.tempus.com/solutions/ehr-integration/ https://www.tempus.com/solutions/foundation-models/ https://www.tempus.com/solutions/hereditary/ https://www.tempus.com/solutions/hub/ https://www.tempus.com/solutions/ifu-ecg-af/ https://www.tempus.com/solutions/ifu-ecg-low-ef/ https://www.tempus.com/solutions/io/ https://www.tempus.com/solutions/ips/ https://www.tempus.com/solutions/lens/ https://www.tempus.com/solutions/life-sciences-sequencing/ https://www.tempus.com/solutions/ls-xf-plus/ https://www.tempus.com/solutions/ls-xh/ https://www.tempus.com/solutions/ls-xm/ https://www.tempus.com/solutions/ls-xr/ https://www.tempus.com/solutions/ls-xr-ivd/ https://www.tempus.com/solutions/ls-xt-cdx/ https://www.tempus.com/solutions/next/ https://www.tempus.com/solutions/next-for-cardiology-providers/ https://www.tempus.com/solutions/next-for-oncology-life-sciences/ https://www.tempus.com/solutions/next-for-oncology-providers/ https://www.tempus.com/solutions/next-trials/ https://www.tempus.com/solutions/notetaker/ https://www.tempus.com/solutions/notetaker-support/ https://www.tempus.com/solutions/np-onboarding/ https://www.tempus.com/solutions/omics/ https://www.tempus.com/solutions/omics-dtc-lab-services/ https://www.tempus.com/solutions/one/ https://www.tempus.com/solutions/pixel-breast/ https://www.tempus.com/solutions/pixel-cardio/ https://www.tempus.com/solutions/pixel-lung/ https://www.tempus.com/solutions/pixel-prostate/ https://www.tempus.com/solutions/pixel-therapy-response-evaluation/ https://www.tempus.com/solutions/real-world-data/ https://www.tempus.com/solutions/studies/ https://www.tempus.com/solutions/tailored-testing/ https://www.tempus.com/solutions/tempus-plus/ https://www.tempus.com/solutions/tempus-pro/ https://www.tempus.com/solutions/test-gui/ https://www.tempus.com/solutions/testing-resources/ https://www.tempus.com/solutions/xe/ https://www.tempus.com/solutions/xf/ https://www.tempus.com/solutions/xm/ https://www.tempus.com/solutions/xt/ https://www.tempus.com/solutions/xt-cdx/ https://www.tempus.com/tech-blog/ https://www.tempus.com/tech-blog/a-deep-dive-into-generative-ai-at-tempus/ https://www.tempus.com/tech-blog/avoiding-the-pitfalls-of-rag-by-optimizing-llms-for-precision/ https://www.tempus.com/tech-blog/innovations-from-tempus-in-clinical-insights-and-decision-support/ https://www.tempus.com/tech-blog/introducing-tempus-os-a-new-era-in-precision-medicine/ https://www.tempus.com/tech-blog/simplifying-complex-queries-with-lens-cohort-builder/ https://www.tempus.com/tech-blog/the-magic-of-blocks-and-assemblies-in-agent-builder/